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chapter 1 
INTRODUCTION 
9 
The association of genetically determined disturbances of purine 
metabolism with defects of the immune system is well documented(10,ll, 
23). Inherited deficiencies of adenosine dearainase(ADA), purine nucleo­
side phosphorylase(PNP) and purine-5'nucleotidase(5'NT) are related to 
dysfunction of different lymphoid subpopulations. ADA deficiency is asso­
ciated .with acombined Τ and В cell defect(lO); very low PNP activities 
were found in patients with a Τ cell dysfunction(ll), whereas lowered 
5'NT activities were observed in patients with X-linked agammaglobulin-
aemia(7). Recently PNP activity was reported to be decreased in patients 
with systemic lupus erythematosus(18), a disease in which decreased 
numbers of Τ suppressor cells have been encountered(15). Although several 
hypotheses can be brought forward, the exact pathophysiological mechan­
ism^) leading to the immune defects are still not completely understood 
(21). Studying purine metabolism in isolated lymphoid subpopulations 
might not only contribute to our knowledge of pathophysiological mechan­
isms in immunodiseases, but also to a better understanding of the role 
of purine metabolism in normal lymphoid cell function. 
Lymphoblastic leukemia is considered to be a malignant disorder 
of lymphocyte differentiation, the malignant transformation occurring 
at various stages of normal lymphoid differentiation(13,14). The latter 
leads to the different immunological subtypes of acute lymphoblastic 
leukemia(13). However, cells from normal differentiation stages(e.g. 
stem cells, committed progenitor cells, pre-thymocytes, etc.) are not 
or hardly available for investigation. Studying purine metabolism in the 
malignant counterpart of these normal differentiation stages might give 
more information about the relation of purine metabolism and normal 
lymphoid differentiation. Moreover, it might become clear why in some 
immunodeficiency diseases lymphoid cells from a certain lineage or 
differentiation stage are affected. The outcome of these studies may 
also provide further diagnostic tools, especially for the discrimination 
of subclasses of leukemias. 
In anti-leukemia chemotherapy, many of the drugs used have a 
rather wide spectrum of action(19); they are not only affecting 
the leukemic cells but also apparently healthy other tissues. Some 
of these anti-leukemic drugs are purine or pyrimidine derivatives 
or are interfering with purine- and pyrimidine metabolismi). 
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Well known purine and pyrimidine related anti-leukemic drugs are 
6-mercaptopurine(6MP), 6-thioguanine(6TG), methotrexate(MTX) and 
cytosine-arabinoside(ara-C). Although a certain knowledge exists 
regarding the mode of action of these compounds(4,6,20,27), in fact 
little is known about the tissue specificity of this action. Part of 
the present study was therefore undertaken in order to explore possib-
ilities for anti-leukemic drugs with a better, higher degree of specif-
icity. 
ENZYMOLOGICAL ANALYSIS OF PURINE METABOLISM IN LYMPHOID CELLS 
In this section the development of a micromethod and the applica-
tion of this method to assay enzyme activities in different lymphoid 
subpopulations is described. The development of such a micromethod was 
necessary because systematically assaying purine interconversion enzymes 
with conventional methods would require too many cells. The amount of 
peripheral blood available from volunteers and the small recovery of 
cells derived when fractionating peripheral blood lymphocytes or other 
lymphoid tissues would become prohibitive. Moreover, sometimes it was 
not possible to obtain large quantities of leukemic cells from patients 
with childhood acute lymphoblastic leukemia(ALL). Some of these patients 
appeared to be leukopenic(cf. chapter 7). 
Conventional analysis of purine enzyme activities requires 105 
to 108 cells per assay(5,7). The described micromethod, using 1,000 to 
6,000 cells per assay, enabled us not only to systematically analyse 
purine enzyme activities in childhood ALL, but also in different sub-
fractions of human lymphoid cells(chapters 4,5,6,7 and 9). The effect 
of different methods of cell destruction on the activity of purine 
enzymes was tested(chapter 2). The best results were obtained with 
lyophilization of the cells and subsequent resuspension in a buffer 
containing the detergent triton X-100. This method of cell destruction 
was used throughout the studies outlined in this thesis. The effect of 
the addition of bovine serum albumin to the cell suspensions on the 
counting efficiency and on the enzyme activities measured was studied 
(chapter 3). 
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Our micromethod was employed in studies on different lymphoid cell 
subpopulations(chapters 4 and 5). The differences in purine enzyme 
activities between Τ and В cells and between Τ and T-T cells were 
γ Ύ 
assessed. The effect of differences in isolation procedures of lymphoid 
cells on purine enzyme activities are discussed mainly in chapter 5. 
One of the major conclusions from this set of experiments was, that the 
presence or absence of bloodplatelets in the lymphoid cell preparations 
could cause considerable differences in enzyme activities. The lymphoid 
cell preparations used in all other experiments described in this thesis 
were essentially platelet-free. 
EXPRESSION OF PURINE METABOLISM IN LEUKEMIA 
The study of purine metabolism in lymphoblastic leukemia might 
serve three purposes: 
1. The search for additional diagnostic biochemical markers in lympho­
blastic leukemia. 
2. The search for a relation between biochemical markers of lymphocytic 
differentiation and the immunological markers. 
3. Based on the specific deviant enzymatic make-up of the malignant 
lymphoblasts, possibilities for specific chemotherapy might be 
explored. 
Chapter 6 contains a brief outline of differences in purine enzyme 
activities found in two major subclasses of ALL. Namely the T-ALL sub­
class, mainly characterized by the receptor for sheep red blood cells 
(Ε-rosettes), and the nonBnonT-ALL subclass, which has neither immuno­
globulins on the cell membrane(nonB) nor the Ε-rosette marker(nonT). 
From a clinical point of view this major subdivision has a prognostic 
value: nonBnonT-ALL patients might have a better prognosis than T-ALL 
patients(l,3). We were able to study these patients in sufficient 
numbers and to quantify the differences in purine enzyme activities. 
A number of additional markers are available at present. Greaves 
et al.(13) described four phenotypic subgroups of ALL. T-ALL is pheno-
typically defined by the presence of the Ε-rosette marker, expression 
of Τ cell antigen and a relatively high activity of terminal 
12 
deoxynucleotidyltransferase and acid phosphatase. Lymphoblasts of B-ALL 
patients have immunoglobulins on their cell membrane. The group of ALL 
patients classified earlier as nonBnonT-ALL patients could be subdivided 
on the basis of the presence of a common ALL(cALL) antigen. Greaves et 
al.(2,12) have developed an antiserum against this antigen, which is 
widely used now. NonBnonT-ALL patients in which the cells react posit-
ively with this antiserum are designated as cALL patients. The nonBnonT-
ALL patients that could not be classified neither with the E-rosette 
marker nor with the presence of immunoglobulins on the cell membrane, 
nor with the cALL marker are designated unclassified(unc.-ALL). Vogler 
et al.(25)described a number of cALL patients, who had 
cytoplasmic IgM heavy chains present in their leukemic cell population. 
Since this marker appears to be related to preß eel Is(9), these cALL 
patients were classified as preB-ALL. Recently an ALL subclass was 
described with a mixed common/T phenotype(17). 
In order to serve the three purposes mentioned above we have 
studied enzyme activities of purine metabolism in relation with the E-
rosette marker, the cALL marker, the presence of immunoglobulins on the 
cells and the preB cell marker in patients with acute lymphoblastic 
leukemia(chapter 7). Since the group of B-CLL patients is likely to 
represent another stage of normal lymphoid differentiation(13) we also 
studied a group of B-CLL patients(chapter 8). 
NUCLEOSIDE TOXICITY IN MATURE AND IMMATURE LYMPHOID CELLS 
The differences in enzyme activities observed in different groups 
and subgroups of lymphoblastic leukemia appeared to be considerable. 
Differences in the activity levels of ADA, PNP, 5'NT and adenylate 
kinase(AdKin) appeared to be most pronounced(chapter 6,7,8). Since the 
handling of purines in the leukemic subgroups was so different, we 
studied intoxication of cells with an enzymatic make-up comparable with 
a certain subgroup of leukemia for intoxication with different nucleo-
sides. As thymocytes may be considered as normal equivalents of certain 
T-ALL cells, we performed a set of toxicity studies with thymocytes. 
The toxicity was related to enzyme activities. From our results it was 
clear that some purine enzymes could probably serve as markers for 
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different subgroups of ALL. In addition we studied the possibilities of 
using purine enzyme activities as markers for differentiation in the 
intrathymic situation(chapter 10). 
Differences in nucleoside toxicity were also studied using mature 
peripheral blood lymphocytes, stimulated with mitogens known to stimul­
ate different lymphoid subpopulations(16). The effects of the nucleosides 
adenosine and deoxyadenosine on DNA synthesis, protein biosynthesis 
and IgG secretion were studied. Although the exact mechanisms are not 
yet clear and the limitations of working with stimulated lymphocytes 
are known to us, it was indicated that different subpopulations of 
mature peripheral blood lymphocytes, including Τ and Τ , have a dif­
ferent sensitivity towards the nucleosides mentioned. Moreover, depend­
ing on the concentrations used, deoxyadenosine exerts a biphasic effect 
on poke weed mitogen stimulated peripheral blood lymphocytes(chapter 10). 
REVIEW 
Finally,in the last chapter.an overview is given of the evidence 
available to date regarding the relation between purine metabolism, 
leukemia and lymphoid cell differentiation. Reports from literature 
are reviewed and considered in relation to the findings reported in 
this thesis. 
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ABSTRACT 
A new micromethod enabling the characterization of several enzymes 
of purine metabolism in small numbers(500-5,000) of lymphocytes is pre­
sented. This method is based on ultramicrotechniques, making use of 
radioactive substrates, which have been publsihed previously. 
The isolation of lymphocytes from peripheral blood by nylon wool 
filtration and Ficoll-Isopaque density centrifugation yielded a lympho­
cyte fraction of about 98% purity. The lymphocyte suspensions were 
diluted to 10 5 to 106 cells/ml and aliquots of \ μΐ were pipetted into 
small incubation vessels, moulded in parafilm immediately before use 
(Parafilm-Micro-Cuvette; PMC). The cells were frozen and lyophilized 
overnight. This procedure yielded maximum enzyme activities as compared 
to sonification and freezing-thawing. Incubations were routinely done 
in fivefold; they were started by addition of 3 yl of the appropriate 
incubation mixture to each PMC. After incubation, the contents of the 
PMC were pressed directly on chromatography paper. Products and sub­
strates were separated by descending chromatography or high voltage 
electrophoresis. 
The present micromethod allows to assay reproducibly with less than 
100,000 cells(500-5,000 cell/incubation) six purine interconversion 
enzymes, including hypoxanthine-guanine phosphoribosyltransferase, 
adenine phosphoribosyltransferase, adenosine deaminase, purine nucleo­
side Phosphorylase, adenosine kinase and purine-5'nucleotidase. 
18 
INTRODUCTION 
The involvement of purine interconversion enzyme defects in impair­
ment of the immune system is now well documented(5,6,7). Although it has 
been suggested that deoxypurine nucleotides might be the toxic metabol­
ites in these immune diseases(l,2), the mechanism which leads to dys­
functions of Τ or В cells, or both of them, is still not completely elu­
cidated. A better understanding of purine interconversions in В and Τ 
cell subfractions might help to obtain a better view on В or Τ cell 
specificity in these immune diseases. One of the possibilities to achieve 
this might be a systematic analysis of purine metabolism in Τ and non-T 
lymphocytes. 
The first purpose of the present study was to investigate the effect 
of cell destruction procedures, such as sonification and lyophilization, 
on a number of purine enzyme activities. This was studied with pure 
lymphocyte preparations from human tonsils. 
Determination of nine purine enzyme activities in lymphocyte sub-
fractions from one peripheral blood sample using conventional methods 
required too much blood. Therefore, the second purpose of the present 
study was to develop new radiochemical micro techniques, which are based 
on previously described ultramicrochemical methods(3,8,9,10,14,15). 
This method has been applied to almost pure, unfractionated lymphocyte 
preparations, using 500 to 5,000 cells per assay. 
MATERIALS AND METHODS 
Isolation of Lymphocytes from Tonsils 
After removal of the surrounding tissues, tonsils were homogenized 
(Potter; Janke & Kunkel KG) in tris-buffered minimal essential medium 
(MEM; Gibco, F-14; pH 7.4) containing 152S(v/v) foetal calf serum(FCS; 
Gibco). After filtration over a wire mesh, the suspension was layered 
on Lymphoprep(gravidity 1.077 gr/ml; Nyegaard AS, Oslo). Lymphocytes 
were collected from the interphase after centrifugation for 20 min. at 
1,000 g(room temperature) and washed once with a solution containing 
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155 niM NH4C1, 10 mM KHC03, 0.1 mM disodium EDTA(pH 7.4). Before use the 
cells were washed twice with 0.9% NaCl(w/v). 
Isolation of Lymphocytes from Peripheral Blood 
Thirty ml of defibrinated(on glass beads; 0 5 mm) venous blood was 
incubated for 15 min. at 37° C. After passage through a nylon wool 
column(4) the effluent was diluted with MEM/tris containing 15% FCS(v/v) 
to a concentration of approximately 109 blood cells/ml. Subsequently 
this cell suspension was carefully layered on top of a density gradient, 
that consisted of 15 ml Ficoll-Isopaque(gravidity 1.085 gr/ml; Flcoll 
400, Pharmacia, Uppsala, Sweden; Isopaque 440 mg J/ml, Nyegaard & Co. 
AS, Oslo) and 5 ml of a lighter Ficoll-Isopaque solution(gravidity 1.055 
gr/ml). The centrifugation was carried out at room temperature(20 min., 
1,000 g). Lymphocytes could be collected from the interphase between the 
two Ficoll-Isopaque solutions. During the isolation the amounts of 
monocytes, granulocytes and lymphocytes were checked with a Hemalog D 
(Technicon Instruments Corp., Tarrytown, NY, USA). The original total 
leukocyte fraction in whole EDTA blood contained 29% lymphocytes, 7% 
monocytes, 62% granulocytes and 6% "large unstained cells"(LUC). Defib­
rination and filtration over a nylon wool column according to de Pauw 
et al.(4) yielded a fraction after Ficoll-Isopaque density centrifuga­
tion which contained over 97% lymphocytes and a very low contamination 
of monocytes, granulocytes and LUC. 
"Macro" Enzyme Assays with Tonsillar Lymphocytes 
Lymphocytes were lysed in several ways: freezing and thawing(-20° C, 
5 cycles), lyophilization and sonification(3 χ 10 sec, output control 7; 
Sonifier B-12, Branson Sonic Power Co., Danbury, CT, USA). For all enzyme 
assays 0.05 to 5 wgr protein per incubation was added(protein estimation 
according to Lowry et al., 12). All enzyme assays were carried out in 
triplicate and in table 1 the mean values are given. Hypoxanthine-
guanine phosphoribosyltransferase(HGPRT; E.C. 2.4.2.8) and adenine 
phosphoribosyltransferase(APRT; E.C. 2.4.2.7) were assayed essentially 
according to De Bruyn et al.(3). Purine nucleoside phosphorylase(PNP; 
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E.C. 2.4.2.1) and adenosine deaminase(ADA; E.C. 3.5.4.4) were assayed 
essentially according to previously described methods(14,15). 
"Micro" Assays with Peripheral blood Lymphocytes 
Lymphocyte suspensions containing 1,000 to 10,000 cells/μΐ were pre­
pared in 0.9% NaCl. Aliquots of 0.5 μΐ were pipetted into small incuba­
tion vessels prepared from parafilm(Parafi lm "M", American Can Co., 
Greenwich, CT, USA). These parafilm micro cuvettes(PMC) were prepared 
immediately before use(8,9,10). The lymphocytes were frozen in the PMC's 
at -20° С for 15 to 30 min. and subsequently lyophilized overnight. All 
enzyme assays were carried out in five-fold. For HGPRT, APRT, ADA and 
PNP the reactions were started by adding 3 μΐ of the appropriate incu­
bation mixture. The concentrations were the same as described above for 
the "macro" assays except for the addition of 0.2%(v/v) triton X-100 
(Sigma) in several experiments. In the HGPRT reaction also 8-lu-C-
guanine(0.13mM; specific activity 55 mCi/mmol; Radiochemical Centre 
Amersham, UK) was used as a substrate; ADA was also tested with 8-1цС-
deoxyadenosine(0.26 nM; specific activity 45 mCi/mmol; NEN chemicals 
GmbH, Dreieich, FRG). Incubation times were 1 to 4 hours at 37° С 
Quantification of enzyme activities was carried out as described else-
where(3,14,15). The adenosine kinase(AK; E.C. 2.7.1.20) assay was adap­
ted from Meyskens and Williams(13). To the lyophilized lymphocytes, 3 μΐ 
of a reaction mixture was added, containing 3 μΜ 8-11+C-adenosine, 1.5 mM 
ATP(Boehringer Mannheim), 0.3 M trisodiumacetate/acetic acid(pH 5.7), 
0.6 mM MgCL·, 12.5 μΜ erythro-9-(2-hydroxy-3-nonyl)-adenine(EHNA), kindly 
supplied by Dr. H.A. Simmonds(Purine Laboratory, Guy's Hospital Medical 
School, London, UK) and 0.2% triton X-100. After incubation(4 hours at 
37° C) separation of substrate and products was performed by means of 
high voltage electrophoresis on Whatmann 3 MM paper(0.05 M citrate 
buffer, pH3.9; 70 V/cm). Purine-5'nucleotidase(5'NT; E.C. 3.1.3.5) assay; 
to the lyophilized lymphocytes 3 μΐ of a reaction mixture was added(ll) 
containing 0.05 mM tris/HCl(pH 8.5), 0.02MMgCl„, 6.25 mM 2-glycero-
phosphate(Sigma) and 0.6 mM 8-lnC-AMP(specific activity 61 mCi/mmol; 
Radiochemical Centre Amersham, UK). Incubation(4 hours at 37° C) was fol­
lowed by separation of substrate and products as in the AK assay. 
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Table 1 : Effect of Different Methods of Cell Destruction on 5 Purine 
Enzyme Activities 
Enzyme 
HGPRT 
APRT 
ADA 
PNP-Hx 
PNP-Ino 
1 
4.3 
7.4 
49.4 
44.0 
15.2 
2 
5.9 
8.9 
85.0 
90.5 
21.8 
3 
4.6 
7.2 
52.2 
71.8 
23.5 
Procedure 
4 5 
6.1 
9.6 
84.0 
110.6 
26.0 
2.9 
7.4 
54.7 
55.0 
20.0 
6 
5.2 
8.3 
69.2 
33.0 
15.4 
7 
4.4 
8.5 
51.2 
51.1 
20.4 
8 
4.9 
7.7 
81.2 
57.6 
24.7 
Procedure 1. freezing and thawing(5 cycles, -20 C) 
2. freezing and thawing(5 cycles, -20° C), with addition of 
0.2% triton X-100 
3. lyophilization and resuspension in 0.01 M tris/HCl(pH 7.4) 
4. lyophilization and resuspension in 0.01 M tris/HCl(pH 7.4), 
with addition of 0.2% triton X-100 
5. lyophilization and somfication after resuspension in 0.01 
M tris/HCKpH 7.4) 
6. somfication preceded by lyophilization 
7. somfication 
8. somfication in the presence of 0.2% triton X-100 
Enzyme activities are expressed in 10~ moles product formed/10 cells, 
hour. For each enzyme the procedure which gives the highest activity is 
underlined. 
RESULTS AND DISCUSSION 
Effect of Various Lysate Preparations on Enzyme Activities 
Tonsillar lymphocytes, suspended in 0.01 M tris/HCl (pH 7.4) were 
lysed in eight different ways in order to investigate, which method of 
cell destruction is to be preferred for the determination of purine 
enzyme activities(table 1). After preparation of the lysate, insoluble 
particles were removed by centrifugation(300 g, 15 min.). As can be seen 
in table 1 the procedures using 0.2% triton X-100 yielded highest enzyme 
activities, especially in the case of freezing and thawing and lyophil-
ization (procedures 2 and 4). This effect was seen with all enzymes tested. 
In the present studies enzyme activities are expressed on a per cell 
basis. When expressing the activities on a protein basis it was found 
that, although with some procedures much more protein was released into 
the soluble fraction than with other procedures(e.g. lyophilization + 
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Table 2: Reproducibility of the "Micro" Assay for ADA and PNP, Assayed 
in Five-Fold in the Same Sample 
probe no. net product formed 
(cpm) 
enzyme activity 
(1СГ9 moles/106 cells.hour) 
ADA 6568 
5620 
6651 
459Θ 
7302 
57.77 
62.95 
53.40 
51.29 
71.04 
mean ± s.d. 59.29 ± 7.95 
PNP 6591 
Θ50Θ 
8549 
6132 
7302 
80.00 
78.51 
90.16 
80.73 
83.72 
mean ± s.d. 82.62 ± 4.62 
ADA assay: incubation with 1,500 cells for 4 hours at 37 C, input 
60,000 cpm S-^C-adenosine. 
PNP assay: incubation with 1,500 cells for 1 hour at 37° C, input 
30,000 cpm 8-1MC-hypoxanthine. 
sonification; procedure 5), the specific enzyme activities were not 
higher as compared to other procedures. For routine determinations the 
method of choice for the preparation of lymphocyte lysates turned out 
to be lyophilization with addition of 0.2% triton X-100(procedure 4). 
Table 3: Purine Interconversion Enzymes in Lymphocytes 
Enzyme Substrate Specific Activity ± s.d. 
HGPRT 
APRT 
ADA 
PNP 
AK 
5'NT 
hypoxanthine 
guanine 
adenine 
adenosine 
deoxyadenosine 
hypoxanthine 
inosine 
adenosine 
AMP 
2.95 
6.49 
8.93 
46.27 
34.36 
63.87 
12.99 
0.74 
12.26 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
0.72 
2.44 
1.56 
10.94 
9.04 
16.70 
1.82 
0.47 
7.08 
Activities calculated from a group of 7 healthy individuals and 
expressed as 10 9 moles/106 cells.hour. 
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"Micro" Chemical Enzyme Determinations 
Nine purine interconversion enzyme activities could reproducibly be 
assayed with relatively small numbers of cells(500 to 5,000). Two 
examples are given in table 2, where the raw data and calculated enzyme 
activities are given of an ADA and PNP assay; measurements were carried 
out in five-fold. 
The mean activities in purified normal human lymphocytes of nine 
enzymatic reactions involved in purine interconversions are shown in 
table 3. ADA and PNP displayed the highest activity in pure lymphocytes, 
whereas relatively low activities were found for HGPRT and AK. The rather 
wide range of specific enzyme activities was attributed to individual 
variation rather than to methodological errors. 
With the present "micro" method it becomes possible to carry out a 
great number of enzyme determinations with small numbers of cells. In 
the present study only radiochemical assays are described, but also 
other substrates(e.g. fluorogenic; Van Laarhoven et al. unpublished) can 
be employed both for experimental and diagnostic purposes. 
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ABSTRACT 
A method is presented for systematic analysis of purine enzymes in 
small lymphocyte subfractions. For the determination of 7 different 
enzymes of purine metabolism(hypoxanthine-guanine phosphoribosyltransfer­
ase, HGPRT; adenine phosphoribosyltransferase, APRT; adenosine deaminase, 
ADA; purine nucleoside Phosphorylase, PNP; adenosine kinase, AK; 5'nucleo-
tidase, 5'NT; AMP deaminase, AMPD) less than 200,000 peripheral blood 
lymphocytes are needed. In micro-incubation vessels(3 μΐ), 1,000 to 6,000 
lyophilized lymphocytes are incubated with radioactive substrates for 
15 to 180 min. Separation of substrates and products is achieved by thtn-
layer chromatography on PEI-cellulose. Addition of BSA to the incubation 
mixtures results in higher specific enzyme activities and narrower ranges 
of mean values of a control group. 
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INTRODUCTION 
As a consequence of adenosine deaminase(ADA) and purine nucleoside 
phosphorylase(PNP) deficiency, accumulation of deoxypurine nucleotides, 
especially deoxyATP and deoxyGTP, may lead to dysfunction of Τ and/or В 
lymphocytes(l), although the selective toxicity of deoxynucleotides 
towards Τ or В cells is still not completely understood. Purine-5'nucleo-
tidase(5'NT) is believed to play a major role in nucleotide breakdown. 
Therefore this enzyme may be of crucial importance in the detoxification 
of deoxynucleotides. Decreased 5'NT activities have been observed in 
patients with congenital primary agammaglobulinaemia(4). 
Differences in purine interconversion pathways in Τ and В lympho­
cytes might account for the selective toxicity of deoxypurine nucleoti­
des. Therefore, systematic analysis of purine interconversion enzymes in 
these different cell types seems to be of interest. 
Systematic analysis of purine metabolism in peripheral Τ and non-T 
cells by conventional methods requires at least 100 ml of blood. We 
present here simple micro-methods for determining enzyme activities in 
lymphocytes obtained from only 5 to 10 ml of blood, and permitting 
enzymatic analysis of small subfractions of lymphocytes. For each assay, 
1,000 to 6,000 cells are used in incubation volumes of 3 μΐ. In addition, 
the effect of bovine serum albumin on these micro-assays has been 
investigated. 
MATERIALS AND METHODS 
Isolation of Lymphocytes from Peripheral Blood 
Venous blood(5 to 10 ml) was defibrinated and passed over a nylon 
wool column as described by De Pauw et al.(11). The resulting cell sus­
pension was diluted with 2 volumes MEM/tris containing 15%(v/v) foetal 
calf serum(FCS) which had been heat inactivated and screened for virus 
and mycoplasma. Subsequently this cell suspension was carefully layered 
on top of a density gradient, consisting of 15 ml Ficoll-Isopaque(gravity 
1.085 gr/ml, Ficoll 400, Pharmacia, Uppsala, Sweden, Isopaque 440 mg J/ml, 
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Nyegaard and Co., AS, Oslo) and 5 ml of a lighter Ficoll-Isopaque solu-
tion(gravity 1.055 gr/ml). The centrifugation was carried out at room 
temperature(20 min., 1,000 g). Lymphocytes were collected from the inter­
phase between the two Ficoll-Isopaque solutions. During isolation, the 
numbers of monocytes, granulocytes and lymphocytes were checked with a 
Hemalog D(Technicon Istruments Corp., Tarrytown, NY, USA). 
Micro-Assays with Peripheral Blood Lymphocytes 
Lymphocyte suspensions containing 2 χ IO6 to 12 χ IO6 cells/ml were 
prepared in 0.9%(w/v) NaCl in Eppendorf micro-test tubes(Eppendorf 
Gerä'te-bau, Hamburg, F.R.G.). Aliquots of 0.5 μΐ were pipetted into small 
incubation vessels prepared from parafilm(Parafi lm "M", American Can Co., 
Greenwich, CT, USA). These parafilm micro-cuvettes(PMC) were prepared 
immediately before use(fig. 1; 5,6,7). The lymphocytes were frozen in the 
PMC's :t -20° С for 15 to 30 min. and subsequently lyophilized overnight. 
All enzyme assays were carried out in quintuplicate. The reactions were 
started by adding 3 μΐ of the appropriate incubation mixture. 
Hypoxanthine-guanine phosphoribosyltransferase(HGPRT; E.C. 2.4.2.8) 
and adenine phosphoribosyltransferase(APRT; E.C. 2.4.2.7) were assayed 
essentially according to De Bruyn et al.(2) and Van Laarhoven et al.(18). 
In the HGPRT reaction 8-1цС-пурохапіпіпе(0.13 mM; specific activity 55 
mCi/mmol; Radiochemical Centre Amersham, RCA, UK) was used as a substrate. 
Purine nucleoside phosphorylase(PNP; E.C. 2.4.2.1) and adenosine deamin-
ase(ADA; E.C. 3.5.4.4) were assayed according to previously described 
methods(15,16). ADA was tested with e-^C-adenosinefO^e mM; specific 
activity 58 mCi/mmol; RCA) and e-^C-deoxyadenosinefO^ö mM; specific 
activity 45 mCi/mmol; NEN Chemicals GmbH, Dreieich, F.R.G.). Reactions 
were allowed to proceed for 15 to 90 min. at 37° C. 
Quantification of enzyme activities was carried out by separating 
products and substrates by means of thin-layer chromatography. For HGPRT, 
APRT and PNP with 8-11(C-inosine(specific activity 60 mCi/mmol, RCA) as a 
substrate(PNP-Ino) and with 8-14C-hypoxanthine as a substrate(PNP-Hx), 
PEI-cellulose plates(Macherey-Nagel; SEL 300 PEI), prewashed overnight 
in water, were used with 0.2 M NaCl as the solvent. Unlabelled 
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Figure 1 : Incubation with lyophilized lymphocytes in parafilm micro-
cuvettes (PMC, 3 μΐ). I, II and III: preparation of the PMC in a teflon 
mould. IV: PMC is filled with cell suspension which is subsequently 
frozen and lyophilized. V: PMC with lyophilized lymphocytes is filled 
with 3 μΐ incubation mixture. VI, VII and VIII: PMC is covered with a 
second strip of parafilm and double sealed with teflon pins on a stain­
less steel block. IX: after incubation in a water bath the second para­
film strip is peeled off. X: the contents of the PMC can be pressed out 
on chromatography paper or an aliquot can be taken and pipetted on thin-
layer chromatography plates. 
metabolites were co-chromatographed and after detection under UV light 
the spots were cut out and counted in a liquid scintillation counter 
(Packard, TriCarb В 2450). Analysis of the ADA reaction mixture was 
performed with tert-butanol(Merck-Schuchardt 82264), Darmstadt, F.R.G.): 
ethylmethylketone(Merck 9708):water:ammonia(Merck 5426) = 20:15:10:15 on 
PEI cellulose plates. 
31 
The adenosine kinase(AK; E.C. 2.7.1.20) assay was adapted from 
Meyskens and Williams(lO). To the lyophilized lymphocytes 3 μΐ of a 
reaction mixture were added, containing 10 μΜ 8-14C-adenosine, 1.5 mM 
ATP(Boehringer, Mannheim), 0.3 M tri sodium-acetate/acetic acid(pH 5,7), 
0.6 mM MgCl„, 12.5 μΜ erythro-9-(2-hydroxy-3-nonyl )-adenine(EHNA), kindly 
supplied by Dr. H.A. Simmonds(Purine Laboratory, Guy's Hospital Medical 
School, London, UK) and 0.2%(v/v) triton X-100(Sigma T-6878). After 
incubation(l hour at 37° C) separation of substrate and products was 
performed by means of thin-layer chromatography as described above for 
HGPRT. 
Purine-5'nucleotidase(5'NT; E.C. 3.1.3.5) assay(8): to the lyophil­
ized lymphocytes 3 μΐ of a reaction mixture were added, containing 0.05 
M tris/HCl(pH 8.5), 0.02 M MgCl2, 6.25 mM 2-glycerophosphate(Sigma 
G-6251), 0.6 mM e-^C-AMPispecific activity 56 mCi/nmol; RCA) and 0.2% 
(v/v) triton X-100. Incubation(3 hours at 37° C) was followed by separ­
ation of substrate and products as in the AK assay. Ecto-5'NT was assayed 
essentially according to Edwards et al.(4). In a total volume of 40 μΐ, 
100,000 intact lymphocytes were incubated for 45 to 60 min. at 37° С 
Activity estimation was carried out as described for 5'NT. 
AMP deaminase(AMPD; E.C. 3.5.4.6) was assayed essentially according 
to Leech and Newsholme(9). In a mixture containing 60 mM Pipes(Merck 
10220), 12 mM AMP(Merck 1428), 6 mM EDTA(Merck 8418), 30 mM KCl(Merck 
4933), 2.5 mM dithiothreitol (Sigma D-8255), 180 μΜ e-^C-AMPÍspecific 
activity 56 mCi/mmol; RCA) and 0.2%(v/v) triton X-100, 6,000 lyophilized 
lymphocytes were incubated for 2 hours at 37° C. 
The specific enzyme activity is calculated from the net product 
formed and is expressed in 10"9 moles/106 lymphocytes.hour. The total 
amount of radioactivity recovered after chromatography varies slightly 
for the individual incubations: this variation is due to micropipetting 
errors. To correct for this, the error in each individual measurement is 
calculated from the sum of product and remaining substrate. Thus, the 
product measured in counts per minute is not directly representative of 
the product actually formed by the enzyme reaction. 
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Table 1: Leukocyte Content at Different Stages of Lymphocyte Isolation 
Lymphocytes Monocytes Granulocytes LUC 
(%) (%) (%) (%) 
Whole EDTA blood 28 
After defibrination 
on glass beads 39 
After filtration 
over nylon wool 91 
After Ficoll-Isopaque 
density centrifugation 97 
ó 
6 
1 
0 
61 
53 
6 
1 
Hemalog D results are given. LUC: large unstained cells,- mainly 
lymphoid cells. 
RESULTS 
Lymphocyte Isolation 
The composition of the various cell suspensions during lymphocyte 
counted cell number 
(106 lymphocytes/ml) 
5 10 15 
expected cell number (106 lymphocytes/ml ) 
Figure 2: Relation between expected cell number, after dilution from a 
stock suspension and actually counted cell number. The BSA concentra-
tions indicated represent the actual amounts of BSA present in the 
diluted cell suspensions. The broken line represents the position 
where the expected cell number equals the counted cell number. 
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Figure 3: Effect of the BSA concentration on 6 different enzyme activ­
ities. The BSA concentrations indicated on the abscissa represent the 
final concentrations in the reaction mixtures, resulting from a six­
fold dilution of the cell suspensions used. The vertical bars indicate 
the standard deviations of determinations carried out in quintuplicate. 
Specific enzyme activities(S.A.) are expressed in 10" moles/10 cells, 
hour. 
purifications is shown in table 1. This procedure of de Pauw et al.(11) 
yields a fraction which contains over 97% lymphocytes with very low 
contamination of monocytes, granulocytes and large unstained cells(LUC). 
Effects of Bovine Serum Albumin(BSA) 
Lymphocyte suspensions isolated from peripheral blood normally 
contained more than 15 χ IO6 cells/ml. Before pipetting the cells into 
the PMC's, suspensions were prepared in the range of 1 χ IO6 to 12 χ IO6 
cells/ml in polypropylene Eppendorf micro-test tubes. When 20 ul 
aliquots were taken and checked for the number of cells, a lower number 
of cells were found with the Coulter counter than expected on the basis 
of the dilution factor(fig. 2). The presence of BSA in the cell 
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Table 2: Reproducibility of the micro-assay for ADA and PNP, assayed in 
quintuplicate on the same sample. ADA assay: incubation with 1,000 cells 
for 0.5 hour at 37° C, input 60,000 cpm 8-1"c-adenosine(0.26 m M ) . PNP 
assay: incubation with 1,000 cells for 15 min. at 37° C, input 30,000 
cpm 8- ''C-hypoxanthine (0.13 mM) . For calculation of enzyme activities 
see under Materials and Methods. 
probe no. 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
net product formed 
(cpm) 
3.137 
5.702 
5.855 
4.781 
6.698 
5.550 
6.858 
7.983 
4.472 
6.515 
(10' 
enzyme activity 
'
9
 moles/10 6 cells.hour) 
ADA 
PNP 
mean ± s.d. 
s.d. 
134 
139 
117 
125 
154 
134 
306 
242 
292 
256 
247 
269 
± 14 
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suspension gave a dilution curve, which was identical with that expec-
ted. In suspensions with low numbers of cells the differences between 
the expected cell concentration and the counted number were the most 
pronounced. 
In the presence of BSA higher specific enzyme activities were ob-
served(fig. 3). This increase was not due to chance enzyme activity 
present in the BSA, since complete incubation mixtures with BSA and 
without cells were used as blanks. The addition of BSA did not produce 
a significant rise in blank values. The purine enzyme activities in 
peripheral blood lymphocytes from a control individual showed highest 
activities in the presence of more than 0.33% BSA(w/v). For routine 
determinations a concentration of 0.67%(w/v) was used. 
Reproducibility 
Table 2 gives an example of ADA and PNP assays carried out in 
quintuplicate with lymphocytes from a healthy control subject. The 
standard deviations of both measurements is approximately 10% of the 
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enzyme activity 
4 0 0 
3 0 0 
2 0 0 
100 
1000 2000 3 000 4 000 
cel ls/ incubat ion 
Figure 4: Relation between the number of lyophilized cells incubated 
and product formation in the adenosine deaminase reaction. Closed 
circles represent the mean activity of determinations carried out in 
quintuplicate. The vertical bars indicate the standard deviations. 
Enzyme activities are expressed in 10~ moles/hour. 
mean value. The reproducibility of the HGPRT, APRT, AK, 5'NT and AMPD 
assays was found to be at a comparable level(data not shown). 
Fig. 4 shows the ADA activity as a function of the number of cells 
incubated. A linear relationship is seen up to at least 4,000 cells. The 
time curve for the ADA reaction is shown in fig. 5. Under the given 
incubation conditions the reaction was linear up to 3 hours at least. 
For routine determinations a cell number of 1,000 cells/incubation and 
an incubation time of 30 min. was chosen. Based on similar determinations 
of other enzyme activities, the individual assay conditions were chosen 
as summarized in table 3. 
36 
enzyme activity 
300-
200 
100 
ADA 
1 2 3 h 
time 
Figure 5: Time-curve for the adenosine deaminase(ADA) reaction. Closed 
circles represent the mean activity of determinations carried out in 
quintuplicate. The vertical bars indicate the standard deviation. 
Enzyme activities are expressed in 10~9 moles/10 lymphocytes. 
Ezyme Activities in Control Lymphocytes 
Of the 7 different enzymes tested, PNP and AMPD displayed the high­
est specific activities(table 4). The activities of the salvage enzymes 
Table 3: Micro-Assay Conditions 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
ΛΚ 
5'NT 
AMPD 
Substrate 
hypoxanthine 
adenine 
adenosine 
deoxyadenosine 
hypoxanthine 
inosine 
adenosine 
AMP 
AMP 
Incubation time 
(min.) 
90 
90 
30 
60 
15 
90 
60 
180 
120 
Cells per 
incubation 
6,000 
3,000 
1,000 
1,000 
1,000 
3,000 
6,000 
6,000 
6,000 
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HGPRT and APRT were considerably lower. The activity of ADA with deoxy-
adenosine was about half that with adenosine. The PNP-catalyzed conver-
sion of hypoxanthine to inosine was considerably more active than that 
in the opposite catabolic reaction(table 4). As compared with assays 
without BSA, all enzyme activities were higher in the presence of 0.67Ï 
BSA in the reaction mixture(table 4, fig. 3). In addition, the standard 
deviations of the mean values of almost all enzymes were smaller when 
BSA was used. 
DISCUSSION 
A relatively simple approach to ultramicrochemistry has been intro-
duced for enzyme assays in lyophilized cultured fibroblasts, which makes 
use of fluorogenic substrates(5,6,7). These methods have also been 
applied to radiochemical assays(2,13,15). Biochemical and kinetic studies 
may be performed with this method, even at the "single cell" level(14,16). 
A principal advantage of ultramicromethods is that a favourable 
signalrnoise ratio can be obtained. The noise, or "blank", in an enzyme 
reaction is almost invariably due to the amount of substrate employed. 
The signal:noise ratio can be improved significantly by decreasing the 
incubation volume(lower blank value) and prolonging the incubation time 
(stronger signal). Additional advantages include: 
1. Very limited amounts of material can be handled. The microtechnique 
described allows a range of biochemical studies to be performed on a 
given blood sample, which would have been impossible with conventional 
techniques. This is of special importance when lymphocyte subfractions 
are to be analyzed(18). 
2. Because of the small incubation volumes(3 μΐ) only small amounts of 
substrates and reagents are needed, which helps to reduce the cost 
of large scale routine measurements. Moreover, the complete reaction 
mixture can be analyzed and no aliquots need to be taken. 
3. Not only radioactive substrates can be used for enzyme assays in 
lymphocytes: the activity of a number of lysosomal hydrolases(e.g. 
hexosaminidase and acid phosphatase), can be readily and reliably 
determined by use of fluorogenic substrates(Van Laarhoven, unpublished 
results). 
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Before pipetting the lymphocytes into the PMC's, suspensions are 
prepared containing theoretically 1,000 to 6,000 eels per 0,5 yl aliquot. 
These suspensions are prepared in plastic Eppendorf reaction vessels. 
When aliqouts were taken for cell counting in a Coulter counter, fewer 
cells than expected are recovered. This effect is most significant in 
the range we normally use for our incubations(fig. 2). When BSA is in­
cluded in the dilution medium, this effect is not seen; 0.5% BSA seems 
to be sufficient. We suspect that in the absence of BSA a certain number 
of cells stick to the wall of the polypropylene Eppendorf vessel. This 
effect is also seen when working with glassware. The smaller the absolute 
number of cells, the more pronounced the loss: e.g. in the case of 
1 χ 10 6 cells/ml the loss is 90% and in the case of б χ IO6 cells/ml the 
loss is 55%. 
When enzyme activities are calculated on a per cell basis, it 
becomes evident that BSA also has a protective effect on all enzymes 
tested. This is illustrated in fig. 3. At a final concentration of 0.33% 
BSA(w/v) in the assay mixture maximum levels of activity were reached 
for almost all enzymes. The stabilizing effect was most pronounced in 
the case of ADA(a factor of 4.0; fig. 3). The enzymes are possibly pro­
tected from denaturation during both the lyophilization step and incub­
ation. The benificial effect of BSA is also evident in the results in 
table 4; the range of control values in the presence of BSA is smaller 
as compared with the range observed when no BSA is added. 
The reproducibility and reliability of the present microassays are 
comparable with conventional methods. This is the case not only with ADA 
and PNP(table 2), but also with the other enzymes tested. The kinetic 
analysis of enzyme reactions with only a few thousand cells(present 
study) is as feasible as conventional analysis with 2.5 χ IO5 cells(4) 
or 10 8 cells(3). The range of specific enzyme activities in control 
individuals obtained with this method is comparable with the range of 
conventional enzyme determinations published by others(3,12). 
With the present micromethod a large number of enzyme activities 
can be measured in lymphocytes from a relatively small blood sample(5 to 
10 ml). The methods are especially advantageous when subfractions of 
lymphocytes are to be studied and when the availability of cell material 
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is limited, e.g. in the case of children with lympho-proliferative dis-
orders. 
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ABSTRACT 
The present study was undertaken to investigate purine interconver­
sion enzymes in lymphocyte subfractions in order to characterize purine 
metabolism. Thus we would like to contribute to the understanding of the 
relation between lymphocyte function and purine metabolism. 
Lymphocytes were isolated from peripheral blood by nylon wool fil­
tration and Ficoll-Isopaque density centrifugation. Separation of this 
lymphocyte fraction into a Τ cell and a non-T cell subfraction was 
carried out by Ε-rosette sedimentation. The activities of 6 purine inter-
conversion enzymes(hypoxanthine-guanine phosphoribosyltransferase, 
adenine phosphoribosyltransferase, adenosine deaminase, purine nucleo­
side Phosphorylase, adenosine kinase and purine-5'nucleotidase) in these 
subfractions were assayed by a newly developed micromethod. Along with 
similarities there were also differences found between the enzyme activ­
ities in Τ and non-T lymphocytes. 
Mitogenic stimulation by phytohaemagglutinin and pokeweed mitogen 
was studied on purified lymphocyte fractions as well as on fractions 
contaminated with 20-30% non-lymphoid cells(by omitting the nylon wool 
filtration step from the isolation procedure). Phytohaemagglutinin had 
hardly any effect on the enzyme activities of both the pure lymphocyte 
fractions and the contaminated fractions. Pokeweed mitogen stimulation 
of contaminated lymphocyte fractions had a marked effect on the enzyme 
activities studied(e.g. up to 5 times for hypoxanthine-guanine phospho­
ribosyltransferase). The effect of pokeweed mitogen on pure fractions 
was less pronounced. 
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INTRODUCTION 
Previously described micromethods for the determination of purine 
interconversion enzyme activitiesin lymphocytes(11) enabled us to analyse 
purine metabolism systematically in lymphocyte subfractions using a rel­
atively small number of cells(500 to 5,000). A relation between purine 
interconversion defects and immune dysfunctions has been established(3, 
4,5). The mechanism by which adenosine deaminase(ADA) deficiency leads 
to impairment of the В and Τ cell and purine nucleoside Phosphorylase 
(PNP) deficiency leads to Τ cell dysfunction is not yet completely under­
stood. A better understanding of purine interconversions in В and Τ cell 
subfractions might help to obtain a better view on В or Τ cell specif­
icity in these immune diseases. One of the possibilities to achieve this 
might be a systematic enzymological analysis of purine metabolism in Τ 
and non-T lymphocytes. Nine purine enzyme activities were measured in Τ 
and non-T lymphocyte subpopulations using 500 to 5,000 cells per assay. 
MATERIALS AND METHODS 
Isolation of Lymphocyte Subfractions 
Lymphocytes were isolated from peripheral blood by nylon wool fil­
tration and Ficoll-Isopaque density centrifugation(2,ll) and diluted to 
2 χ 106 cells/ml. Sheep erythrocytes were treated with neuraminidase 
(Behringwerke) and diluted in Earle's balanced salt solution(BSS) to 
1 χ 108 cells/ml. Equal volumes of lymphocytes and neuraminidase treated 
sheep erythrocytes were mixed and incubated at 37° C; after 15 min. the 
cells were spun down and Ε-rosettes were allowed to form(l hour, 0° C). 
After a second Ficoll-Isopaque density centrifugation the non-rosetted 
non-T cells were collected from the interphase(7). The rosetted Τ cells 
were obtained from the pellet, after lyzing the sheep erythrocytes with 
a solution containing 155 mM NH.C1, 10 mM KHC03 and 0.1 mM disodium EDTA 
(pH 7.4). 
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"Micro" Assays with Lymphocytes 
Enzyme incubations were carried out according to Van Laarhoven et 
al.(11). The following enzymes were assayed: ADA with adenosine and 
deoxyadenosine as a substrate, hypoxanthine-guanine phosphoribosyltrans-
ferase(HGPRT) with both hypoxanthine and guanine as a substrate, adenine 
phosphoribosyltransferase(APRT), adenosine kinase(AK) and purine-5'nuc-
leotidase(5'NT) as a substrate. 
Mitogenic Stimulation of Unfractionated Lymphocyte Preparations 
The isolated lymphocytes were resuspended in tris-buffered minimal 
essential medium(MEM, Gibco F-14; pH 7.4) containing 20% human A serum. 
After dilution of the cells to a concentration of 3 χ IO5 cells/ml, 
portions of 1 ml each were divided into sterile tubes(Nunc nr. 1090). To 
test phytohaemagglutinin(PHA) stimulation, an equal number of tubes was 
cultured for 3 days at 37° С with and without addition of 0.5 μΐ PHA-P 
(Difco 3110-57). In similar experiments 25 μΐ/ml pokeweed mitogen(PWM; 
Gibco) was added to a final concentration of 25 pgr/ml. Cells were cul­
tured for 7 days at 37° С Twentyfour hours before harvesting 0.5 yCi/ml 
3H-thymidine(specific activity 24 Ci/mmol; Radiochemical Centre Amersham, 
UK) was added to the cultures. The cells were harvested by filtration on 
glass fiber filters (Mi H i pore AP 2002500). After incubation of the 
filters(J hour, 20° C) in liquid scintillation counting vials with 0.5 ml 
NCS tissue solubilizer(Radiochemical Centre Amersham, UK) diluted(l:3) 
with counting fluid(MI 92, Packard), 10 ml MI 92 was added, containing 1% 
acetic acid(v/v). For the enzymatic assays the cells were collected after 
3 days(PHA) and 7 days(PWM) by centrifugation(600 g, 10 min.), resuspen­
ded in 0.9% NaCl(w/v) and lyophilized as described above. 
RESULTS AND DISCUSSION 
The activities of HGPRT and PNP in Τ and non-T subfractions were in 
the same range(table 1). Mean activities of APRT, AK and 5'NT were higher 
in Τ cells as compared to non-T cells. One enzyme was more active in 
non-T than in Τ cells: ADA. This was found with both deoxyadenosine and 
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Table 1 : Purine Interconversion Enzymes in Lymphocyte Subfractions 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
AK 
5'NT 
Substrate 
hypoxanthine 
guanine 
adenine 
adenosine 
deoxyadenosine 
hypoxanthine 
inosine 
adenosine 
AMP 
Τ fraction 
3.24 
5.ΘΘ 
9.82 
61.67 
35.53 
74.45 
15.56 
0.8Θ 
12.31 
± 1.01 
± 2.28 
±5.88 
± 27.73 
± 13.18 
± 43.44 
± 4.60 
± 0.63 
± 7.08 
non-T 
3.14 
5.66 
4.48 
91.62 
63.72 
66.89 
12.59 
0.47 
3.29 
fraction 
±1.68 
± 2.54 
± 2.54 
± 49.01 
± 38.65 
± 34.21 
± 4.24 
± 0.31 
± 2.46 
η 
10 
10 
10 
10 
9 
10 
10 
8 
7 
Activities±standard deviation, calculated from a group of healthy 
individuals and expressed as 10~9 moles product formed/106 lymphocytes 
.hour. 
adenosine as a substrate(table 1). These latter findings are different 
from those reported by Huang et al.(6) who found that ADA activities of 
complement-receptor negative(T) cells were approximately 10 times higher 
than those of compiement-recetor positive(B) cells. Differences in ADA 
activity in В and Τ cells have also been reported by several other groups 
(9,10). Purine nucleoside Phosphorylase was shown to display similar 
activities in Τ and non-T cells. A number of investigators however, has 
reported that PNP activity is higher in Τ cells. PNP has even been sug­
gested as a Τ cell marker on the basis of histochemical findings(l). 
These inconsistencies might be due to the differences of isolation pro­
cedures used. Our isolation procedure is based on the Ε-rosette forming 
capacity. Other workers made use of other immunological markers such as 
complement-receptors(6). Moreover, our subfractions are hardly contamin-
ated(<3%) with monocytes or granulocytes. Such data are not available 
from other reports(l,6). Tritsch and Minowada(9) compared leukemic Τ 
cell lines with normal В cell lines and reported higher ADA activities 
in malignant Τ cell lines. To our knowledge there are no reports on 
HGPRT, APRT, AK and 5'NT activities in lymphocyte subfractions. 
As can be seen in table 1 there exists a rather wide range of enzyme 
activities in healthy controls. This is due to individual variation and 
not to methodological errors(ll). In addition, in a given individual 
enzyme activity ratios are constant, e.g. PNP activities are consistently 
higher than APRT activities(table 1). 
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Table 2: Effect of Culture Time on Purine Interconversion Enzymes in 
Unfractionated Lymphocytes in the Absence of Mitogens 
Enzyme 
HGPRT 
ADA 
PNP* 
5'NT 
100% 
100% 
100% 
100% 
P1 
0 
(4.5) 3 
(99) 
(12. 
(19. 
,θ) 
• 7) 
days 
100% 
100% 
100% 
100% 
C 2 
Culture Time 
(5.7) 
(88] 
(15. 
(20, 
I 
.7) 
.0) 
3 
Ρ 
68% 
70% 
95% 
54% 
day s 
С 
83% 
74% 
76% 
77% 
7 
Ρ 
39% 
33% 
77% 
91% 
days 
С 
50% 
33% 
67% 
112% 
methods(contamination with non-lymphoid leukocytes less than 3%). 
2
"Contaminated" fractions(C) are isolated in the same way as "pure" 
fractions but the nylon wool filtration step is omitted(contamination: 
2 to 3% monocytes, 20 to 30% granulocytes). Values in parentheses 
represent the absolute enzyme activities in 10~ moles/10 cells.hour. 
""As a substrate for the PNP assay, 8- V-inosine was used. 
Mitogenic Stimulation of Unfractionated Lymphocytes 
In order to test the effect of the mitogens PHA and PWM on unfrac­
tionated lymphocytes, two different lymphocyte preparations were 
employed. A "pure" fraction was obtained by the complete procedure as 
described under materials and methods. A "contaminated" fraction was 
obtained by following the same procedure, but omitting the nylon wool 
filtration step. The "pure" preparation contained more than 97% lympho­
cytes, 1% monocytes and 1% granulocytes(according to Hemalog D determin­
ations). The "contaminated" fraction contained 72% lymphocytes, 2% mono­
cytes and 25% granulocytes. 
In order to be able to assess the real stimulation index of purine 
enzyme activities an experiment was performed in which, in the absence 
of mitogens, the activity of HGPRT, ADA, PNP, and 5'NT was tested after 
3 days(culture time for PHA stimulation test) and after 7 days(culture 
time for PWM stimulation test). Three out of four enzymes tested(HGPRT, 
ADA and PNP) showed a decrease in activity during cui turing, whereas one 
enzyme(5'NT) displayed a lower activity after 3 days, but after 7 days 
the activities were again around the original level. It was concluded 
that the results of the PHA stimulation experiments should be related 
to the control values obtained after 3 days of cui turing in the absence 
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Table 3: Effect of Mitogens on 3H-Thymidine Incorporation and on 
Purine Interconversion Enzymes in Unfractionated Lymphocytes 
3H-Thymidine 
Incorporation Index 
HGPRT 
ADA 
ΡΝΡ
1
* 
5'NT 
PHA(3 
P1 
103 
1.3 
1.0 
1.1 
1.2 
days) 
C 2 
120 
2.5 
1.0 
1.3 
1.0 
PWM(7 
Ρ 
25 
3.6 
2.4 
1.5 
1.1 
days) 
С 
25 
4.6 
2.3 
1.6 
3.4 
"Pure" fractions. "Contaminated" fractions. 3The values given repre­
sent the ratio between the activity measured with and without mitogen; 
for PHA stimulation the values after 3 days of culturing were used, 
and for PWM stimulation the values after 7 days. ^As a substrate for 
the PNP assay, 8-1^C-inosine was used. 
of this mitogen. The same was done in the PWM experiments(culturing time 
7 days). 
The "pure" lymphocytes were hardly stimulated by PHA as judged from 
the 3H-thymidine incorporation. The response of the "contaminated" 
lymphocytes to PHA was considerably higher(Table 3). PWM stimulated both 
the "pure" and the "contaminated" cells to the same extent. The activit­
ies of the purine enzymes tested remained unchanged after PHA stimula­
tion in both lymphocyte preparations with the possible exception of 
HGPRT in the "contaminated" lymphocytes. The HGPRT activities of "pure" 
and "contaminated" lymphocytes after 7 days of PWM stimulation were 
clearly increased. A less pronounced rise was observed for ADA, whereas 
PNP activity did not show significant stimulation. The marked rise after 
PWM stimulation of 5'NT activity in "contaminated" lymphocytes as com­
pared to "pure" cells was ascribed to contaminating cells, especially 
granulocytes. Our results concerning the effect of culture time on 
lymphocytic HGPRT, PNP, ADA and 5'NT activities in the absence of the 
mitogens are essentially in agreement with data reported by Raivio and 
Hovi(8) on Τ cell enriched lymphocyte preparations. On the other hand, 
our data on ADA after PHA stimulation do not show the increase in 
activity as described by the latter workers. It should be emphasized 
however, that the present study was carried out under other experimental 
49 
conditions. This makes comparison with other reports(6,9,10) difficult. 
On the basis of findings with PHA stimulated intact lymphocytes(8) in-
creased levels of purine phosphoribosyltransferase activities might be 
expected. This is indeed the case with HGPRT in the "contaminated" cells, 
but not in "pure" cells. As judged from the 3H-thymidine incorporation, 
the "contaminated" cell population was synthetizing DNA more actively 
than the "pure" lymphocytes after PHA stimulation. Therefore, it seems 
that the rate of purine reutilization is associated with the rate of 
DNA synthesis. This phenomenon is also observed in PWM stimulated "pure" 
and "contaminated" cells. Although satisfying explanations for our 
findings cannot yet be given, the differential responses to PHA and PWM 
seem to point to differences in purine metabolism in PHA and PWM 
responsive cells. 
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ABSTRACT 
Human peripheral blood lymphocytes(PBL) were prepared by depleting 
peripheral blood mononuclear cells(PBMC) of adherent cells(AC) and 
separated in Τ and В cell enriched fractions. Τ cells were subdivided 
in Τγ and Τ-Τγ cells. Eight enzymes involved in purine metabolism were 
assayed in the fractions mentioned above. No significant differences in 
enzyme activities were noticed between the PBMC and the AC depleted PBL 
fractions. In the В cell enriched fraction the activities of hypoxan-
thine-guanine phosphoribosyltransferase(HGPRT), purine nucleoside phos-
phorylase(PNP), ecto-5'nucleotidase(5'NT), adenosine kinase(AK), AMP 
deaminase(AMPD) and adenylate kinase(AdKin) were found to be at least 
twice as high as in the Τ cell enriched fraction. Strong indications 
were obtained that platelet contamination in some of the isolated 
fractions might at least in part influence the noted differences in 
enzyme activities. When comparing Τγ and Τ-Τγ cells, higher specific 
activities of PNP and adenine phosphoribosyltransferase(APRT) were found 
in Τ-Τγ cells, whereas AdKin activity was found to be higher in the Τγ 
fraction. Due to the differences in enzymatic make-up Τγ cells might be 
more sensitive to purine nucleoside intoxication than Τ-Τγ cells. 
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INTRODUCTION 
In the last decade it has become clear, that a number of immunol­
ogical diseases are related to imbalances of purine metabolism in 
lymphocyte subpopulations(7,12,26). Information regarding the enzymatic 
make-up and metabolic characteristics of lymphocyte subpcpulations, both 
in healthy individuals and in patients, might contribute to a better 
diagnosis of immunological diseases and be of importance for the devel­
opment of immunoregulatory drugs. Not only Τ and В cell subpopulations, 
but also Τ and В cell subsets should be included in such studies. 
Different activity levels of enzymes involved in purine metabolism 
have been described in subpopulations of human peripheral blood lympho­
cytes^,10,14,17,21,22). With respect to Τ and В lymphocytes conflicting 
data were reported on adenosine deaminase(ADA; E.C. 3.5.4.4), purine 
nucleoside phosphorylase(PNP; E.C. 2.4.2.1) and ecto-5'nucleotidase(5'NT; 
E.C. 3.1.3.5) activities. To our knowledge no systematic studies on 
these enzyme activities in Τ cell subsets have been published. 
In the present study a recently described micromethod(23) has been 
used to investigate the activities of purine interconversion enzymes 
(fig. 1) in various human peripheral blood lymphocyte subpopulations, 
including Τ and В cells and the Τ cell subset bearing surface receptors 
for the Fc portion of IgG(Ty cells). These lymphocyte fractions have 
been assayed for ADA, PNP, 5'NT, hypoxanthine-guanine phosphoribosyl-
transferase(HGPRT; E.C. 2.4.2.8), adenine phosphoribosyltransferase 
(APRT; E.C. 2.4.2.7), adenosine kinase(AK; E.C. 2.7.1.20), AMP deaminase 
(AMPD; E.C. 3.5.4.6) and adenylate kinase(AdKin; E.C. 2.7.4.3) activities. 
MATERIALS AND METHODS 
Lymphocyte Preparation 
Peripheral blood mononuclear cells(PBMC) from 5 healthy volunteers 
were prepared by centrifugation of heparinized blood, diluted with two 
volumes of Hank's balanced salt solution, on Ficoll-Metrizoate(1.077 
gr/ml; 21). For removal of adherent cells(AC), PBMC were resuspended in 
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in Hepes buffered RPMI 1640(Flow Labs., Rockville, MD) supplemented with 
20%(v/v) foetal calf serum(FCS; Microbiological Ass., Bethesda, MD) at a 
cellular concentration of 2 χ IO7 cells/ml. This suspension was incubated 
in a plastic Petri dish(Falcon 3045) for 1 hour at 37° C(6 ml/dish). 
Peripheral blood lymphocytes(PBL = P6MC minus AC) were separated 
in Τ and В lymphocyte fractions by density sedimentation of spontaneous 
rosettes formed by Τ lymphocytes and sheep erythrocytes treated with 
2-amino-ethyl-isothiouronium bromide(AET; 18). Τ cells were further 
separated into Τγ enriched and Τγ depleted(T-Ty) fractions according to 
Moretta et al.(13) by rosetting with ox erythrocytes coated with rabbit 
anti-bovine eryhtrocytes IgG(Nordic Lab.). Contaminating erythrocytes 
in each lymphocyte preparation were lyzed by incubation with 0.16 M 
ammonium chloride in a 0.01 M potassium bicarbonate, 0.1 mM EDTA buffer. 
Identification of monocytes and polynuclear cells was performed by the 
peroxidase reaction(16). The В cells were identified by membrane 
fluorescence(16), employing FITC/swine anti-human immunoglobulin serum 
(Nordic Lab.). Τ cells were counted as cells forming rosettes with AET 
treated sheep erythrocytes. 
Enzyme Assays 
Enzyme assays were carried out essentially according to a previous­
ly described radiochemical micromethod(23). HGPRT and APRT were assayed 
by measuring the conversion of 1 ЦС labeled hypoxanthine and adenine to 
the corresponding mononucleotides IMP and AMP, respectively. ADA activ­
ity was assayed by following the deamination of adenosine to inosine. 
PNP was assayed in the anabolic reaction: from hypoxanthine to inosine. 
AK activity was determined by measuring the conversion of adenosine to 
AMP. The a,ß-methyleneadenosine-5'diphosphate(A0PCP) inhibitable degrad-
ation of AMP to adenosine was taken as 5'NT activity(5). AMPD was assayed 
by measuring the conversion of AMP to IMP(23). AdKin was assayed accor-
ding to Leech and Newsholme(ll) adapting their system to our micromethod. 
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Table 1 : Characterization of the Lymphocyte Preparations 
Marker 
E
aet 
slg6 
Peroxidase 
PBMC1, 
total 
82.4 ± 2.7 
14.4 ± 5.3 
13.5 ± 1.0 
PBL2, AC 3 
depleted 
81.2 + 2.4 
11.3 ± 3.4 
4.0 ± 1.4 
Τ 
94.0 ± 1.9 
0.2 ± 0.4 
0.5 ± 0.6 
В 
NT5 
78.8 ± 5.4 
6.5 ± 2.5 
The figures indicate the percentage of cells(mean ± s.d.; n=5) from a 
particular fraction possessing the investigated marker. :Peripheral 
blood mononuclear cells. Peripheral blood lymphocytes. Adherent 
cells. ''Cells rosetting with АЕГГ treated sheep erythrocytes. 5Not 
tested. 6Surface immunoglobulin bearing cells. Peroxidase positive 
cells. 
Statistical Analysis 
The differences in enzymatic activities between the various cell 
populations were analyzed by a two-tailed t-test of Student. 
RESULTS 
Characterization of the Lymphocyte Fractions 
The isolated PBMC from 5 healthy donors contained 82.4% E . pos­
itive cells, 14.4% slg bearing cells and 13.5% peroxidase positive cells 
(mean values; table 1). After adherence of this cell population to 
plastic Petri dishes the number of E . and slg positive cells hardly 
showed any change, whereas the percentage of peroxidase stained cells 
significantly decreased. These AC depleted PBL were used for the separ­
ation of Τ and В subpopulations. After E . rosette depletion the Τ cell 
pellet contained 94.0% E . positive cells, but virtually no slg bearing 
cells and no peroxidase stained cells. The Τ depleted preparations con­
tained 78.8% slg bearing cells and 6.5% peroxidase positive cells 
(table 1). 
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g u a n i n e - ^ hypoxanthine adenine 
Figure 1: A simplified scheme of purine interconversion pathways. List 
of the enzymes and their abbreviations: ADA-adenosine deaminase; AdKin-
adenylate kinase; AK-adenosine kinase; AMPD-AMP deaminase; APRT-adenine 
phosphoribosyltransferase ; HGPRT-hypoxanthine-guanine phosphoribosyl-
transferase; 5'NT-purine-5'nucleotidase; PNP-purine nucleoside Phosphor­
ylase. 
Enzyme Activities 
The results of the enzyme determinations in the various subfractions 
are summarized in table 2. No statistically significant differences of 
the specific activities were noticed between the unfractionated PBMC and 
the AC depleted preparations of PBL(table 2). 
When comparing the Τ and В cell subpopulations a significant dif­
ference in the activities of HGPRT(p<0.01) and 5'NT(p<0.05) was seen. 
The activities of these enzymes were twice as high in the В cell popul­
ation as compared to the Τ cell population. The differences in activities 
of PNP(p<0.001), AK(p<0.01), AMPD(p<0.02) and AdKin(p<0.001) between the 
Τ and В cell subpopulations were also found to be significant. In В cell 
preparations the activities were about a threefold higher when compared 
to Τ cells. 
In the Τ cell subsets, Τγ and Τ-Τγ, no significant differences could 
be found in HGPRT, ADA, 5'NT, AdKin and AMPD activities. A significant 
difference however, was found in the PNP activity in these subsets. PNP 
activity was 43% higher in Τ-Τγ cells than it was in Τγ cells(p<0.05). 
APRT activity was found to be lb% higher in Τ-Τγ cells than in Τγ cells 
(p<0.05). AK activity was twice as high in Τ-Τγ cells as compared to Τγ 
cells(p<0.02). On the other hand, though not significant(p>0.05), AdKin 
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was nearly twice as high in the Τγ cells as in the Τ-Τγ cells. 
DISCUSSION 
The present results show no significant differences in enzyme ac­
tivity levels of unfractionated PBMC and AC depleted PBL(table 2). A 
possible explanation for these findings is that the enzymatic activities 
in the peroxidase positive cells do not differ much from those of 
purified lymphocytes(4,15). Another, more likely, possibility is that, due 
to the relatively small contamination of peroxidase positive cells, no 
significant changes of enzymatic activities are seen after removal of 
these eel Is(mainly monocytes). According to Edwards et al.(6) the 5'NT 
activity in PBL is 21.9 10"9 moles/106 cells.hour. In peripheral mono­
cytes 5'NT activity is 4.2 10"9 moles/106 cells.hour. Extrapolating 
these data to our cell preparations, this would mean that our AC contam­
inated PBMC fraction would have a 5'NT activity of 19.5 10"9 moles/106 
eel Is.hour. Our AC depleted PBL fraction would have a 5'NT activity of 
21.2 10"9 moles/106 cells.hour. Such differences are not readily 
detected with the present assay methods. 
Our data on 5'NT activities in В and Τ enriched fractions are con­
sistent with some earlier reports(17,20) and at variance with others 
including ours(6,22). In our earlier studies different methods were used 
both for the lymphocyte isolation and for the 5'NT measurement. In the 
present study we used heparin as anti-coagulant and the AC were removed 
by adherence to plastic; in our previous work lymphocytes were purified 
from defibrinated blood and were filtered through a nylon wool column 
(3,22). The present procedure led to cellular preparations contaminated 
with platelets, whereas the other method led to platelet-free prepara­
tions. Still more relevant is our observation that В lymphocyte prep­
arations obtained after rosette forming cell depletion were much more 
enriched in platelets than the Τ lymphocytes. When comparing the enzy­
matic activities between two lymphocyte preparations, it is essential 
to assess their platelet contamination since thrombocytes show consider­
able PNP and AdKin activities. In earlier AC depleted PBL preparations 
that were essentially free of platelets(as a consequence of defibrination 
with glass beads) mean PNP activity was 209 10"9 moles/106 cells.hour. 
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AdKin activity was 265 IO"9 moles/106 cells.hour(24). In table 2(pla-
telet contaminated, AC depleted PBL) these activities were 390 and 734 
10"9 moles/106 eel Is.hour, respectively. The other enzymes showed com­
parable activities in platelet free and platelet contaminated PBL(24). 
This leads to the conclusion that the higher AdKin and PNP activ­
ities in the В cell fractions, at least in part might be ascribed to 
the platelet contamination. With respect to the other enzymes, the dif­
ferences in activity levels do not seem to be due to contaminating cells. 
From the foregoing it is clear that when comparing enzymatic activities 
in lymphoid cell subfractions it is necessary to carefully characterize 
the various fractions, in order to account for the different isolation 
procedures. 
Differences of ADA activity in Τ and В lymphocytes do not seem to 
be significant(14,21,22). Our present data confirm these findings. Only 
Huang et al.(10) have found a considerable higher ADA activity in cells 
bearing C 3 receptors(B cells) as compared to cells which lacked this 
receptor(T cells). 
The statistically significant differences found in APRT, PNP and 
AK activities in Τγ and Τ-Τγ cells cannot be obscured by the presence 
of platelets, since the latter are removed in the first Ε-rosette deple­
tion step. The lower activity of PNP in Τγ cells seems inconsistent with 
the data of Levinson et al. (12). These authors found in Τ lymphocytes 
from patients with systemic lupus erythematosus(SLE) a decreased activity 
of PNP as compared to Τ cells from control individuals. In SLE decreased 
numbers of Τ suppressor cells(Ty cells) have been reported(8). From our 
finding, that Τγ cells have lower PNP activity than Τ-Τγ cells, it would 
be expected that in patients with relatively few Τγ cells, the PNP 
activity in total Τ lymphocytes should increase. 
The present results on Τγ and Τ-Τγ cells suggest that Τγ cells might 
be more sensitive to purine nucleoside intoxication as compared to the 
Τ-Τγ cells. As a consequence of a higher capacity for nucleotide tri­
phosphate synthesis(AdKin) and a lower breakdown capacity for nucleotides 
(5'NT), deoxyribonucleotides may more easily be accumulated. Deoxyribo-
nucleotides(e.g. deoxyATP) are well known inhibitors of ribonucleotide 
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reductase, and may thus lead to impairment of DNA synthesis(19). This 
selective sensitivity was illustrated in experiments where cells were 
stimulated with concanavalin A and phytohaemagglutinin under ADA defic­
ient conditions, The phytohaemagglutinin stimulated cells(mainly Τμ 
cells; 9) were much less sensitive to adenosine and deoxyadenosine in­
toxication than concanavalin A stimulated cells(both Τμ as well as Τγ 
cells; 9,25). 
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ABSTRACT 
The purpose of the present study was to investigate whether certain 
purine enzymes might be useful as differentiation markers in acute 
lymphoblastic leukemia. A micromethod has been developed for radiochem­
ical assays of adenosine deaminase, purine nucleoside Phosphorylase and 
5'nucleotidase. In Τ type acute lymphoblastic leukemia hardly detectable 
levels of 5'nucleotidase were consistently observed in lymphoid cells 
derived from bone marrow. Adenosine deaminase showed very high activ­
ities as compared to normal Τ lymphocytes, whereas purine nucleoside 
Phosphorylase levels were significantly lower than those in normal cells. 
In nonBnonT type acute lymphoblastic leukemia no deviant 5'nucleotidase 
activities were observed. Adenosine deaminase activity however, was 
three-fold higher as compared to control values. The enzymes studied are 
indeed useful as biochemical markers. In addition, attractive possibil­
ities for enzyme directed chemotherapy might be opened up by taking 
advantage of the differences in enzymatic make-up in various leukemic 
and normal cells. 
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INTRODUCTION 
Enzymes of purine nucleotide synthesis in lymphoid cells from 
patients with acute lymphoblastic leukemia(ALL) have been studied by a 
number of investigators. Scholar and Calabresi(10) reported that activ­
ities of several enzymes of purine metabolism in leukemic lymphoid cells 
were changed as compared to activities in normal lymphocytes. 
Elevated levels of adenosine deaminase(ADA; E.C. 3.5.4.4) were found 
in lymphoid cells from patients with ALL. In T-ALL ADA activities were 
found to be seven-fold(ll) or even fourty seven-fold(5) higher than in 
normal lymphocytes. In contrast, ADA levels in nonBnonT-ALL were only 
slightly elevated, two to four-fold(5). 
Purine nucleoside phosphorylase(PNP; E.C. 2.4.2.1) was reported to 
be decreased only in T-ALL(2). In normal mononuclear cells the median 
activity was 79 units, whereas in T-ALL cells the median was significant­
ly lower(38 units). 
In T-ALL an inverse linear relation has been reported between 
5'nucleotidase(5'NT; E.C. 3.1.3.5) activity and the number of E-rosette 
positive cells. The mean 5'NT activity in Τ lymphocytes was significantly 
lower as compared to normal lymphocytes and null lymphoblasts(9). 
A recently described micromethod(13) enabled us to assay nine dif­
ferent enzyme activities of the purine interconversion pathway in 
lymphoid cells from patients with ALL. Activities of ADA, PNP, assayed 
in the anabolic direction, 5'NT assayed both with intact cells(ecto-
enzyme) and with lyophilized cells(total 5'NT activity, hypoxanthine-
guanine phosphoribosyltransferase(HGPRT; E.C. 2.4.2.8), adenine phospho-
ribosyltransferase(APRT; E.C. 2.4.2.7), adenosine kinase(AK; E.C. 
2.7.1.20), adenylate kinase(AdKin; E.C. 2.7.4.3) and AMP deaminase(AMPD; 
E.C. 3.5.4.6) were assayed in lymphoid cells from 20 controls, 24 
patients with nonBnonT-ALL and 12 patients with T-ALL. 
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MATERIALS AND METHODS 
Patients 
At the time of diagnosis, 36 chidren with ALL(aged between 1 and 14 
years) were investigated. In all cases the diagnosis was obtained on 
bone marrow aspirates and confirmed at the Reference Centre of the Dutch 
Working Group on Leukemia in Children(SNWLK), The Hague, The Netherlands. 
Immunological classification of ALL 
The immunological classification was performed only in almost com­
pletely homogeneous(>95%) leukemic cell populations from bone marrow 
and/or peripheral blood. The leukemic cells were isolated by the Fi col 1-
Isopaque gradient centrifugation method as described previously(l). Sheep 
erythrocyte(E) rosettes were used as a standard Τ cell marker(l). If more 
than 20% of the leukemic cell population formed Ε-rosettes at 4° C, the 
diagnosis Τ cell-ALL was made. As a criterion for В cell-ALL the presence 
of more than 20% surface immunoglobulin(slg) bearing cells was used. 
Immunofluorescence studies were performed using tetramethyl rhodamine 
isothiocyanate(TRITC)-labeled anti-human Ig(1 ). Leukemic cell populations 
that did not meet the criteria mentioned above were classified as 
nonBnonT-ALL. As antisera against the common-ALL antigen could not yet 
be used in all cases studied, the last subgroup of ALL could not be sub­
divided^) into "common-ALL" and "unclassified-ALL" according to the 
Greaves' nomenclature^). 
Enzyme Assays 
The nine enzymes indicated previously, were assayed with radioactive 
substrates, using 1,000 to 6,000 cells per assay, according to the micro-
method published earl i er(13). AdKin was assayed according to Leech and 
Newsholme(8) adapting their system to our micromethod. Lymphoid cells 
from controls were isolated from peripheral blood(13), whereas in the 
case of patients the cells were taken from peripheral blood and/or bone 
marrow(see Immunological Classification). 
68 
Table 1 : Purine Enzymes in Lymphoid Cells from Controls and ALL-Patients 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
ecto-5'NT 
AK 
AMPD 
AdKin 
Controls 
(n=20) 
6.9 
13.6 
134 
209 
18.4 
7.6 
7.9 
267 
265 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
3.31 
4.2 
46 
70 
11.7 
3.0 
3.6 
106 
183 
nonBnonT-ALL 
(n=24) 
13.8 
10.2 
491 
200 
25.9 
8.3 
6.8 
314 
791 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
7.1 
5.9 
333 
97 
23.1 
7.7 
4.4 
347 
411 
T-ALL 
(n=12) 
11.4 
6.9 
1069 
124 
1.0 
0.8 
6.3 
151 
283 
± 5.1 
± 2.6 
± 467 
± 69 
± 1.8 
± 0.7 
± 2.6 
± 120 
± 230 
Mean specific activities ± standard deviations in 10 9 moles/106 cells, 
hour. 
Statistical Evaluation 
Statistical evaluation was performed using the two tailed Student 
t-test for grouped values with separate variance estimate. 
RESULTS 
In table 1 the activities of nine different enzymes involved in 
Table 2: Statistical Evaluation of Purine Enzyme Activities in Control 
Lymphocytes vs. Leukemic Cells 
Enzyme nonBnonT-ALL T-ALL 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
ecto-5'NT 
AK 
AMPD 
AdKin 
++
1(p<0.001) 
3(p<0.05) 
(p<0.001) 
5 
+ 
+ (p<0.01) 
f(p<0.02) 
+ +
 1,(p<0.001) 
t + (p<0.001) 
+ (p<0.01) 
++ (p<0.001) 
++ (p<0.001) 
n.s. 
+ (p<0.02) 
n.s. 
++Highly significant increased activity in leukemic cells. -t-Signific-
antly increased activity in leukemic cells. Hsignificantly decreased 
activity in leukemic cells. "Ч+НідЫу significant decreased activity in 
leukemic cells, n.s. No significant difference. 
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purine interconversions are shown. Lymphoid cells isolated from normal 
healthy controls, patients with nonBnonT-ALL and from patients with 
T-ALL were used. Statistical evaluation of these data revealed that when 
comparing enzyme activities in control lymphoid cells with enzyme activ­
ities in nonBnonT-ALL lymphoid cells, HGPRT, ADA and AdKin values were 
higher in nonBnonT-ALL than in controls, whereas APRT showed a lower 
activity(table 2). 
Comparing control values with T-ALL values, significantly lower 
enzyme activities of APRT, PNP, 5'NT, ecto-5'NT and AMPD were observed 
in T-ALL lymphoid eel Is(tabi e 2). On the other hand HGPRT and ADA activ­
ities were higher in T-ALL(table 2). 
The activity of APRT, PNP, 5'NT, ecto-5'NT and AdKin were signif­
icantly lower in T-ALL cells as compared to nonBnonT-ALL cells(table 3). 
Only ADA activities were higher in T-ALL than in nonBnonT-ALL. 
DISCUSSION 
The reported data on ADA(5,12), PNP(2) and 5'NT(9) in acute lympho­
blastic leukemia are confirmed in this study. ADA is clearly elevated 
in T-ALL, whereas in nonBnonT-ALL intermediate values between T-ALL and 
control enzyme activities are found. PNP is significantly decreased only 
in T-ALL. 5'NT activity assayed in lyophil i zed cells, or in intact cells 
Table 3: Statistical Evaluation of Purine Enzyme Activities in Leukemic 
Cells from T-ALL vs. nonBnonT-ALL. 
HGPRT n.s.1 
APRT +2(p<0.05) 
ADA t+3(p<0.001) 
PNP + (p<0.02) 
5'NT 4· + " (p<0.001) 
ecto-5'NT 4·+ (p<0.001) 
AK n.s. 
AMPD n.s. 
AdKin 4· (p<0.02) 
n.s. No significant difference. 2+Significantly decreased in T-ALL. 
3t+Highly significa 
decreased in T-ALL. 
nt increased in T-ALL. "Ч+Highly significant 
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as an ecto-enzyme,was hardly detectable in cells from T-ALL patients. 
The elevated HGPRT activity and the decreased APRT activity in ALL 
have not been reported earlier according to our knowledge. The increased 
AdKin activity in nonBnonT-ALL is consistent with other data obtained by 
our group. It was found that the intracellular concentration of ATP was 
significantly elevated in cells from nonBnonT-ALL patients(6). 
Data obtained in our laboratory and from others show that ADA, PNP 
and 5'NT activities fluctuate in several stages of lymphoid cell differ­
entiation and maturation(3,4). Human thymocytes, immunologically charac­
terized as young lymphoid cells, showed high ADA and low 5'NT activities. 
The ADA/PNP activity ratio in these cells was much higher than in 
peripheral blood lymphocytes(14). One might suspect that the differences 
in enzymatic activities in the subclasses of the leukemias mentioned 
reflect the stage of maturation in which the cells have been arrested, 
rather than an alteration caused by the leukemic transformation itself. 
The most suitable enzymatic parameter to discriminate between 
normal lymphocytes on the one hand and leukemic lymphoblasts on the 
other hand seems to be the ADA activity. A clear cut discrimination 
between T-ALL and nonBnonT-ALL is provided by 5'NT(lower inT-ALL), and 
AdKin(also lower inT-ALL). 
Due to these differences in enzymatic make-up one might speculate 
on employing these differences in the design of a more selective 
"enzyme directed chemotherapy". Theoretically, 6-mercaptopurine(6MP), 
a widely used anti-leukemic analogue of hypoxanthine, might be metab­
olized more effectively to its toxic nucleotide form by ALL cells than 
by normal lymphoid cells, since HGPRT activities are found to be lower 
in the latter(tables 1 and 2). Another illustration is the inhibition 
of ADA by analogues of adenosine, such as coformycin. Accumulation of 
nucleosides(e.g. deoxyadenosine) might be more toxic to Τ leukemic cells 
than to normal lymphocytes and nonBnonT leukemic cells. Phosphorylation 
of deoxyadenosine to deoxyAMP and susequently to deoxyATP can occur in 
non-leukemic and in leukemic cells to a comparable extent. However, 
since leukemic Τ cells hardly possess the capacity to dephosphorylate 
toxic deoxyribonucleotides(low 5'NT) this might lead to inhibition by 
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deoxyATP of ribonucleotide reductase and thus impairment of DNA 
synthesis(ll). 
The data presented in this paper suggest that enzymes of purine 
metabolism, -can be used as additional diagnostic tools in acute lympho­
blastic leukemia, 
-might be interesting as markers for lymphoid cell differen­
tiation, 
-might be suitable targets for enzyme directed chemotherapy. 
Further studies to verify these statements are underway in our laboratory. 
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ABSTRACT 
Adenosine deaminase(ADA), purine nucleoside phosphorylase(PNP), 
5'nucleotidase(5'NT), ecto-5'NT, hypoxanthine-guanine phosphoribosyl-
transferase(HGPRT), adenine phosphoribosyltransferase(APRT), adenosine 
kinase(AK), AMP deaminase(AMPD) and adenylate kinase(AdKin) activities 
were assayed in leukemic cells from bone marrow and/or peripheral blood 
of 43 newly diagnosed children with acute lymphoblastic leukemia(ALL). 
These enzyme activities have been investigated in relation to some 
other immunological markers. ADA activity was higher in Ε-rosette pos­
itive leukemia(E+ ALL), while HGPRT, APRT, PNP, 5'NT, ecto-5'NT and 
AdKin activities were found to be lower in E ALL as compared to E ALL. 
In common ALL(cALL) antigen positive leukemia, mean ADA activity was 
significantly lower as compared to cALL" leukemia, whereas PNP, 5'NT, 
ecto-5'NT and AdKin activities were significantly higher. cALL cells 
with cytoplasmic immunoglobulin M(IgM) heavy chains were found to have 
mean 5'NT activities twice as high as cALL cells lacking cytoplasmic 
IgM heavy chains. In two patients who had surface immunoglobulins(slg) 
on their cell membranes, low 5'NT activities were found. When measuring 
enzyme activities after 2 to 4 days of prednisone monotherapy, only 
mean ADA and HGPRT activities decreased in nonBnonT-ALL. These decreases 
were not significant in T-ALL patients. Mean enzyme activities in the 
leukemic cells of five patients with relapse, were comparable to those 
in newly diagnosed patients, except for 5'NT, which was found to be 
within the activity range of control peripheral blood lymphocytes. It 
is concluded that ADA and AdKin activities are suitable as markers for 
E ALL and cALL leukemias, respectively. 5'NT might help to distinguish 
between cALL cells having and lacking preß characteristics. Since 5'NT 
activity may also be decreased in B-ALL, it is not suitable as a T-ALL 
marker. Enzymes of purine metabolism in leukemic relapse need further 
investigation. 
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INTRODUCTION 
Studies on patients with immunological dysfunctions have revealed 
that genetically determined deficiencies of certain enzymes of purine 
metabolism are intimately related to lymphocytic malfunction(14,15). 
This as a consequence of a differentiation and/or maturation block 
originating from the enzyme deficiencies(26). Since lymphoblastic 
leukemia may be cosidered as a disorder of lymphocyte differentiation 
(17), it is of interest to study systematically purine metabolism in 
lymphoid cells from patients with acute lymphoblastic leukemia(ALL). 
Such a study might serve three purposes: 
1. The search for additional diagnostic biochemical markers in acute 
lymphoblastic leukemia. 
2. The search for a relation between biochemical markers of lymphocytic 
differentiation and the immunological markers. 
3. Based on the specific deviant enzymatic make-up of the malignant 
lymphoblasts, possibilities for specific chemotherapy might be 
explored. 
In previously published studies, which focussed on a single or a 
few enzymes, inconsistent data have been reported on altered purine 
enzyme activities in ALL. Scholar and Calabresi(23) reported that activ­
ities of several enzymes of purine metabolism(various nucleotide kina­
ses, adenosine deaminase and purine nucleoside Phosphorylase) in 
lymphoid cells from two patients with ALL were not consistent. In one 
patient an adenosine deaminase(ADA) activity comparable with the 
control value was observed. In the other a seven-fold increased ADA 
activity was found. In ALL patients with a Τ cell phenotype(T-ALL), 
ADA activities were found to be 7-fold(25) or even 47-fold(9) higher 
than in normal lymphocytes. On the other hand, ADA levels in ALL 
patients without a Τ cell or а В cell phenotype(nonBnonT-ALL) were 
reported to be only two to four-fold elevated(25). Contrasting data 
were also reported to be higher in lymphoid cells from ALL patients 
than in peripheral blood lymphocytes(PBL) from controls, it should be 
mentioned, that in nonBnonT-ALL a higher ADA activity was observed than 
in T-ALL(24). Liso et al.(20) did not find a difference in ADA activity 
between nonBnonT-ALL and T-ALL. 
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Purine nucleoside phodphorylase(PNP) was reported to be decreased 
only in T-ALL(3). In T-ALL an inverse linear relationship has been 
reported between the 5'nucleotidase^'NT) activity and the number of 
Ε-rosette positive cells(21). The mean activity of 5'NT in malignant 
Τ lymphoblasts was significantly lower as compared to normal lympho­
cytes and leukemic nonBnonT lymphoblasts. 
In the present study we have systematically assayed nine different 
enzymes, namely: ADA(E.C. 3.5.4.4), PNP(E.C. 2.4.2.1), 5'NT(E.C. 3.1.3.5), 
ecto-5'NT, hypoxanthine-guanine phosphoribosyltransferase(HGPRT; E.C. 
2.4.2.8), adenine phosphoribosyltransferase(APRT; E.C. 2.4.2.7), 
adenosine kinase(AK; E.C. 2.7.1.20), AMP deaminase(AMPD; E.C. 3.5.4.6) 
and adenylate kinase(AdKin; E.C. 2.7.4.3). These enzyme activities have 
been related with a number of clinical and immunological parameters in 
a series of 43 successive ALL patients. 
We studied enzyme activities in relation to prednisone monotherapy 
in order to investigate the usefulness of enzyme activities as markers 
for the effectiveness of the chemotherapeutic regimen. From earlier 
studies by our group it was known that the mean percentage of cells in 
(S+G?+M)-phase is lower after prednisone treatment(2). 
MATERIALS AND METHODS 
Patients 
Fourty-three children with ALL(aged between 1 and 14 years) were 
investigated at the time of diagnosis. The study was made on bone marrow 
aspirates, except for the patients 38, 39, 57 and 67(table 1). The 
diagnosis was confirmed at the Reference Centre of the Dutch Working 
Group on Leukemia in Children(SNWLK), The Hague, The Netherlands. Out 
of this group, cells from 22 patients were investigated enzymologically 
again after 2 to 4 days prednisone monotherapy(dose 40 mg/m2 once daily). 
Isolation of Lymphoid Cells from Bone Marrow and/or Peripheral Blood 
The lymphoid cells were isolated by the Ficoll-Isopaque gradient 
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centrifugation method as described previously(2), using tris buffered 
minimum essential medium(MEM) containing 5%(v/v) foetal bovine serum. 
These cells were used both for immunological and enzymological charac­
terization. 
Immunological Classification of ALL 
The immunological classification was performed as a rule in almost 
completely homogeneous(>95%) leukemic cell populations from bone marrow 
and/or peripheral blood. Sheep erythrocyte(E) rosettes were used as a 
Τ cell marker(2). If more than 20% of the leukemic cell population 
formed Ε-rosettes at 4° C, the diagnosis Τ cell ALL was made. In a 
number of cases anti-T cell antiserum(Anti-Leu-l monoclonal antibody, 
Beckton Dickinson, Sunnyvale, CA, USA) could be used in an indirect 
immunofluorescence assay, using fluorescein isothiocyanate(FITC)-labeled 
goat anti-mouse IgG antiserum. Again the 20% borderline was used as a 
criterion for positivity. As a criterion for В cell ALL the presence of 
more than 20% surface immunoglobulin(slg) bearing cells was used. 
Immunofluorescence studies were performed using tetramethyl rhodamine 
isothiocyanate(TRITC)-labeled anti-human Ig(2). Leukemic cell populations 
that did not meet the criteria mentioned above were classified as 
nonBnonT-ALL. 
Antisera against common-ALL antigen(cALL) could not be 
used in all cases studied. However, after anti-cALL antibody became 
available(J5 Coulter Clone monoclonal antibody, Coulter Electronics Inc., 
Hialeah, FL, USA), a number of patients of the nonBnonT-ALL group could 
be classified as cALL(more than 20% cALL positive cells) or unclassified-
ALL(unc.-ALL; no significant numbers of membrane markers) according to 
Greaves' nomenclature(16). The binding of J5 to the leukemic cells was 
assessed by indirect immunofluorescence with fluoresceinated goat anti-
mouse IgG antiserum. 
PreB cell characterization was performed in an immunofluorescence 
assay on cytocentrifuge preparations of fixed bone marrow cells using 
TRITC-labeled anti-human IgM and FITC-labeled anti-human light chains 
(к or λ) antisera. Cells lacking detectable slg(deterained as described 
above) but containing cytoplasmic IgM heavy chains in the absence of 
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light chains were denominated as preB cells(4). 
Enzyme Assays 
The activities of ADA, PNP, 5'NT, HGPRT, APRT, AK, AMPD and AdKin 
were assayed with radiochemical substrates, making use of our micro-
methods described previously(28). PNP was assayed using e-^C-hypoxan-
thine as a substrate. 5'NT was assayed on lyophilized cells, whereas 
ecto-5'NT activity was measured in intact cells, essentially according 
to Edwards et al.(11). With respect to AMPD and AdKin, the method of 
Leech and Newsholme(19) was adapted to our microsystem(28). Both bone 
marrow and peripheral blood samples were assayed from 16 patients, 
whereas in another 6 patients only peripheral blood samples were 
assayed(table 1). 
Statistics 
The data were statistically analyzed using the two-tailed Student's 
t-test with separate variance estimate. 
Flow Cytophotmetric Studies 
The number of bone marrow cells in (S+Gg+MJ-phase was determined 
(Dept. of Hematology, University Hospital, Nijmegen, The Netherlands) 
using a flow cytophotometric technique described earlier(2). 
In Vitro Effects of Prednisone and Prednisolone 
To test the possible in vitro effects of prednisone and prednisol-
one, control peripheral blood lymphocytes were assayed for the enzymes 
as described onder "Enzyme Assays", in the presence of 10 ng/ml(0.03 yM) 
of one of the compounds. 
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RESULTS 
Immunological Markers of the Patients 
Several immunological characteristics determined in a group of 43 
children with ALL are listed in table 1. In our group of patients, 29 
cases could be classified as nonBnonT-ALL; subdivision in cALL and 
une.-ALL was only possible after an anti-cALL antiserum became available 
to us(fig. 1). Eighteen nonBnonT-ALL patients(from the group of 29) 
could be investigated with the recently available anti-cALL serum. 
Sixteen cases were of the cALL type and 2 remained unclassified(fig. 1). 
From the 14 patients in our group, who didnot have a nonBnonT phenotype 
12 were Ε-rosette or anti-T cell serum positive(>20% positive cells) 
and classified as T-ALL. Two patients in our group were of the В cell 
type(>20% slg bearing cells). 
Though in patients 6 and 7 most immunological markers could not be 
Figure 1 : Immunological classification of the ALL patients studied. 
l=nonBnonT-ALL patients; no further marker studies performed. 
2=nonBnonT-ALL patients; cALL positive. 
3=nonBnonT-ALL patients; unclassified ALL. 
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Table 1 : Characteristics of Acute Lymphoblastic Leukemia Patients in 
this Study 
Patient 
1 
6 
7 
θ 
10 
11 
12 
13 
14 
15 
18 
21 
23 
25 
26 
29 
31 
32 
35 
37 
3Θ 
39 
40 
43 
45 
46 
50 
53 
55 
57 
59 
61 
62 
63 
64 
65 
67 
6Θ 
500 
501 
502 
503 
539 
Classific­
ation 
nonBnonT 
nonBnonT 
nonBnonT 
nonBnonT 
nonBnonT 
nonBnonT 
une. 
nonBnonT 
τ 
Τ 
nonBnonT 
nonBnonT 
common 
common 
nonBnonT 
nonBnonT 
В 
une. 
Τ 
Τ 
common 
common 
common 
common 
common 
common 
Τ 
Τ 
common 
Τ 
common 
common 
common 
common 
common 
common 
common 
Τ 
Τ 
Τ 
Τ 
Τ 
Β 
WBC 
22.0 
15.θ 
6.9 
4.0 
6.4 
0.8 
232 
1.Θ 
308 
142 
7.2 
434 
13.2 
27.8 
12.9 
5.6 
91.8 
38.3 
317 
28.4 
4.2 
5.0 
3.4 
8.3 
2.2 
7.6 
126 
365 
41.7 
122 
3.4 
12.9 
5.5 
10.4 
11.3 
189 
16.8 
121 
-
-
-
-
-
%blasts 
90 
100 
88 
80 
95 
90 
95 
98 
95 
95 
95 
98 
90 
99 
65 
92 
95 
82 
87 
36 
-
-
94 
78 
90 
94 
86 
90 
97 
91 
91 
99 
96 
90 
72 
94 
-
88 
-
-
-
-
-
%Ε 
0 
-
3 
4 
1 
3 
3 
0 
37 
86 
2 
4 
1 
0 
0 
0 
2 
16 
76 
56 
-
-
1 
5 
2 
2 
74 
80 
3 
19 
1 
1 
2 
2 
1 
0 
-
78 
>20 
>20 
>20 
>20 
-
%slg 
0 
-
-
0 
0 
0 
0 
0 
-
0 
0 
0 
-
0 
0 
0 
77 
1 
-
1 
-
-
0 
1 
2 
0 
0 
0 
2 
5 
1 
1 
0 
1 
0 
3 
-
0 
-
-
-
-
>20 
%cALL 
-
-
-
-
-
-
0 
-
-
-
-
-
85 
60 
-
-
-
3 
1 
-
-
-
74 
93 
60 
81 
0 
52 
88 
70 
87 
91 
38 
92 
87 
92 
-
63 
-
-
-
-
-
%anti-T 
-
-
-
-
-
-
0 
-
-
-
-
-
1 
1 
-
-
-
-
-
-
-
-
-
-
-
-
-
21 
4 
68 
2 
78 
6 
3 
8 
1 
-
70 
-
-
-
-
-
ΒΜ/ΡΒ 
m 
m 
m 
m 
m 
m 
m,b 
m 
m 
m,b 
m,b 
m 
m,b 
m,b 
m,b 
m,b 
m,b 
m,b 
m,b 
m 
b 
b 
m,b 
m,b 
m 
m 
m,b 
m,b 
m 
b 
m 
m,b 
m 
m 
m,b 
m 
b 
m 
m 
m 
m 
m 
b 
The patients are numbered according to our computerized datafile. Mis­
sing numbers represent patients with other hematological malignancies. 
Initial white blood cell counts(WBC) are given in 109 cells/liter. The 
percentage of lymphoblasts is determined microscopically, using bone 
marrow smears stained with May-Grünwald Giemsa technique. Patients 38, 
39, 57, and 67 were classified on the basis of peripheral blood findings. 
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determined, these patients were classified as nonBnonT-ALL on the basis 
of morphological aspects and a stimulatory capacity in the mixed lympho­
cyte reaction. In the peripheral blood of patients 38 and 39 more than 
20% E cells were found. The percentage of cALL cells were 25 and 54, 
respectively. These patients were diagnosed as cALL, because the percen­
tage of malignant cells in the peripheral blood were 29 and 54, respec­
tively. The E cells most probably represent the normal peripheral Τ 
cells. In the bone marrow of these patients no elevated numbers of E 
cells were found. In patient 61, besides a high percentage of cALL 
eells{91%) also many anti-T positive cells(78%) were found. This patient 
could be classified as belonging to a subgroup expressing both the cALL 
and T-ALL antigens(a "minor T-ALL" subtype according to Greaves' clas-
sification(16), or a "c/T-ALL subtype according to the classification 
of Huhn et al.(18)). By taking into account clinical parameters, as 
white blood cell count and mediastinal mass, we preferred to include 
the patient in the cALL group. Clinical parameters were also decisive 
for the diagnosis T-ALL in patients 53, 57 and 68, who showed amounts 
of cALL and anti-T positive cells comparable to those found in patient 61. 
Enzyme Activities and the E-rosette Marker 
A relation between enzyme activities of purine metabolizing enzymes 
and subgroups of ALL according to the Greaves' classification(16) have 
been described by us before(29). In the present investigation we have 
looked for relationships with immunological markers in those groups of 
ALL patients having different enzyme activities. When plotting the 
enzyme activities measured, against the Ε-rosette marker, two groups of 
enzyme activities could be distinguished. With respect to ADA a group 
of patients with low to intermediate values(fig. 2) and relatively few 
The immunological markers E(rosette forming cells with sheep erythro­
cytes), slg(surface immunoglobulin bearing cells), cALL(cells positive 
for the common-ALL antiserum) and anti-T(cells positive for the anti-T 
cell serum) are given as the percentage of positive cells. The cells 
used for enzymological characterization were isolated from bone marrow 
(m) and/or peripheral blood(b). Samples of the patients numbered 500-539 
were kindly provided to us by colleagues from other clinics in the 
Netherlands. Detailed immunological phenotypes were not available to us. 
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Figure 2: ADA, PNP, and 5'NT activitydO 9 moles/10 6 cells.hour) in 
relation to the percentage of cells forming rosettes with sheep eryth­
rocytes (E) in ALL. The grey area represents the range of these para­
meters in control peripheral blood lymphocytes. Correlation coefficients 
(r) and the significances (p vâitae)of these correlations are given. 
E-rosetting cells and a group with high ADA activities and relatively 
many E-rosetting cells could be seen. In a similar way, distinctions 
could also be made in the case of low versus high activities of PNP, 
5'NT(fig. 2), ecto-5'NT and AdKin. In order to perform statistics, a 
distinction had to be made between E and E leukemias. Quite arbitra-
rily, but considering that this figure was already used in the immunol-
ogical classification, the borderline between E and E ALL'S was con-
sidered to be at 20% Ε-rosette positive cells. It should be noted that 
shifting this border-line up or down 10% did not have any effect on the 
ρ values noted in table 2; only minor effects on the mean enzyme activ­
ities could be seen. 
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Table 2: Purine Enzyme Activities in Leukemic Bone Marrow Cells: 
the Ε-rosette marker 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
ecto-5'NT 
AK 
AMPD 
Ad Kin 
E-Rosetting 
<20%(n=26) 
15.4 ± 7.0 
10.8 ± 7.2 
491 ± 314 
218 ± 116 
26.3 ± 25.0 
8.1 + 7.3 
6.3 ± 4.1 
290 + 315 
973 ± 531 
Cells 
>20%(n=ll) 
10.8 ± 5.6 
6.7 ± 2.8 
1088 ± 452 
115 ± 71 
1.3 + 1.9 
0.7 ± 0.5 
6.3 ± 2.7 
157 ± 124 
220 ± 143 
ρ value 
<0.05 
<0.05 
<0.001 
<0.005 
<0.001 
<0.001 
n. s. 
n.s. 
<0.001 
Enzyme Activities are expressed in 10 9 moles/106 cells.hour(mean ± 
s.d.). n.s.=not significantly different. 
Significant differences in specific activities of purine enzymes 
were observed(table 2, fig. 2) from E + ALL(n=ll) and from E~ ALL(n=26). 
Mean ADA activity was about 2.5 times higher in bone marrow cells from 
E + ALL as compared to E~ ALL(p<0.001). On the other hand the mean PNP 
activity in E~ ALL was about twice the value of that in E ALL(p<0.005). 
Although considerable variation in 5'NT activities in ALL was observed, 
significantly lower and nearly undetectable 5'NT activities in bone 
marrow cells from E ALL were evident. AdKin activity was significantly 
higher in E" ALL than in E + blasts(p<0.001). 
In part of the patients(n=16), the above mentioned enzyme activities 
were also assayed in lymphoid cells from peripheral blood(data not shown). 
Statistical analysis of these data revealed that the same differences 
were found as with bone marrow cells, although the ρ values were less 
significant. 
In fig. 2. it can be seen that there is a small overlap of ADA 
activity in the E and E~ ALL cases. One E ALL(patient 68) is in the 
ADA activity range(mean ± s.d.) of the E" ALL and three E~ ALL'S 
(patients 11, 12 and 40) are in the ADA activity range(mean ± s.d.) of 
the E ALL. Though the mean PNP activities are significantly different, 
the overlap in enzyme activity of the E and E ALL is considerable. 
ALL E cases, except one(patient 68) are,in the lower part of the 
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E" ALL activity range. 5'NT is low in all cases of E ALL(fig. 2). Four 
patients(patients 12, 25, 31 and 32) from the E~ ALL group showed 5'NT 
activities in the E ALL range. The difference between the two distinct 
populations was highly significant(p<0.001, table 2). With the membrane-
bound enzyme ecto-5'nucleotidase, essentially the same data were obtain-
ed(p<0.001). 
Enzyme Activities and the cALL Marker 
There was a marked difference(fig. 3, table 3) in ADA activity 
between cALL (>20% cALL antiserum positive cells; n=15) and cALL" bone 
marrow cells(<20% cALL antiserum positive cells; n=4). ADA activity was 
higher in cALL" blasts(p<0.01). On the other hand PNP, 5'NT and AdKin 
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Figure 3: ADA, 5'NT and AdKin activity(10-9 moles/106 cells.hour) in 
relation to the percentage of cells positive for the cALL antiserum in 
ALL. The grey area represents the range of the respective enzyme activ­
ities in control peripheral blood lymphocytes. Correlation coefficients 
(r) and the significances(p-value) of these correlations are given. 
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Table 3: Purine Enzyme Activities in Leukemic Bone Marrow Cells: 
the Common ALL Marker 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
ecto-5'NT 
AK 
AMPD 
Ad Kin 
<20%l 
10.8 
7.8 
1186 
88 
0.6 
0.7 
5.2 
116 
220 
CALL 
!n=4) 
± 1.6 
± 2.0 
± 296 
+ 24 
± 0.8 
± 0.6 
± 1.2 
± 70 
± 41 
Positive Cells 
>20%(n=15) 
14.5 ± 8.4 
9.8 ± 7.4 
511 ± 330 
197 ± 114 
28.5 ± 26.9 
8.8 ± 6.9 
5.1 ± 2.9 
251 ± 329 
982 ± 517 
ρ value 
n.s. 
n.s. 
<0.01 
<0.005 
<0.001 
<0.001 
n.s. 
n.s. 
<0.001 
Enzyme activities are expressed in 10 ' moles/106 cells.hour(mean ± 
s.d.). n.s.=not significantly different. 
activities were higher(table 3) in bone marrow cells from cALL leukemia 
(p<0.005, p<0.001 and p<0,001, respectively). Again these differences 
in enzymatic activities were less pronounced in cells derived from per­
ipheral blood(data not shown). 
From fig.3 it becomes clear that two patients(patients 40 and 53) 
out of the cALL group have an ADA activity that is in the range of the 
cALL" patients. Concerning the 5'NT activity, two cALL patients(patients 
25 and 53) are in the cALL" activity range. In the case of AdKin this 
overlap is seen in one patient(patient 53). 
Enzyme Activities and the Cytoplasmic IgM Heavy Chain Marker 
Recently we have had the opportunity to test leukemic cells for 
the preB cell phenotype as defined by the presence of cytoplasmic IgM 
heavy chains(4). We tested 7 of our patients, who were classified as 
cALL. In the 3 patients who had cytplasmic IgM heavy chains present in 
their leukemic cells(patients 55, 65 and 67), the mean 5'NT activity was 
found to be 78.1 ± 2.7 10"9moles/106 cells.hour. On the other hand the 
patients who did not show this preB marker(patients 40, 62, 63 and 64), 
had a mean 5'NT activity of 31.5 ± 20.3 10"9 moles/106 cells.hour 
(p<0.02). A comparable difference was observed with ecto-5'NT(p<0.05). 
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HGPRT activity was higher in the cases in which no cytoplasmic IgM heavy 
chains were seen(21.5 + 4.2 10"9 moles/106 eel Is.hour), compared to 
cytoplasmic IgM heavy chains containing cells(8.6 ± 1.5 10"9 moles/106 
cells.hour). The ρ value was found to be below 0.005. All other enzymes 
tested showed comparable activities in these two groups of patients. 
Enzyme Activities and the slg Marker 
Two patients(patients 31 and 539) appeared to have more than 20% 
slg+ cells. ADA activities(144 and 88 10 - 9 moles/106 cells.hour, respec­
tively) were found to be lower than ADA activities found in cALL 
leukemia(table 3) and E ALL(table 2). PNP activities were found to be 
variable(440 and 135 10"9 moles/106 cells.hour, respectively). A very 
low activity was seen for 5'NT(0.9 and 0.1) and ecto-5'NT(0.2 and 0.1 
10"9 moles/106 cells.hour, respectively), which was comparable to 
activities found in E ALL. AdKin activities were in the range of E ALL. 
Enzyme Activities after Prednisone Monotherapy 
In 22 of the ALL patients the systematic analysis of purine inter-
conversion enzymes was repeated after 2 to 4 days of monotherapy with 
prednisone(dose: 40 mg/m2 once daily in the morning). Bone marrow samples 
were obtained in the morning about 24 hours after the last dose of 
prednisone. The mean activities of HGPRT, APRT, ADA, PNP, AK, AMPD and 
AdKin in nonBnonT-ALL seemed to be decreased after prdenisone therapy 
(table 4). However, these differences were only statistically significant 
in the case of ADA(p<0.01) and HGPRT(p<0.05). In fig. 4 it can be seen 
that, with the exception of three cases, ADA activities decrease after 
prednisone therapy. Such a pattern was not seen with other enzymes. 
Prednisone and prednisolone were also tested in vitro for inhibition or 
stimulation of the various enzymes. Both compounds did neither inhibit 
nor stimulate the enzyme acticities determined. 
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Table 4. Purine Enzyme Activities in Leukemic Bone Marrow Cells. 
Effect of Prednisone Monotherapy 
Enzyme 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
ecto-5'NT 
AK 
AMPD 
AdKin 
nonBnonT-
before 
monotherapy 
15.4 
10.6 
550 
201 
36.8 
10.0 
5.6 
368 
949 
± 7.9 
± 6.6 
± 327 
± 117 
± 26.3 
± 8.1 
± 3.8 
± 379 
± 497 
-ALL(n=17) 
after 
monotherapy 
11.9 ± 6.0 
7.4 ± 2.8 
373 ± 177 
196 ± 109 
39.5 ± 25.3 
12.1 ± 13.7 
4.9 + 2.8 
327 ± 409 
840 + 410 
ρ value 
<0.05 
n.s. 
<0.01 
n.s. 
n. s. 
n.s. 
n.s. 
n.s. 
n.s. 
Specific enzyme activities(10" moles/10 cells.hour) in bone marrow 
lymphoid cells of patients with nonBnonT-ALL before and after monother­
apy with prednisone. n.s.=not significantly different. 
Enzyme Activities and Leukemic ReTapse 
Leukemic cells from 5 nonBnonT-ALL patients(not included in table 1) 
have been enzymatically analyzed during relapse. Comparison of enzyme 
activities showed that in 26 newly diagnosed nonBnonT-ALL patients mean 
5'NT activity was 27.6 ± 24.5 Η Γ 9 moles/106 cells.hour. In the 5 
patients who were in relapse, mean 5'NT activity was found to be 
10.0 ± 8.5 10" 9 moles/106 cells.hour. The calculated ρ value was <0.01 
which was considered to be statistically significant different. Other 
enzyme activities showed no statistically significant differences between 
newly diagnosed patients and patients in relapse. 
DISCUSSION 
Correlations between enzymological membrane markers in ALL and 
activities of enzymes of purine metabolism have been described by 
several authors(3,9,21,23,25,29). Our present findings confirm and extend 
these earlier reports. ADA was found to have the highest activities in 
E + ALL(1088 ± 452 10" 9 moles/106 cells.hour, table 2), when comparing 
with E" ALL(491 ± 314 10" 9 moles/106 cells.hour, table 2) and normal 
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Figure 4: ADA activities(10~ moles/10 cells.hour) in bone marrow cells 
from ALL patients, before and after 2 to 4 days monotherapy with pred-
nisone. The vertical bars indicate the mean ± s.d. in nonBnonT-ALL(·; 
cALL and une.-ALL included) and T-ALL(T). The grey area represents the 
range of ADA activities in control peripheral blood lymphocytes. The 
numbers refer to the patients in table 1. 
control peripheral blood lymphocytes(134 ± 46 10~9 moles/106 cells.hour, 
ref. 29). In cALL lymphoblasts the ADA activity was lower than in cALL 
leukemia and comparable with that of E- ALL(tables 2 and 3). The ADA 
activity of E~ ALL and cALL leukemias is intermediary between the 
enzyme activity of E ALL and control lymphocytes. The relative differ-
ences in ADA activity between control lymphocytes and lymphoblasts from 
cALL patients was in the same range as described by others(9,25). The 
patients in the E ALL group are mostly diagnosed as T-ALL; the E ALL 
group showed an almost complete overlap with the cALL group, whereas 
a similar overlap was observed between the E ALL and the cALL- group. 
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Coleman et al.(9) however, found an ADA activity in T-ALL patients 
that was about 30 times higher than in control lymphocytes. The ADA 
activity in our group of E ALL patients is about 8 times higher than 
in control lymphocytes. In our enzyme assay lyophil i zed lymphoid cells 
were used. Coleman et al.(9) assayed ADA activity in cell extracts pre­
pared from sonicated lymphoid cells. We have previously shown that in 
sonicated control lymphocytes ADA activity is considerably lower than 
in lyophilized cells(27). This might be a reason for the differences in 
absolute ADA activity in sonicated cells(58 10~9 moles/106 cells.hour, 
ref. 9) versus lyophilized cells(143 10" 9 moles/106 cells.hour, ref. 29). 
Apparently ADA activity in Τ lymphoblasts is not markedly affected by 
this difference in the lyzing procedure, since comparable ADA activities 
were found by both groups(9,29). 
The essentially different results of Liso et al.(20), who found no 
difference of ADA activity between nonBnonT-ALL and T-ALL, may be as­
cribed to the different age of their patients. We were dealing with 
childhood ALL(1 to 14 years), whereas Liso's patients were mostly 
adults(12 to 68 years). Extrapolation of the biochemical findings des­
cribed in the present paper to adult ALL, therefore does not seem to be 
valid. 
The relatively low ADA activity found by Simpkins et al.(24) in 
T-ALL as compared to nonBnonT-ALL might be explained by the different 
way of expressing(per mg protein) the enzyme activity. If a much higher 
protein content per cell in T-ALL is present, the specific activity 
expressed on a protein basis becomes relatively lower than when expressed 
on a per cell basis. 
In our two cases with slg ALL the ADA activity seems to be in the 
normal range or slightly dereased, the latter finding being in agreement 
with Coleman et al.(9). Recently in one patient with B-ALL an elevated 
ADA activity, as compared to normal lymphocytes, nonBnonT and Τ leukemic 
cells, was reported(22). Interestingly, the blasts of the latter patient 
were morphologically classified as being of the L~ subclass(FAB classif­
ication). Our patients and those described by Coleman et al. (9) were 
found to be of the L,(Burkitt's type) subclass. These data seem to in­
dicate that heterogeneity exists in malignant В lymphoblasts, and that 
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ADA activity might be of help in the diagnosis of the different subclas­
ses. However, the number of B-ALL patients investigated should be exten­
ded before this hypothesis can be confirmed or denied. 
PNP activity in E ALL was significantly lower than in E~ lympho-
blasts. In control lymphocytes the PNP activity was about twice(209 ± 70 
10"9 moles/106 cells.hour, ref. 29) that of the activity in E + ALL. 
These data are in agreement with findings by others(3,22). However, in 
one s Ig ALL we found a PNP activity that seemed decreased and was in 
the E ALL range. In the other slg+ ALL patient we noted a PNP activity 
about twice that of control lymphocytes(29). Reaman et al.(22) have 
reported a PNP activity in a B-ALL patient, which was in the range of 
the Τ leukemic cells. In our opinion these different data can hardly be 
due to the different assay methods used. They could be merely due to the 
heterogeneity of В lymphoblasts derived from the B-ALL patients in the 
different studies. 
5'NT activity in E + ALL is very low. Hardly any AMP degrading activ­
ity was seen in these lymphoblasts. In our cALL leukemias the mean 5'NT 
activity(28.5 ± 26.9 10"9 moles/106 cells.hour, table 3) was about twice 
that of normal lymphocytes(18.4 ± 11.7 10"9 moles/106 cells.hour, ref. 
29). A possible explanation for the extremely large range in 5'NT activ­
ity^.d. is about 100% of the mean) is the heterogeneity within this 
subgroup of ALL. In this context an interesting observation was made. 
In three cALL+ patients with preB characteristics the activity of 5'NT 
was about twice as high as in the cells of four cALL patients without 
cytoplasmic IgM heavy chains. A similar difference was found with regard 
to HGPRT, but not with the other enzymes. Our finding of a higher mean 
5'NT activity in cALL+ leukemia's than in control lymphocytes is contra­
dictory with the findings of Reaman et al.(21). Whether this difference 
is due to the different ways of correcting for phosphatase activity, 
which is not specific for the ribose-5'-P bond, is not clear. But it is 
known that such phosphatases can even be markers for certain subtypes 
of leukemia(6). 
Our findings concerning ADA and PNP activities in s Ig ALL are 
partly in contradiction to the findings of others. However, the findings 
on the 5'NT activity in this subgroup of ALL seem rather unanimous. Like 
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other authors(9,22), we observe in both cases of B-ALL a decreased 5'NT 
activity that is in the range of the E ALL. In conclusion, we cannot 
agree with the suggestion that 5'NT activity is an enzymological marker 
for distinct subclasses of ALL. 
To our knowledge the differences in HGPRT and APRT activity in E 
ALL and E" ALL have not been described earlier. These differences were 
found to be not significant when comparing cALL and cALL leukemias. 
However, the numbers of patients were rather limited. Further exploration 
of the possible diagnostic value of these findings is indicated. 
The activity of AdKin is significantly higher in E~ and/or cALL 
leukemias than it is in E + and/or cALL" leukemias. To our knowledge this 
has not been described before. The higher activity of this nucleotide 
metabolizing enzyme in E" and/or cALL+ leukemia is in agreement with 
other data obtained by our group(lO). It was shown that nonBnonT lympho-
blasts had a significantly higher ATP concentration(1005 ± 205 10" 1 2 
moles/106 cells) than control lymphocytes(500 ± 150 10" 1 2 moles/106 
cells). In Τ lymphoblasts the ATP content is not significantly elevated. 
The possible implications of the elevated ATP concentration in certain 
cases of ALL for the energy charge of leukemic blasts are subject of 
further investigation. 
Since it is assumed that lymphoblasts from patients with ALL are 
arrested in a certain stage of their differentiation(17) it is interes­
ting to compare our biochemical findings in ALL with normal lymphoid 
cells from various differentiation stages. Lymphoid cells derived from 
the thymus are known to have relatively low 5'NT(12,30), high ADA 
(1,5,30) and low PNP(30) activities. In 6 separate thymocyte subfractions 
the ecto-5'NT activity ranged from 0.4 to 2.0 10"9 moles/106 cells.hour 
(30). Since lymphoblasts from T-ALL might have been arrested at different 
stages of the thymic differentiation, this can explain the relatively 
wide range of 5'NT activity in T-ALL. The same is the case with ADA and 
PNP activity. In relatively immature(phytohaemagglutinin unresponsive) 
thymocytes the ADA activity is about half the activity in relatively 
mature(phytohaemaggluti ni η responsive) thymocytes(30). PNP activity in 
the latter fractions is comparable with normal peripheral blood Τ lympho­
cytes, whereas in the immature fractions PNP activity is about 10% of 
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that value. 
The biochemical consequences of the differences in purine enzyme 
activities for the leukemic cells have not been studied extensively yet. 
However, since the major differences found are in the ADA, PNP, 5'NT 
and AdKin activities, it might be anticipated that handling of purine 
nucleosides in E ALL differs from that in cALL or in preB-cALL. Due to 
the relatively low 5'nucleotidase/kinase activity ratio, nucleosides 
(e.g. adenosine, deoxyadenosine, guanosine and deoxyguanosine) can be 
phosphorylated to a much higher extent in E ALL than in other subtypes 
of ALL. Under certain conditions these phosphorylated nucleosides are 
toxic,especially to lymphoid cells(5,13). E ALL cells e.g., might be 
more vulnerable to deoxyguanosine intoxication than other subclasses of 
leukemia. Such toxic effects were already found in thymocytes with a 
comparable enzymatic make-up(8). On the other hand the deaminating 
capacity(ADA activity) towards adenosine and deoxyadenosine in E ALL 
cells is very high. Therefore adenosine and/or deoxyadenosine might be 
less toxic to these cells. Systematic analysis of purine nucleoside 
metabolism in leukemia might become helpful, not only in diagnosis but 
also for the development of a more selective chemotherapy in ALL. 
The impact of the significantly decreased ADA and HGPRT activities 
in nonBnonT-ALL patients(table 4, fig.4) after prednisone monotherapy 
is not clear. No correlation appeared to exist neither with the ADA 
activity and the number of leukemic blasts in bone marrow, nor between 
the ADA activity and the number of cells in (S+G2+M)-phase. Since nearly 
all patients showed a decreased ADA activity after prednisone therapy 
(fig. 4), further investigation seems to be justified. 
It was surprising that when comparing newly diagnosed nonBnonT-ALL 
patients with patients in relapse, all purine enzyme activities were in 
the same range, except 5'NT. The finding that in nonBnonT-ALL relapse 
a lower 5'NT activity was observed might point to the development of a 
different leukemic (sub)clone. Before any final conclusions can be drawn 
more patients have to be studied. Longitudinal studies should be perform-
ed, measuring 5'NT and other purine enzymes, in order to establish 
whether such enzyme activities have also any prognostic significance in 
leukemic relapse. 
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ABSTRACT 
Adenosine deaminase(ADA), 5' nucleotidase(5'NT), ecto-5'NT, purine 
nucleoside phosphorylase(PNP), hypoxanthine-guanine phosphoribosyltrans-
ferase(HGPRT), adenine phosphoribosyltransferase(APRT), adenosine kinase 
(AK), AMP deaminase(AMPD) and adenylate kinase(AdKin) activities were 
assayed in peripheral blood lymphoid cells from 20 patients with В cell 
type chronic lymphocytic leukemia(CLL). Significantly decreased mean 
activities of ADA, 5'NT, ecto-5'NT, PNP and AMPD were observed when com­
paring B-CLL lymphoid cells with control peripheral blood lymphocytes 
(PBL). AK and AdKin) activities however, were found to be higher in B-CLL. 
Relatively wide ranges of ADA and 5'NT activity were observed. In 
patients with paraproteinaemia, 5'NT activity was found to be relatively 
high and in the range of the activities in normal PBL. ADA activity 
seemed to'be slightly higher in patients without paraproteinaemia. No 
correlation could be found between the enzyme activities and the number 
of cells rosetting with sheep erythrocytes or bearing surface immuno-
globulin(slg). A relationshipwas suggested between 5'NT activity and Ig 
production. 
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INTRODUCTION 
In the last decennium considerable differences in the activities 
of enzymes of purine metabolism have been described in various groups 
of human leukemias. In those papers data have been reported on a few 
enzymes in chronic lymphocytic leukemia(CLL): adenosine deaminase(ADA, 
1,6,11,13,16), purine nucleoside phosphorylase(PNP, 1,2,13) and 5'nuc-
leotidase(5'NT, 9,10). No simultaneous studies on several enzymes of 
purine metabolism in a group of CLL patients have been described. Mean 
ADA activity in leukemic cells from patients with CLL was reported to be 
2 to 3-fold lower than in normal peripheral blood lymphocytes(PBL, 6,11). 
Simpkins et al.(14) however, recently described ADA activities in CLL 
lymphoid cells which were comparable to ADA activities in control PBL. 
In 6 out of 7 patients, Borgers et al.(2) found a weak histochemical 
staining for PNP in CLL lymphoblasts, in contrast to the clear staining 
of control PBL. In only one patient the histochemically determined PNP 
activity was comparable to the pattern observed in control lymphocytes. 
Ambrogi et al.(l) confirmed the decreased ADA and PNP activities in CLL. 
In their studies ADA activity was 2 to 3-fold lower and PNP activity was 
3 to 6-fold lower as compared to PBL from normal donors. 5'NT activity 
was found to be low in lymphocyte membranes in 7 out of 10 CLL patients 
(9). In crude lymphocyte homogenates comparable results were obtained(9). 
We have undertaken a systematic analysis of activities of nine 
enzymes involved in purine metabolism in lymphoid cells from 20 patients 
with B-CLL. ADA, PNP, 5'NT, ecto-5'NT, hypoxanthine-guanine phosphorib-
osyltransferase(HGPRT), adenine phosphoribosyltransferase(APRT), 
adenosine kinase(AK), AMP deaminase(AMPD) and adenylate kinase(AdKin) 
activities have been assayed in lymphoid cells from CLL patients. 
MATERIALS AND METHODS 
Patients 
Eight female and twelve male patients, aging from 44 to 77 years, 
were investigated. Several immunological markers are listed in table 1. 
The percentage of cells with surface immunoglobulins(slg) varied from 
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Table 1 : Immunological Markers of Chronic Lymphocytic Leukemia Patients 
Patient 
529 
530 
531 
532 
533 
534 
535 
536 
537 
538 
540 
541 
542 
543 
544 
545 
546 
547 
548 
549 
Age 
62 
58 
77 
45 
75 
65 
52 
59 
44 
73 
53 
62 
76 
54 
52 
64 
71 
60 
58 
69 
Sex1 
f 
f 
f 
m 
m 
f 
m 
m 
m 
m 
m 
m 
f 
f 
m 
m 
m 
m 
f 
f 
Paraproteins 
-
-
-
IgM/: 
-
-
IgM/I 
-
-
-
-
-
-
IgMX 
-
-
IgG< 
IgG< 
-
-
IgGK 
:gGX 
E 3 
s 
1 
16 
5 
2 
7 
3 
8 
6 
18 
0 
5 
13 
18 
3 
2 
5 
7 
2 
8 
25 
E * 
m 
75 
62 
65 
5 
84 
16 
3 
55 
79 
35 
40 
78 
35 
16 
87 
51 
51 
36 
71 
52 
slg5 
39 
70 
90 
70 
88 
90 
70 
75 
69 
61 
76 
60 
70 
90 
73 
50 
49 
80 
80 
77 
The patients are numbered according to our computerized data file. The 
missing number represents a patient with another hematological malig­
nancy. m=male, f=female. Paraproteins present or paraproteins absent 
(-). The percentage of cells forming rosettes with sheep erythrocytes. 
The percentage of cells forming rosettes with mouse erythrocytes. The 
percentage of cells bearing surface immunoglobulins. 
39 to 90%; the percentage of cells rosetting with mouse erythrocytes(E ) 
ranged from 13 to 87%. In the 4 patients with a relatively low amount 
of E
m
+
 cells(<20%), the percentage of slg+ cells was 70 to 90%. Para-
protei naemi a was observed in 5 patients, 3 of them had a low percentage 
of E cells. In two cases a double paraproteinaemia was found(table 1). 
Isolation of Lymphoid Cells 
Cells were isolated from heparinized blood by Ficoll-Hypaque 
gradient centrifugation(d=1.077 gr/ml). Τ cells were identified by their 
capacity to spontaneously form rosettes with sheep red blood cells(E ) 
and В cells were recognized by rosetting with mouse red blood cells(E ), 
as described by Gupta et al.(5) and by the presence of slg. The 
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percentage of slg bearing cells was determined by immunofluorescence 
using affinity purified FITC-labelled antibodies as described by Gathings 
et al.(4). 
Enzyme Assays 
Enzyme activities were assayed making use of radiochemical sub-
strates with an earlier described micromethod(17). HGPRT(E.C. 2.4.2.8) 
and APRT(E.C. 2.4.2.7) were assayed by measuring the conversion of 
hypoxanthine and adenine to their nucleotides, IMP and AMP respectively. 
PNP(E.C. 2.4.2.1) was assayed in both the catabolic and the anabolic 
direction. Since both methods essentially showed the same results, only 
the anabolic activity is given. The deamination of adenosine to inosine 
was measured as the ADA(E.C. 3.5.4.4) activity. 5'NT(E.C. 3.1.3.5) ac-
tivity was determined in lyophilized cells as well as in intact cells 
(ecto-5'NT) with methods described by Ip and Dao(7) and by Edwards et al. 
(3), respectively. The two activities showed good correlations. Only 5'NT 
activity is given in tables 2 and 3. AK(E.C. 2.7.1.20) activity was 
assayed by following the conversion of adenosine to AMP. AMPD(E.C. 
3.5.4.6) and AdKin(E.C. 2.7.4.3) were essentially assayed according to 
Leech and Newsholme(8) adapting their method to our micromethod. Enzyme 
activities are expressed in 10"9 moles product formed/106 cells.hour. 
Table 2 : Activities of Purine Enzymes in Peripheral Blood Lymphoid 
Cells from B-CLL Patients and from Normal Controls 
Enzyme Controls(n=20) B-CLL(n=20) 2p value 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
AK 
AMPD 
AdKin 
1 -9 
Enzyme activities(mean ± s.d.) are expressed in 10 moles of product 
6.9 ± 3.31 
13.6 ± 4.2 
134 ± 46 
209 ± 70 
18.4 ± 11.7 
7.9 ± 3.6 
267 ± 106 
265 ± 183 
7.0 ± 4.9 
13.2 ± 6.5 
49.2 ± 43.3 
132 ± 96 
3.8 ± 6.8 
17.3 ± 6.7 
190 ± 105 
768 ± 425 
n.s. 
n. s. 
<0.001 
<0.01 
<0.001 
<0.001 
<0.02 
<0.001 
formed/106 cells.hour. 
p-values in the two tailed Student's t-test using the separate variance 
estimate 
n.s.=not significantly different. 
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Figure 1: ADA, PNP, 5'NT and ecto-5'NT activities(IO-9 moles/106 cells, 
hour) in control peripheral blood lymphocytes and lymphoid cells from 
patients with B-CLL. The mean values are indicated with a horizontal 
line. +=CLL patients with paraproteinaemia. 
RESULTS 
The mean activities obtained in the enzymatic analysis of a group 
of 20 B-CLL patients are depicted in figs. 1 and 2. Data on individual 
patients are given. Mean activities of ADA, PNP, 5'NT and ecto-5'NT in 
cells from CLL patients are significantly lower than in normal peripheral 
blood lymphocytes. Mean ADA activity is about — of the control value, 
whereas PNP is only slightly lower(table 2). The most pronounced decrease 
in activity is found for 5'NT. In PBL from B-CLL patients the mean 5'NT 
activity is 3.8 10"9 moles/106 cells.hour(table 2). In contrast to the 
decreased enzyme activity levels described above, significantly higher 
values in B-CLL were observed for AK and AdKin. AK activity was about 
twice as high in B-CLL than in control PBL, whereas for AdKin a 3-fold 
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higher activity was found in B-CLL(table 2). Computerized Statistical 
evaluation of the biochemical and immunological data was performed. No 
statistical differences or correlations in enzyme activities were detec­
ted in CLL patients in relation to the E or slg markers. However, a 
correlation between the E marker and the 5'NT and ecto-5'NT activity 
m 
seemed to exist. The correlation coefficients were -0.57 and -0.50 for 
5'NT and ecto-5'NT, respectively, with a statistical significance 
(p value) of 0.004 and 0.013, respectively. 
When comparing CLL patients with and without paraproteinaemia, a 
significant difference was observed(table 3). The mean 5'NT activity was 
about 10-fold higher(table 3, fig. 1) in CLL patients with paraprotein-
aemia(range 5.1 to 30.1 10"9 moles/106 cells.hour) than in CLL patients 
without paraproteinaemia(range 0.1 to 3.4 10"9 moles/106 cells.hour). 
Spec- act. 
HGPRT 
p=0.955 
5 
controls CLL 
(n=21) (n.20) 
45-
3 0 -
2 5 
2 0 
1 Ы 
10-
5 -
APRT 
Ρ 
. 
и 
τ 
I 
* 
0.818 
t 
" —r-
X 
• 
τ 
. 
controls CLL 
( η =20) (n.20) 
3 5 -
30-
2 5 · 
2 0 1 
15-
10-
5-
A К 
p.0.000 
9 
* ! 
_ ^ 
. 
i 
« 
• 
! 
ν 
• 
! 
-
t 
4 0 0 · 
300 
2 0 0 
100-
AMPD 
Ρ 
i 
I 
t 
t 
0 . 0 2 3 
• 
; 
• 
-^-
л 
•t 
» 
AdKin 
p . 0 . 0 0 0 
controls CLL 
(n=21) (n=20) 
controls CLL 
(n.22) (n.20) controls CLL (n=8) ln=20> 
Figure 2: HGPRT, APRT, AK, AMPD and AdKin activities(IO-9 moles/106 
cells.hour) in control peripheral blood lymphocytes and lymphoid cells 
from patients with B-CLL. The mean values are indicated with a horizon­
tal line. +=CLL patients with paraproteinaemia. 
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Table 3 : Purine Enzyme Activities in B-CLL Patients with or without 
Paraproteinaemia 
Enzyme Patients WITH 
Paraproteinaemia 
(n=5) 
Patients WITHOUT 
Paraproteinaemia 
(n=15) 
ρ value 
HGPRT 
APRT 
ADA 
PNP 
5'NT 
AK 
AMPD 
AdKin 
7.1 ± 3.91 
13.5 ± 6.7 
28.8 ± 8.7 
154 ± 126 
11.5 ± 10.6 
19.5 ± 9.5 
232 ± 161 
915 ± 377 
6.9 ± 5.3 
13.1 ± 6.7 
56.0 ± 48.3 
125 ± 88 
1.2 ± 1.5 
16.6 ± 5.8 
176 ± 81 
720 ± 441 
n.s. 
n.s. 
<0.05 
n.s. 
<0.05 
n.s. 
n.s. 
n.s. 
Enzyme activities(mean ± s.d.) are expressed in 10~9 moles/106 cells, 
hour. 2P values in the two tailed Student's t-test using the separate 
variance estimate. n.s.=not significantly different. 
DISCUSSION 
In contrast with findings in acute lymphoblastic leukemia(ALL, 18) 
mean ADA activity in B-CLL was a factor 3 lower than in normal PBL 
(table 2). This is in agreement with data reported by others(l,6,16). 
However, in contrast to the findings of Huang et al.(6) and Ambrogi et 
al.(l), who only observed ADA activities below the mean control level, 
we observed a considerable range from 8%(patients 533 and 537) to 116% 
of the mean control value(table 2). The ADA activity of four patients 
(patients 529, 531, 538 and 542) was within our control range(fig. 1). 
These conflicting results might be due to the fact that in the studies 
mentioned only limited numbers of patients were studied(8 and 4, respec­
tively). 
The correlation between ADA activity and the percentage of В cells 
in CLL patients that was described by Tung et al.(16), could not be 
confirmed in our group of patients. In the present study В cells were 
defined by the E and s Ig markers. The complement receptor was used as 
а В cell marker in the study of Tung et al.(16). The fact that Simpkins 
et al.(14) reported comparable ADA activities in CLL lymphoid cells and 
in control lymphocytes, might be due to the difference in the enzyme 
assay. Simpkins et al.(14) used the indirect photometric assay of Tung 
et al.(16) in hypotonically lyzed cells. A selective lysis of cells 
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night be consequence of this method. Together with expressing the enzyme 
activity on a protein basis and not on a per cell basis, as we do, this 
might lead to different results. When comparing the ADA activities in 
CLL with various immunological markers, a significant difference was only 
found between CLL patients with paraproteinaemia and CLL patients 
without paraproteinaemia. 
Although it is rather difficult to compare the histochemical 
findings of Borgers et al.(2) with our biochemical studies, they seem 
to be in agreement. The weak staining for PNP of the majority of lymphoid 
cells in 6 B-CLL patients most probably represents the relatively low 
PNP activity in most of the CLL patients. Like Borgers et al., we also 
find CLL patients, who show a PNP activity comparable to control values. 
As was also the case with ADA, Ambrogi et al.(l) observed a relatively 
narrow range of low PNP activity in B-CLL patients. In our group of CLL 
patients however, 7 patients had PNP activities within our control range 
(fig. 1). Again this discrepancy might be attributed to the relatively 
limited number of patients(n=7) studied. 
Our findings of 5'NT activity in CLL are in agreement with data 
reported by others(lO). In our group of patients a 5-fold lower mean 
5'NT activity was observed than in control PBL. This difference would 
even be more pronounced when CLL В cells were compared with normal 
peripheral В cells, because these have a higher 5'NT activity than 
peripheral Τ cells(12,15,19). In our group, 4 out of the 20 patients 
showed 5'NT activities within our normal range(fig. 1). These patients 
(patients 532, 535, 543 and 546) all had paraproteinaemia(tabie 1). A 
significant correlation between the number of cells rosetting with 
mouse erythrocytes(E ) and the 5'NT(r=-0.57, p=0.004) and ecto-5'NT 
(r=-0.50, p=0.013) activities was found. When plotting these parameters, 
leukemic cell populations with relatively low 5'NT activity and a low 
percentage of E cells as well as populations with low 5'NT activity 
and a high percentage of E cells were seen. This apparent relation 
needs further investigations before conclusions can be drawn. 
The differences in mean AK, AMPD and AdKin activities in CLL 
lymphoid cells as compared to PBL were found to be statistically signif-
icant(table 2). The ranges of AMPD in CLL patients and in control persons 
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were almost completely overlapping. Only the distribution of the indiv­
idual activities in these ranges seemed to differ(fig. 2). The difference 
in mean AK and AdKin activities were more pronounced. Though 7 CLL 
patients fell in the normal range of the AK activity, none of the activ­
ities of the patients were below the mean control value(fig. 2). In the 
case of AdKin only one control value was found to be in the CLL activity 
range(fig. 2). 
It should be noted that in general the activities of the catabolic 
enzymes 5'NT, ADA and PNP are lower in CLL patients than in control 
individuals. In contrast, the anabolic enzymes AK and AdKin show in­
creased activities in CLL lymphocytes as compared to control PBL. Since 
AK and AdKin are involved in the synthesis and interconversion of 
nucleotides in cells, these enzymatic changes might have severe con­
sequences for the energy charge in lymphoid cells from CLL patients. 
Analysis of intracellular concentrations of purine nucleotides has to 
be done to clarify this point. 
Considering the mean 5'NT activity in B-CLL patients with and 
without paraproteinemia, a significant difference was observed. The 
patients without paraproteinemia showed a 10-fold lower mean 5'NT 
activity as compared with the patients with paraproteinaemia(table 3, 
fig. 1). A correlation between Ig production and 5'NT activity has been 
established earlier(3). It was shown that in patients with congenital 
agammaglobulinaemia 5'NT activities were decreased. In this disease the 
relatively low 5'NT activity might in part be attributed to the absence 
of peripheral В cells(12). Since В cells appear to have higher 5'NT 
activity than Τ cells(12,15,19), the consequence of this shift in 
lymphoid cell populations might be a lower net 5'NT activity. However, 
also in Τ cells of congenital agammaglobulinaemia a decreased 5'NT 
activity was observed(15). This supports the hypothesis that abnormal 
Τ cells may be responsible for the perpetuation of the disease and the 
low 5'NT activities. 
Our findings may support a relationship between 5'NT activity and 
Ig production because B-CLL patients with a paraproteinaemia, which was 
related to the leukemic cell population, had a much higher 5'NT activity. 
However, the higher 5'NT activity may also be a reflection of a more 
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mature В cell population in the CLL patients with paraproteinaemia, 
irrespective of the capacity of Ig production. Moreover a relationship 
with the occurrence of IgM heavy chains in the cytoplasma has also been 
established in ALL cells, where preß leukemias(having cytoplasmic IgM 
heavy chains) had a twice as high 5'NT activity(18) as the nonBnonT-ALL 
patients(not having cytoplasmic IgM heavy chains). It should be 
emphasized however, that further studies have to be performed on the 
role of 5'NT activity in В and Τ lymphocyte differentiation and function. 
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ABSTRACT 
Separation of human thymocytes according to size was performed 
using centrifugal elutriation. Six fractions were obtained. Two fractions 
(1 and 2) predominantly containing small sized thymocytes appeared to 
be poorly stimulated by phytohaemagglutinin(PHA). The number of cells 
agglutinating by peanut agglutinin(PNA) was relatively high in these 
fractions, whereas the number of cells staining for a-naphtyl acetate 
esterase(ANAE) was relatively low. It was concluded that fractions 1 
and 2 mainly exist of immature thymocytes. The fractions predominantly 
containing medium sized cells(3 to 6), were considered to be relatively 
mature thymocytes. Fractions 3 to 6 were PHA responsive, contained a 
high number of ANAE staining cells and relatively few cells agglutin-
ating by PNA. The activities of adenosine deaminase(ADA), purine nuc 
leoside phosphorylase(PNP), ecto-5'nucleotidase(ecto-5'NT) and deoxy-
cytidine kinase(dCK) were greatly different in these thymocyte fractions. 
Fractions 1 and 2 exhibited relatively low ADA, PNP and dCK activities, 
whereas these activities were higher in fractions 3 to 6. Ecto-5'NT 
activity was the highest in fraction 3. It could be shown that the 
ADA/PNP activity ratio is a marker for thymocyte maturation. Within 
thymocyte fractions a good correlation was found between the ecto-5'NT 
/dCK activity ratio and the inhibition of the PHA response by the 
nucleosides deoxyguanosine and deoxyadenosine. From these studies it 
was concluded that, since the number of cells contributing in the PHA 
response and the number of cells contributing in the purine enzyme 
activities differ considerably, it is not allowed to relate purine 
enzyme make-up with toxic effects of nucleosides in unseparated 
thymocytes. 
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INTRODUCTION 
The relevance of an intact purine metabolism for lymphoid cell 
function has been documented by a number of reports. Inherited deficien­
cy of adenosine deaminase(ADA) is associated with a defect in both Τ 
and В cell development in a considerable number of patients with severe 
combined immunodeficiency disease(12,16). Purine nucleoside phosphoryl-
ase(PNP) deficiency is associated with selective Τ cell dysfunction 
(13,23). A relatively low 5'NT activity has been described(8) in patients 
with congenital X-linked agammaglobulinaemia. A metabolic consequence 
arising from ADA and PNP deficiency is the accumulation of deoxynucleo-
sides in all somatic cells. Normally these compunds can be broken down 
to purine bases. Especially the lymphoid system has a high capacity to 
phosphorylate (deoxy)nucleosides to (deoxy)nucleotides(3,5,29). The 
latter compounds subsequently inhibit ribonucleotide reductase(lO), an 
enzyme essential for DNA synthesis. 
Not only with respect to lymphoid cell function, but also in 
relation to lymphocyte maturation, purine enzymes play an important 
roll. This is particularly true with regard to Τ cell maturation. The 
activities of deoxycytidine kinase and ecto-5'nucleotidase were found 
to be different in Τ cells at various stages of maturation. Thymocytes 
had a relatively low activity of ecto-5'nucleotidase(ecto-5'NT, 6) as 
compared to peripheral blood Τ lymphocytes(PBL-T). Deoxycytidine kinase 
(dCK) was higher in thymocytes than in PBL-T. The findings of relatively 
high ADA and low ecto-5'NT activities in thymocytes seem to parallel the 
findings of high ADA and low ecto-5'NT activities in Τ cell acute 
lymphoblastic leukemia(ALL, 18,22,27). The latter studies suggest that 
purine enzymes might be used as markers of Τ cells at various differen­
tiation stages(4) and that the pathways of purine nucleoside handling 
can differ considerably during Τ cell differentiation. Thymocytes appear 
to possess a relatively high phosphorylating capacity for deoxynucleo-
sides(6). Furthermore, due to a low ecto-5'NT activity(6,9) these cells 
have a low capacity to break down toxic nucleotides. Although evidence 
is accumulating that due to their enzymatic make-up, thymocytes are very 
vulnerable in inherited ADA and PNP deficiency, the exact mechanism of 
disturbed lymphocytic differentiation is not yet completely understood. 
113 
The different sensitivity towards deoxynucleosides of mature and 
immature Τ cells has been studied in vitro in relation to the prolifer­
ative response(6). However, these studies have been performed in unsep-
arated Τ cells from peripheral blood and lymphoid organs(thymus, tonsil, 
etc.)· Little is known about the intra-organ development and maturation 
of lymphoid cells. This applies particularly to the thymus: data on 
proliferative responses in which only a minority of cells is assayed(19) 
are related to enzyme activities in unseparated suspensions where all 
cells are assayed. We therefore studied purine metabolism at the intra-
thymus level using fractions enriched in mitogen responsive cells. Using 
centrifugal elutriation we were able to separate six subsets of thymo­
cytes. The enzymatic make-up of the various thymocyte fractions were 
studied in relation to the inhibition of proliferative response by 
deoxynucleosides. 
MATERIALS AND METHODS 
Thymocytes and Thymocyte Separation 
Human thymus tissue was obtained from children(aged 2 to 7 months), 
undergoing cardiac surgery for other purposes. All thymus tissue included 
in this study shared a normal architecture in histological examination 
(formalin fixed and paraffine embedded tissue, stained with hematotoxilin 
eosin). The tissue was minced in small pieces; the thymocytes were har­
vested in Hepes buffered RPMI 1640 and washed twice. Separation accor­
ding to size was performed by centrifugal elutriation under sterile con­
ditions at 4° C, using a Beekman J21C centrifuge equipped with a JE-6 
elutriation rotor. This procedure has been extensively described else-
where(ll). By stepwise decreasing the rotor speed, б fractions were 
obtained: the percentage of cells recovered in each fraction as well as 
the composition of each fraction is given in table 1. The data on phyto-
haemagglutinin(PHA) mitogen stimulation(stimulation indexes) in the 
fractions are also given(table 1). Data on immunological phenotyping 
for peanut agglutinin(PNA) binding capacity, for terminal deoxynucleo-
tidyl transferase(TdT) staining(markers for immature cortical thymocytes) 
and for a-naphtyl acetate esterase(ANAE) staining(a marker for more 
mature, mainly medullary thymocytes) are depicted in figure 1. The 
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Table 1: Some Characteristics of Thymocyte Fractions After Separation 
on Size 
Fraction 
Unseparated 
thymocytes 
1 
2 
3 
4 
5 
6 
Cell 
recovery 
(%) 
100 
50 
30 
8 
4 
3 
1 
Mono-* 
cytes 
(%) 
2 
0 
0 
0 
1 
2 
9 
Large 
sized 
cells 
(%) 
4 
0 
0 
1 
5 
10 
20 
Medium1 
sized 
cells 
(%) 
24 
7 
15 
52 
57 
54 
55 
Small' 
sized 
cells 
(%) 
70 
93 
85 
47 
37 
34 
16 
PHA2 
SI 
27 
3 
4 
26 
4b 
22 
6 
May Grünwald Giemsa staining. Results of PHA response are given as 
stimulation indexes(SI, 5 χ IO5 cells/culture). 
160-
80 
60-
Figure 1: Relative shifts in percentages of PNA binding, TdT positive 
and ANAE positive cells in various fractions obtained by separation on 
size of human thymocytes. Results are given as mean percentages of pos­
itive cells(± s.d.), the initial values being set to 100%. 
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nature and characteristics of the present cell populations have been 
published in more detail elsewhere(19). 
Peripheral Blood Τ Lymphocytes(PBL-T) 
Heparinized blood was obtained from the donor of the thymus and 
from healthy control donors. Mononuclear cells were isolated by Ficoll 
Isopaque(d=1.077 gr/ml) density gradient centrifugation. Τ lymphocytes 
were purified by sheep erythrocyte rosetting, Ficoll-Isopaque density 
centrifugation and isotonic ammonium chloride lysis of erythrocytes, 
following well established procedures. The sheep erythrocytes were pre-
treated with 2-aminoethyl isothiouronium bromide hydrobromide(Sigma 
A-5879, ref. 15). 
Mitogen Stimulation Tests 
Cultures were performed in round-bottom microtiter plates(Greiner, 
Alphen, The Netherlands) in RPMI 1640 with bicarbonate, L-glutamin, 
antibiotics and 20% heat inactivated human AB serum. Cells were tested 
at 10 5 cells/culture. This amount of cells was chosen to enable compar­
ison with PBL-T(usually cultured at 5 χ IO5 cells/culture). The rather 
low proliferative response after mitogen stimulation of unseparated 
thymocytes or of thymocyte subfractions was enhanced by supplementing 
the culture medium with both conditioned medium of human thymic epithe­
lial monolayer cultures(17) and medium of human peripheral blood mono­
nuclear cells after allogeneic and PHA stimulation. To obtain this 
latter conditioned medium, blood mononuclear cells of two donors were 
incubated together in the presence of PHA for two days, followed by ex­
tensive washing of the cells. After a second incubation for two days, 
the supernatant was harvested. Both conditioned media were used in the 
culture medium at a dilution of l:30(optimal dilution assessed in prior 
experiments). The conditioned media showed no mitogenic effect in 
thymocytes nor blood mononuclear cells; the media had an enhancing 
effect on the proliferative response after PHA stimulation of unsepara­
ted thymocytes and of thymocyte subfractions, whereas no effect was 
observed on the response of peripheral blood mononuclear cells. The 
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culture medium, including the supplements, showed neglegible activity 
of purine enzymes. In mitogen stimulation 16 pg PHA(HA15, Wellcome, 
Beckenham, U.K.) was applied. In the study on (deoxy)nucleoside inhib­
ition of the response, deoxyguanosine(Sigma D-900) was added in a final 
concentration of maximum 3 mM with a stepwise dilution(l:3) to a minimum 
of 1 μΜ. Deoxyadenosine(Sigma D-5875) was added in final molarities of 
maximal 300 μΜ and minimal 0.14 μΜ, in combination with deoxycoformycin 
(Warner-Lambert, Detroit, USA) in a molarity of 5 μΜ. In the inhibition 
studies with (deoxy)adenosine, cell cultures were first incubated with 
deoxycoformycin for 20 minutes to block all activity of adenosine 
deaminase present, followed by addition of (deoxy)adenosine. Cultures 
were incubated for about 90 hours at 37° С in humidified air with 5% 
COp. During the last 16 to 18 hours 1 pCi (methyl-3H)-thymidine(5 Ci/mol, 
Radiochemical Centre, Amersham, U.K.) was present in each culture. The 
cells were harvested on glassfiber filters with an automatic harvester 
(Skatron, Lierbyen, Norway). Air dried filters were sampled in scintil­
lation vials(Packard) and counted in toluene scintillator(Packard, 
containing 0.1 gr/1 Р0Р0Р and 5 gr/1 РР0). All cultures were performed 
in quadruplicate. Stimulation indexes(SI) were calculated as the mean 
counts per minute in mitogen stimulated cultures, divided by the mean 
counts per minute in unstimulated cultures. From (deoxy)núcleos i de 
inhibition curves(counts per minute vs. concentration of inhibition) the 
concentration of nucleoside was determined, at which the proliferative 
response was 50% of the PHA response in absence of inhibitors. 
Enzyme Assays 
The activities of adenosine deaminase(ADA, E.C. 3.5.4.4) and 
purine nucleoside phosphorylase(PNP, E.C. 2.4.2.1) were assayed by 
making use of an earlier described micromethod(26), using radiochemically 
labeled adenosine and hypoxanthine, respectively. In 1,000 cells the 
ADA activity was determined by measuring the deamination of adenosine 
to inosine. Substrate and product were separated on PEI-cellulose thin 
layer chromatography plates. The specific activity was calculated from 
the amount of labeled inosine formed and expressed in 10"9 moles of 
inosine formed/106 cells.hour. Essentially the same method, with hypo-
xanthine as a substrate, was used to determine the PNP activity. 
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Ecto-5'nucleotidase(ecto-5'NT, E.C. 3.1.3.5) activity was assayed in 
intact cells using 1MC-AMP as a substrate. This method has been described 
earlier by Edwards et al.(8). Deoxycytidine kinase(dCK, E.C. 2.7.1.74) 
was assayed essentially according to Ullman et al.(25). In a 8 μΐ para-
film microcuvette(26) J μΐ of a cell suspension(12 χ IO6 cells/ml) was 
pipetted. The cells were frozen(15 min, -20° С) and lyophilized over­
night. Threeyl of an incubation mixture containing 5 μΜ 14C-deoxycytidine 
(Radiochemical Centre, Amersham), 2 mM ATP, 5 mM MgCl?, 0.5 mM cytidine, 
0.5 mM deoxyuridine, 50 mM K2HP04/KH2P04(pH 7.4) and 0.33%(v/v) triton 
X-100(Packard Instrument, Brussels, Belgium) were added; incubation 
(1 hour, 37° C) was stopped in ice. One μΐ of the reaction mixture was 
spotted on PEI-cellulose thin layer chromatography plates(Machery-Nagel, 
SEL 300 PEI). The plates were prewashed in distilled water overnight. 
The chromatography was performed using 0.15 M NaCl as a solvent. 
Unlabelled deoxycytidine and deoxyCMP were cochromatographed and after 
detection under UV light the spots were cut out and counted in a liquid 
Spec. act 
1500 
1250-
1000 
750 
500-
250 
Figure 2: ADA and PNP activities(10-9 moles/106 cells.hour) in thymo­
cyte fractions(1 to 6), unseparated thymocytes(U) and peripheral blood 
Τ lymphocytes(Τ). The mean values(± s.d.) of five separate experiments 
are indicated. 
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Spec. act 
7.5-
5.0 
2.5 
Figure 3: Ecto-5'NT and dCK activities(10-9 moles/106 cells.hour) in 
thymocyte fractions(1 to 6), unseparated thymocytes(U) and peripheral 
blood Τ lymphocytes(Τ). The mean values(± s.d.) of 5 separate exper­
iments are indicated. 
scintillation counter. Specific activity was expressed as 10~9 moles 
deoxycytidine nucleotides/106 cells.hour. 
RESULTS 
Enzyme Activities 
The activities of ADA, PNP, ecto-5'NT and dCK were assayed in 
peripheral blood Τ lymphocytes(PBL-T), unseparated thymocytes(U) and 
thymocyte subfractions separated on size with the elutriation technique. 
The mean specific enzyme activities of 5 separate experiments are shown 
in the histograms of figs. 2 and 3. ADA activity was found to be relat­
ively low in PBL-T(156 10"9 moles/106 cells.hour). In unseparated 
thymocytes ADA activity was considerably hicjiier(721 IO"9 moles/106 cells, 
hour). In the PHA unresponsive fractions 1 and 2, ADA activity was 722 
and 772 10"9 moles/106 cells.hour, respectively. In the PHA responsive 
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fractions ADA activity ranged from 936 to 1357 10"9 moles/106 cells.hour 
(fractions 3 to 6). In contrast to the ADA activity PNP activity was 
highest(fig. 2) in the PBL-T(51 10"9 moles/106 cells.hour). In thymocyte 
subfractions the PNP activity increased with the fraction number and 
ranged from 35 10"9 moles/106 cells.hour in fraction 1 to 172 10"9 moles/ 
106 cells.hour in fraction 6. 
The activity of dCK(fig. 3) was found to be comparable in unsepar-
ated thymocytes and PBL-T(0.088 and 0.064 10-9 moles/106 eel Is.hour, 
respectively). As was the case with ADA and PNP the lowest dCK activities 
in thymocyte subfractions were found in the PHA unresponsive fractions 
1 and 2(0.082 and 0.098 10"9 moles/106 cells.hour, respectively). In the 
PHA responsive fractions 3 to 6 the dCK activity ranged from 0.156 to 
0.38 10"9 moles/106 cells.hour. The results of ecto-5'NT activity deter-
minations were essentially different compared to the enzyme activities 
described above(fig. 3). Whereas an increasing enzyme activity was seen 
with the fraction number in the case of ADA, PNP and dCK, the maximal 
ecto-5'NT activity in thymocyte subfractions was observed in fraction 3 
(2.0 10"9 moles/106 cells.hour). The activity in the remaining subfrac-
tions ranged from 0.4 10~9 moles/106 cells.hour in fraction 1 to 1.4 
10"9 moles/106 cells.hour in fraction 4. Ecto-5'NT activity in PBL-T 
was about 12-fold higher than in unseparated thymocytes. It should be 
emphasized that, although the standard deviations especially from 
ecto-5'NT are rather high, the activity patterns in all five experiments 
are basically comparable; e.g. in every experiment maximal 5'NT activity 
was found in fraction 3. 
Inhibition of PHA Response by (Deoxy)nucleosides 
Deoxyadenosine and adenosine were added in different concentrations 
to PHA stimulated cultures after pre-incubation for 20 min. with 5 yM 
deoxycoformycin. Deoxyguanosine was used without any further additives. 
In fig. 4 the results of an experiment carried out in quadruplicate are 
shown. The results are presented as the (deoxy)nucleoside concentration 
at which the PHA response was 50% of the response without any addition. 
Four comparable experiments were carried out, which essentially showed 
the same results. The mean PHA responses without any addition of 
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3 U 5 6 U Τ 
Figure 4: Inhibition of proliferative responses after PHA stimulation 
by adenosine(χ), deoxyadenosine(o) and deoxyguanosine(·) in thymocyte 
fractions(3 to 6), unseparated thymocytes(U) and peripheral blood Τ 
lymphocytes(Τ). The (deoxy)nucleoside concentrations given, indicate 
the concentration at which 50% of the PHA response without any addition 
is seen(n=4). 
nucleosides or deoxycoformycin in the experiments of fig. 4 are for 
PBL-T: 35,000 cpm; unseparated thymocytes(U): 7,000 cpm; fraction 3: 
15,000 cpm; fraction 4: 50,000 cpm; fraction 5: 30,000 cpm; fraction 6: 
40,000 cpm. Fractions 1 and 2 were considered to be unresponsive(<1500 
cpm). When deoxyguanosine was added, the PHA responses of PBL-T and 
unseparated thymocytes were inhibited to a comparable extent. Thymocyte 
fractions 3, 4, 5 and 6 were inhibited each to an increasing extent by 
deoxyguanosine(fig. 4). Fractions 1 and 2 could not be evaluated because 
these fractions showed only marginal proliferative responses after PHA 
stimulation. Comparing the effects of deoxyadenosine and adenosine in 
the presence of the ADA inhibitor deoxycoformycin, cells were more 
sensitive to deoxyadenosine than they were to adenosine. Again PBL-T 
and unseparated thymocytes were inhibited by deoxyadenosine to a 
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comparable extent. In thymocyte subtractions this inhibition was minimal 
in fraction 3, whereas fraction 6 was mostly inhibited. 
DISCUSSION 
The application of a micromethod using 1,000 to 6,000 cells per 
incubation on one hand and an elutriation technique for the isolation 
of small subpopulations of thymocytes(11) on the other hand enabled us 
to study several aspects of purine metabolism in thymocyte subfractions. 
The finding of relatively high ADA activity in thymocytes as com-
pared to PBL-T is compatible with the high levels of ADA activity 
observed in T-ALL(4,22,27). Using an immunohistochemical technique, 
Chechik et al.(4) have elegantly shown that cells positive for a human 
thymus associated leukemia antigen, which appeared tobe ADA, were predominan 
present in the cortical regions of the thymus. In the thymic medulla, 
ADA positive cells were observed less. It has been shown that the thymic 
cortex contains less mature lymphocytes than the medulla(2). Apparently 
it is not correct to compare the qualitative results of Chechik et al. 
with the quantitative data we have obtained. In our experiments highest 
ADA activities are observed in the PHA responsive(i.e. more mature, 
medullary thymocyte containing) fractions. Fractions 3 to 5 contained 
relatively high numbers of ANAE positive cells and little PNA positive 
cells(fig. 1). This indicates that fractions 3 to 5 are relatively 
mature as compared to fractions 1 and 2. 
In rat thymocytes fractionated on Ficoll-Hypaque density gradients 
the highest levels of ADA activity were observed in fractions enriched 
in immature cortical thymocytes(l). These results lead to the conclusion 
that intrathymic ADA activities in the rat are expressed differently 
from humans. In contrast to the findings on ADA, the findings on PNP 
activities in rat and human thymocyte subfractions seem to be similar. 
As was the case in our PHA unresponsive human thymocyte fractions, 
lowest PNP activities are also found in rat thymocyte fractions enriched 
for cortical thymocytes(i.e. less mature). Higkest PNP activities are 
found in PHA responsive human thymocyte fractions(figs. 1 and 2) and in 
medullary rat thymocyte enriched fractions(l). Although there is an 
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Figure 5: ADA/PNP and ecto-5'NT/dCK activity ratios in thymocyte frac­
tions (1 to 6), unseparated thymocytes(U) and peripheral blood Τ lympho­
cytes (Τ). The mean values(± s.d.) of 5 separate experiments are indicated. 
apparent contradiction regarding ADA activity between the results ob­
tained in rats and in humans, it seems justified to state that stages 
in Τ cell maturation in the thymus can be characterized by either the 
absolute level of PNP or the relative levels of ADA and PNP(fig. 5). 
PHA unresponsive thymocytes have relatively high ADA/PNP activity ratios 
(21 and 19), whereas PHA responsive thymocytes have relatively low 
ADA/PNP activity ratios(14 to 7). The same applies to unseparated 
thymocytes and peripheral blood cells. The mean ADA/PNP ratio in thymo­
cytes is found to be 15, in PBL-T this ratio is 1. 
Although ADA and PNP appear to be of vital importance for normal lymphoid 
cell differentiation, little is known about the exact role of both 
enzymes in precursor Τ cells. Shore et al.(21) have shown that precursor 
Τ cells derived from ADA deficient patients may be induced to form 
rosettes with sheep red blood cells by incubation with normal thymic 
epithelial monlayers. When these monolayers are treated with an ADA 
inhibitor, this induction is inhibited. It is known that deoxyadenosine 
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in the presence of an ADA inhibitor blocks proliferative responses(28). 
however, from the fact that, when once entered blastogenesis thymocytes 
become less vulnerable to the addition of deoxyadenosine and deoxycofor-
mycin(24), it might be concluded, that ADA activity is more vital for 
thymocytes in early maturation stages. 
The ratio of deoxynucleoside phosphorylating capacity and deoxy-
nucleotide dephosphorylating capacity has been subject of a number of 
studies. Since no substantial difference between deoxynucleotide forming 
capacities was observed between Τ and В lymphoblasts(29), another 
metabolic basis for the differential toxicity of deoxynucleosides was 
suspected(5,7). The higher levels of ecto-5'NT activity in В cells was 
found to provide В cells with a more effective way of breaking down 
deoxynucleotides(3). In order to predict the possible effects of nucleo­
sides on Τ cells of various maturation stages, the activity ratio of 
ecto-5'NT/dCK was calculated. The relatively low ecto-5'NT activity in 
thymocytes as compared to PBL-T was described previously(6,9). The dif­
ference found between dCK activity in PBL-T and thymocytes(6) was not 
found in our studies. Comparable activities of dCK were observed in 
thymocytes and PBL-T(fig. 3). Whereas dCK activity was increasing with 
cell size, ecto-5'NT had a maximal activity in fraction 3. When the 
relationship between nucleoside toxicity and the nucleotide synthesis/ 
nucleotide breakdown ratio also applies to the intrathymic situation, 
the conclusion seems justified that the cells in fraction 3 are most 
vulnerable to nucleoside toxicity. 
Inhibition studies with nucleosides showed a comparable effect of 
deoxyguanosine and deoxyadenosine to PBL-T and unseparated thymocytes. 
Previously it was reported that thymocytes are more vulnerable towards 
deoxyguanosine intoxication than PBL-T(6). In the latter study 50% 
inhibition of the PHA response was observed at a deoxyguanosine concen­
tration of 150 uM in PBL-T. This lower level of deoxyguanosine intoxica­
tion as compared to our studies might be explained by the different 
numbers of cells used. Cohen et al.(6) used 5 χ IO4 cells/well, whereas 
we used 105 cells/well. Yet, why the relative effects on PBL-T and 
thymocytes are found to be different, remains unclear to us. It might 
well be that the addition of the conditioned media in order to enhance 
proliferative responses accounts for this phenomenon. The activities of 
124 
PNP as well as ADA were assayed in these supplements and found to be 
neglegible. A change in deoxynucleoside toxicity induced by the con­
ditioned media might be possible in the more immature cells. Deoxy-
guanosine and deoxyadenosine are believed to interfere with DNA synthesis 
through their phosphorylated derivatives deoxyGTP and deoxyATP, respec­
t i v e l y ^ ^ ) . These nucleotides inhibit ribonucleotide reductase which 
catalyzes the formation of deoxyribonucleotides necessary for DNA syn-
thesis(lO). In the thymocyte subpopulations, which were all cultured 
under identical conditions, we find an excellent correlation between 
deoxyguanosine and deoxyadenosine effects on the PHA response and the 
enzymes that may influence the concentrations of deoxyGTP and deoxyATP. 
Relatively low ecto-5'NT activity may provide the cells with a rather 
poor possibility to breakdown formed nucleotides. Previously the reduced 
rate of deoxyATP degradation in Τ cell lines as compared to В cell lines 
was explained by a relatively low 5'NT activity(3,29). Nucleoside kina­
ses, the enzymes that catalyze the phosphorylation of deoxyguanosine and 
deoxyadenosine to their respective nucleotides, are supposed to play an 
essential role in the specific intoxication of the lymphoid system in 
ADA and PNP deficiency(25). From our experiments in thymocyte subfrac­
tions it is indicated that the activity ratio of ecto-5'NT/dCK(fig. 5) 
is related to nucleoside toxicity in these subfractions. When the stat­
istical correlation is calculated between the ecto-5'NT/dCK activity 
ratio of fractions 3 to 6 and the concentration of (deoxy)nucleosides 
at which 50% of the PHA response is seen, a highly significant correla­
tion coëfficient(Pearson's correlation coefficients >0.9) is found for 
the three nucleosides tested. In other words, the higher the ratio, the 
higher deoxynucleoside concentrations are needed to obtain 50% inhibition 
of the PHA response. 
The knowledge of this biochemical heterogeneity with regard to 
enzymatic make-up and nucleoside toxicity in the intrathymic situation 
is of importance when studying mechanisms of cytotoxicity in relation 
to mitogenic responses. Since cells contributing to the PHA response 
(fractions 3 to 6) and cells hardly contributing to the PHA response 
(fractions 1 and 2) differ considerably in their relative and absolute 
enzyme activities(figs. 2, 3 and 5), and a relation is indicated 
between some of these enzyme activities and nucleoside intoxication, it 
is not allowed to relate enzyme activities and nucleoside induced 
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inhibition of the PHA response in unseparated thymocytes. 
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ABSTRACT 
Human peripheral blood lymphocytes were stimulated with different 
mitogens(phytohaemagglutinin, PHA; pokeweed mitogen, PWM; concanavalin 
A, ConA; and protein A, SpA) known to activate different subpopulations 
3H-Thymidine and 3H-leucine incorporation were studied in the presence 
and absence of adenosine, deoxyadenosine and the adenosine deaminase 
inhibitor erythro-9-(2-hydroxy-3-nonyl)-adenine hydrochloride(EHNA). 
In addition the effects on in vitro IgG secretion induced by PWM or SpA 
have been studied. 
Adenosine and deoxyadenosine added to the cultures together with 
EHNA inhibit the Τ cell mitogenic response. 3H-Thymidine incorporation 
in ConA and PWM stimulated Τ cells is more affected by EHNA and (deoxy)-
adenosine than in PHA stimulated cultures. At very low EHNA concentra­
tions a facilitating effect on the protein secretion is observed in the 
PHA stimulated cultures. These findings suggest that different subsets 
of Τ cells have different sensitivities. EHNA and adenosine inhibit the 
IgG production by PWM stimulated cells. This inhibition might be secon­
dary to a blockade of either the В cell or the T-helper cell activity, 
or to enhancement of T-suppressor activity. We favour the latter pos­
sibility. Deoxyadenosine in combination with EHNA enhances IgG secretion 
in PWM stimulated cells at low concentrations, whereas higher concen­
trations have an inhibitory effect. 
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INTRODUCTION 
Adenosine and deoxyadenosine are known inhibitors of the in vitro 
proliferative response of peripheral blood lymphocytes(PBL) to various 
mitogens(3,4,9,ll,13,18,19). Erythro-9-(2-hydroxy-3-nonyl)-adenine 
hydrochloride(EHNA), an inhibitor of the enzyme adenosine deaminase(ADA), 
potentiates the inhibitory effects of both adenosine and deoxyadenosine. 
The incorporation of 3H-leucine into protein appeared to be a more sen­
sitive index of adenosine toxicity than the incorporation of 3H-thymidine 
(3). A differential sensitivity of cultured human Τ and В lymphoblasts 
towards the toxic effects of adenosine and deoxyadenosine has been ob­
served: Τ cells are more sensitive than В cel Is(5,15). On the basis of 
3H-thymidine incorporation, mouse splenic cells stimulated by lipopoly-
saccharide(LPS) were less sensitive to the addition of adenosine than 
the concanavalin A(ConA) stimulated cells(17). Using a plaque forming 
cell assay, a biphasic effect of adenosine was seen on the in vitro 
antibody production in mice. Concentrations of adenosine around ImM 
stimulated antibody production in vitro, whereas concentrations above 
1.5 mM had inhibitory effects(17). 
The effects of adenosine and deoxyadenosine on subpopulations of 
regulatory lymphoid cells are poorly documented, both in animal models 
and in humans. In a first approach to this issue we have compared the 
effects on 3H-thymidine and 3H-leucine incorporation in parallel cultures 
stimulated with different mitogens known to activate different subpop­
ulations (phytohaemaggluti ni η , PHA; ConA; pokeweed mitogen, PWM; protein 
A from Staphylococcus aureus, SpA). In addition, the effects on in vitro 
IgG secretion induced by PWM or SpA(both Τ dependent polyclonal В cell 
activators) have been studied. 
Adenosine and deoxyadenosine probably exert their effects according 
to different mechanisms. These may include intra- and extracellular 
events. Intracellular accumulation of deoxyATP, decreased phosphoribosyl-
pyrophosphate(PRPP) availability and inhibition of transmethylation 
reactions might occur(for review see 16). Ectracellular mechanisms might 
involve activation of adenosine receptors leading to increased or de­
creased levels of cyclic AMP within the cell depending on the type of 
adenosine receptor involved(2). It seems likely that different types of 
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cells involved in the immune response express different sensitivity to 
one of these mechanisms. 
MATERIALS AND METHODS 
Cell Preparation 
PBL from healthy volunteers were prepared by centrifugation of 
heparinized blood, diluted with two volumes of Hank's balanced salt 
solution on Ficoll-Metrizoate(gravity 1.077 gr/ml; 1). 
Mitogens 
PHA(PHA-P, Wellcome) was used in a final concentration of 1 pgr/ml; 
ConA and PWM were purchased from Gibco and used at a final dilution of 
5 ygr/ml and l/100(v/v), respectively. Purified protein A was obtained 
from Pharmacia Fine Chemicals AB(Uppsala, Sweden, batch No. C12414); it 
was used in a final concentration of 10 pgr/ml. 
Culture Conditions 
Cel ls(25 χ 101*) were cultured in flat bottomed mi cropl ates (Micro-
test II, No. 3040F; Falcon, B.D. Oxnard CA) in 250 μΐ culture medium. 
This consisted of Hepes buffered RPMI 1640(Flow Labs., Rockville, MD) 
supplemented with 40 mM glutamine, 40 ygr/ml gentamycin, 0.05 μΜ 
2-mercaptoethanol and 102(ν/ν) foetal calf serum(FCS; Microbiological 
Ass., Bethesda, MD, batch No. 90874). All cultures were set up in 
triplicate. Incubation was performed at 37° С in a humidified atmosphere 
with or without 5% C0-. 
Measurement of DNA Synthesis 
Five microCuries of methyl-3H-thymidine(specific activity 10 Ci/ 
mmol, IRE., Fleurus, Belgium) in 0.05 ml RPMI was added to the culture 
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18 hours prior to harvesting. Cells were collected on glass fiber filter 
paper(Reeve Angel fibre filter, grade: 934 AH, Whatman Inc., NJ, USA) 
using a MASH II cell harvester(Microbiological Ass., Bethesda, MD, USA). 
The 3H-thymidine incorporation was determined by counting the radioac­
tivity of the filter discs in a Tri-Carb liquid scintillation counter 
(Packard Instrument Co.). 
Assessment of Protein Synthesis 
Twentyfour hours before harvest, the microplates were centri fuged, 
the cells washed once with leucine free RPMI 1640, and the pellet resus-
pended in leucine free culture medium supplemented with 20 mCi/ml 3H-
leucine(specific activity 53 Ci/mmol, The Radiochemical Centre, Amersham). 
No further mitogen was added at this time. After 24 hours at 37° C, the 
plates were centrifuged and replicate supernatants were collected pooled 
and frozen at -40° С before determination of their Ig content. Cells were 
then collected on glass filter paper and the 3H-leucine incorporation 
was determined by counting the radioactivity of the filter discs. For 
determination of protein secretions the supernatants were precipitated 
by trichloroacetic acid(5%(w/v) final concentration). 
Measurements of Ig Secretion 
The assay for the measurement of Ig secretion was performed in 
microplates: 50 μΐ of the supernatant(see above) was mixed with 50 μΐ 
of monospecific sheep antihuman Fe serum; either anti-Fc of IgG, or 
anti-Fc of IgA, or anti-Fc of IgM. After 60 min. incubation at room 
temperature, the mixture was supplemented with 50 μΐ of a solution con­
taining 30 ugr of either IgG, IgA or IgM purified myeloma protein. These 
purified myeloma proteins were added in large excess in order to achieve 
a maximal precipitation efficiency in each assay. All assays were per­
formed in triplicate. The myeloma proteins and the corresponding anti sera 
were prepared as previously described(6,7). The antisera were used at a 
dilution providing antibody excess as determined by precipitation assays. 
Their specificity has been assessed by a combination of Ouchterlony and 
immunoelectrophoresis(14). The plates were then sealed and incubated 
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overnight at room temperature. The precipitates were collected on glass 
filter paper(Whatman GF/B) and washed with cold phosphate buffered saline 
using a Skatron(Flow Lab.) cell harvester. The dried discs were first 
treated with 200 μΐ Soluene II(Packard Instrument Co.) before addition 
of 7 ml toluene scintillation fluid. For each assay, the non-specific 
binding was measured on supernatants from heat-killed cells, processed 
under exactly the same conditions. After subtraction of the non-specific 
binding(mean ± standard deviation), the results were expressed in cpm 
per 250,000 cells originally present in the culture. 
RESULTS 
Mitogenic Responses to PHA, ConA and PWM 
The 3H-thymidine incorporation into both PHA and ConA stimulated 
cells is inhibited at concentrations of EHNA exceeding 10 uM(fig. la 
and lb). However, in the ConA stimulated cultures the inhibitory effect 
of EHNA is more pronounced. Adenosine(10 μΜ) potentiates these effects 
but again the ConA stimulated cultures seem more sensitive than the PHA 
stimulated cultures(fig. la and lb). In the presence of 1 μΜ deoxyadeno-
sine hardly any thymidine incorporation at all EHNA concentrations tested 
is observed. EHNA inhibits the proliferative response of the PWM stim­
ulated cells to an extent comparable to the ConA stimulated cultures 
(fig. lb and lc). This inhibitory action is strongly potentiated by 
adenosine and even more by deoxyadenosine. 
Parameters of Τ Lymphocyte Activation 
PHA stimulation was studied in more detail, using 3H-thymidine in­
corporation as a parameter for proliferative response and 3H-leucine 
incorporation as a parameter for protein biosynthesis. Labelling of both 
intracellular and excreted proteins was inhibited at EHNA concentrations 
higher than 10 yM(fig. 2a). Adenosine and deoxyadenosine increased this 
inhibitory effect. In the presence of adenosine(10 μΜ) the proliferative 
response was effected at EHNA concentrations above 10 μΜ. With deoxy-
adenosine(l μΜ) significant inhibition was already observed at an EHNA 
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Figure 1: Effect of EHNA only(·) and with addition of adenosine (10 μΜ; 
χ) or deoxyadenosine(1 μΜ; о), on the proliferative response of human 
peripheral blood lymphocytes stimulated by PHA, ConA and PWM. The means 
(s.d. <15%) of three experiments carried out in three-fold are indicated. 
The hatched area represents the mean normal control value ± two standard 
deviations. 
concentration of 1 μ Μ ( ^ . 2a). In PHA stimulated cultures EHNA affected 
intracellular 3H-leucine incorporation more profoundly than the 3H-
thymidine incorporation: at 10 μΜ EHNA, protein synthesis was clearly 
depressed, whereas 3H-thymidine incorporation was not(fig. 2b and 2a). 
Addition of 10 μΜ adenosine greatly enhanced the inhibitory effect of 
EHNA on 3H-leucine incorporation. Deoxyadenosine(l μΜ) abolished leucine 
incorporation at EHNA concentrations above 1 μΜ, whereas at 0.1 μΜ EHNA 
no significant inhibition was observed(fig. 2b). The labelling of ex­
creted proteins(fig. 2c) seemed less affected by EHNA than the labelling 
of intracellular proteins. On the contrary at 0.1 μΜ EHNA even increased 
amounts of radioactivity were measured in the excreted protein fraction 
(fig. 2c). An inhibitory effect of EHNA alone was only seen at the 
highest concentration used(100 μΜ). Even more clearly as was the case 
with thymidine incorporation, adenosine(10 μΜ) and deoxyadenosine(l μΜ) 
potentiated the effect of EHNA. 
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Figure 2: Effect of EHNA only(·) and with addition of adenosine(10 μΜ; 
χ) or deoxyadenosine(1 μΜ; о), on the proliferative response, protein 
synthesis and protein secretion of human peripheral blood lymphocytes 
stimulated by PHA. The means(s.d. <15%) of three experiments carried 
out in three-fold are indicated. The hatched area represents the mean 
normal control value ± two standard deviations. 
Parameters of Τ cell Dependent В Lymphocyte Activation 
In this set of experiments PWM and SpA were used as Τ cell depen­
dent В lymphocyte mitogens. Since essentially the same results were ob­
tained with both mitogens, only the data on PWM are reported. Next to 
3H-thymidine and 3H-leucine incorporation, the secretion of 3H-IgG, 
3H-IgA and 3H-IgM was studied in the PWM stimulated cultures. Only the 
data on IgG are reported, since IgA and IgM measurements essentially 
showed the same results. 
In PWM stimulated cultures, EHNA alone inhibits IgG synthesis at 
concentrations higher than 100 μΜ. Both adenosine(10 μΜ) and deoxyaden-
osine(l μΜ) show a strong synergistic action(fig. 3c). As IgG production 
is not necessarily related to lymphocyte proliferation, the influence of 
the above compounds on 3H-thymidine and 3H-leucine uptake in parallel 
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Figure 3: Effect of EHNA only(·) and with addition of adenosinedO μΜ; 
χ) or deoxyadenosine(1 μΜ; о), on the proliferative response, protein 
synthesis and IgG secretion of human peripheral blood lymphocytes 
stimulated by PWM. The means(s.d. <15%) of three experiments carried 
out in three-fold are indicated. Th hatched area represents the mean 
normal control value ± two standard deviations. 
cultures has been assessed. The results indicate that parallelism exists 
between the inhibition of labeled IgG secretion and the intracellular 
thymidine and leucine incorporation(fig. 3a, 3b and 3c). In PWM stimul­
ated cultures, EHNA alone showed only at 1000 μΜ clear inhibitory effects 
on both thymidine and leucine incorporation. As in the PHA stimulated 
cultures(fig. 2a en 2b), the presence of EHNA and 10 μΜ adenosine en­
hanced these effects. In the presence of 1 μΜ deoxyadenosine, thymidine 
and leucine incorporation were even more reduced; at EHNA concentrations 
of 100 and 1000 μΜ incorporation levels were at the limit of detection 
(fig. 3a and 3b). 
Using increasing amounts of adenosine with 1 μΜ EHNA, incorporation 
of thymidine and leucine and secretion of IgG appeared to be dose depen­
dentif ig. 4a, 4b and 4c). Note that in cultures without any EHNA added, 
adenosine had no significant effect on these three parameters. In 
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Figure 4: Effect of adenosine with(x) or without(·) addition of EHNA 
(1 μΜ) on the proliferative response, protein synthesis and IgG secre­
tion of human peripheral blood lymphocytes stimulated by PWM. The means 
(s.d. <15%) of three experiments carried out in three-fold are indicated. 
The hatched area represents the mean normal control value ± two standard 
deviations. 
parallel experiments deoxyadenosine alone(l to 1000 μΜ) had no striking 
effect on thymidine and leucine incorporation, nor on 3H-IgG secretion 
(fig. 5a, 5b and 5c). In the presence of 1 μΜ EHNA however, a dramatic 
inhibition of thymidine uptake was already observed at 0.1 μΜ deoxy­
adenosine. This was in contrast with the biphasic effect on the 3H-
leucine and 3H-IgG secretion. At 0.1 and 1 μΜ deoxyadenosine, labelling 
was significantly increased in the presence of 1 μΜ EHNA, whereas at 
10 and 100 μΜ deoxyadenosine a striking decrease of leucine incorporated 
and 3H-IgG secreted was seen. In cultures performed in the presence of 
0.1 μΜ deoxyadenosine and 1 μΜ EHNA an inhibition of thymidine uptake 
was coexistent with an increase of 3H-leucine incorporation and IgG 
secretion(fig. 5). 
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Figure 5: Effect of deoxyadenosine with(x) or without(·) addition of 
EHNA(1 μΜ) on the proliferative response, protein synthesis and IgG 
secretion of human peripheral blood lymphocytes stimulated by PWM. The 
means(s.d. <15%) of three experiments carried out in three-fold are 
indicated. The hatched area represents the mean control value ± two 
standard deviations. 
DISCUSSION 
The present results confirm and extend previous findings: in the 
presence of an ADA inhibitor, Τ cell mitogenic responses are inhibited 
by adenosine and deoxyadenosine(3,13,18). When comparing thymidine and 
leucine incorporation as parameters, the latter seems a more sensitive 
index(fig. 2a and 2b; ref. 3). 
Inhibiting ADA activity with varying amounts of EHNA will eventually 
lead to an accumulation of a certain amount of adenosine and deoxyaden­
osine. Apparently this has no detrimental effect on thymidine and leucine 
uptake in the PWM stimulated cultures. On the other hand when inhibiting 
ADA with a fixed EHNA concentration and adding extra adenosine or deoxy­
adenosine, the accumulation of these compounds and their derivatives 
might lead to effects mediated by the different mechanisms mentioned in 
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the introduction, depending on the respective concentrations. 
The present results show that 3H-thymidine incorporation in cultures 
stimulated by ConA and PWM is more sensitive to the inhibitory effects 
of EHNA and (deoxy)adenosine than in the PHA stimulated cultures(fig. 1). 
These results suggest that subsets of Τ cells are differently affected. 
Indeed it has been shown that PHA and ConA stimulate different though 
overlapping Τ cell subsets(lO). ConA stimulates both suppressor and 
helper cells and PHA mainly stimulates T-helper cells. Due to this fact, 
one might speculate that T-suppressor cells are more vulnerable as com­
pared to T-helper cells to the inhibitory effects of adenosine and deoxy-
adenosine in combination with EHNA. It should be pointed out that the 
relative amounts of thymidine and leucine incorporated may vary between 
different experiments. For instance in comparable experiments, fig. la 
and fig. 2a, the thymidine incorporation in the presence of 10 μΜ EHNA 
and 10 μΜ adenosine is 75% and 50% of the untreated control, respectively. 
However, within one experiment the variation was never more than 10 to 
15%. This stresses the importance of a precise definition of both the 
methods used to purify mononuclear cells and the culture conditions(8). 
Among these the nature of the serum is particularly critical. Indeed it 
is known that serum differs in adenosine and ADA content, even after 
heat inactivation. 
Interesting is the observation of the parallelism observed in the 
PHA stimulated cultures between the effects of these compounds on 
thymidine incorporation on one hand and leucine incorporation on the 
other hand. However, inhibition is more pronounced in the latter situa-
tion(fig. 2). Still more interesting is the observation of a facilitating 
effect of a very low concentration of EHNA(0.1 μΜ) on the protein 
secretion. At present no explanation can be given for this finding. 
From the data in fig. 3c and 4c, it is evident that the combination 
of EHNA and adenosine inhibits the 3H-IgG production by PWM stimulated 
cells. This inhibition might be secondary to a blockade of either the В 
cell, or to enhancement of T-suppressor activity. 
As opposed to adenosine, deoxyadenosine exerts a biphasic effect 
(fig. 5). At low concentrations and in the presence of EHNA and 1 μΜ 
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deoxyadenosine it enhances labeled IgG secretion, whereas higher concen­
trations have an inhibitory effect. This enhancing effect is associated 
with a reduction in thymidine uptake. As it is known that DNA synthesis 
is necessary for suppressor activity and not for T-helper activity(12), 
these data could be interpreted as indicating a blockade of suppressor 
cells at deoxyadenosine concentrations below 1 μΜ. The above hypothesis 
is amenable to experimental testing, namely by comparing the effects of 
adenosine to those of deoxyadenosine in the presence of EHNA on purified 
preparations of T-helper and T-suppressor cells. 
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INTRODUCTION 
After Giblett and associates(65) in 1972 had postulated a causal 
relationship between a genetic deficiency of an enzyme of purine metab­
olism, adenosine deaminase(ADA), and a combined deficiency of Τ and В 
cell function, a serious effort has been made to elucidate the role of 
purine metabolism in immune function(120,136,170). The metabolic basis 
for immunodeficiencies, the selective sensitivity of the immune system 
for deficiencies of enzymes of purine metabolism and the different 
susceptibility for deoxynucleosides between Τ and В cells, have been 
subject of extensive studies during the last decade. 
These studies were mainly carried out in in vitro systems. Mouse 
3T6 fibroblasts(69), human lymphoblastoid cell lines(104) as well as 
freshly isolated eel Is(81) are some examples of these in vitro systems. 
Both animal(177) and human(133) in vivo studies were also done for 
investigating the relation between purine metabolism and the immune 
system. These studies provided evidence that purine metabolism plays an 
essential role in the development of the immune sytem. This was also 
illustrated by the finding, that different activity levels of purine 
metabolizing enzymes were found in various stages of lymphoid differen­
tiation. 
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Studies on purine metabolism in lymphocytic leukemia showed that 
the enzymatic make-up of lymphoid cells in certain types of lymphocytic 
leukemia was comparable to the enzymatic make-up of lymphoid cells in 
certain stages of their development. Therefore, this paper discusses 
the intimate realtionship between immunodeficiency diseases, normal 
lymphocytic differentiation, lymphocytic leukemia and purine metabolism. 
In scheme 1, relevant enzymatic reactions and metabolites of purine 
and pyrimidine metabolism are depicted(scheme 1 is located at page 179). 
1. INBORN ERRORS OF PURINE METABOLISM AND IMMUNODEFICIENCY DISEASE 
Adenosine Deaminase Deficiency 
ADA catalyzes the deamination of adenosine and deoxyadenosine to 
inosine and deoxyinosine(scheme 1, fig. 1). Giblett et al.(65) were the 
first to report absence of ADA activity in red cell lysates from two 
young unrelated girls. These girls had a clear dysfunction of Τ and В 
cells, which was manifested by recurrent infections, delayed hypersen­
sitivity reaction, poor in vitro mitogenic stimulation, low IgG and 
IgM plasma levels, lack of blood group antigens and other defects. After 
this first report on ADA deficiency related with severe combined immuno­
deficiency disease(SCID) several other patients were described(115,116, 
162,190). It appeared that 22% of the SCID patients was ADA deficient 
(89). Skeletal abnormalities next to the presence of a rudimentary 
thymus with no clear architecture and small lymph nodes were reported 
(190). ADA activity levels in lymphocytes from SCID patients who had 
no detectable ADA activity in their red blood cells, were less than a 
few percent of normal lymphocytic ADA activity(76,114). Studies on 
normal tissues and tissues from SCID patients revealed that in the 
normal tissues ADA activity was highest in the thymus(87). ADA deficient 
SCID patients showed only residual ADA activities in the tissues studied 
(85,87,148,178). The relative residual ADA activity however, was found 
to be highest in the liver(31%) and not in lymphoid organs such as 
thymus(0.2%), spi een(1.1%) and lymph node(3.6%). 
In one study on red cell lysates from a SCID patient, evidence 
was presented that the deficient ADA activity was due to a genetically 
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Figure 1: Purine enzyme defects associated with immunodeficeincy. ADA= 
adenosine deaminase. 5'NT=purine-5'nucleotidase. PNP=purine nucleoside 
Phosphorylase. 
programmed production of an ADA inhibitor(173). General agreement 
however, exists that the inherited deficiency of ADA is caused by a 
structural mutation(44,86). In a case were no tissue or tissue culture 
material was available from a child who died of SCID, the mutant ADA 
was investigated in cell hybrid clones, derived from one of the hetero­
zygous parents(76). In this study it was shown that a structural muta­
tion on chromosome 20 was causally related to the SCID. Similar data 
were obtained in a study on fibroblasts from 4 SCID patients with red 
blood cell ADA deficiency. The residual enzyme activities in fibroblast 
lysates from these patients ranged up to 27% of the mean control value 
(85). 
Two cases with residual ADA activity have been reported with 
an apparently normal immune function. The so called Kung boy, who 
had strongly decreased ADA activity in red blood cells but only mildly 
decreased ADA activity in leukocytes and cultured fibroblasts, showed 
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normal levels of serum immunoglobulins, normal mitogenic stimulation 
of peripheral blood lymphocytes and normal numbers of Τ and В lympho-
cytes(96). A 20 month old male child white normal white blood cell 
counts and normal responses to mitogen but with less than 1% of normal 
red blood cell ADA activity was described more recently(88). In lymphoid 
cell lines from this patient ADA activity was about 30% of normal values 
and about 50-fold higher than in lymphoid cell lines from ADA deficient 
SCID patients. This patient is resembled by a patient, described by 
Perignon et al.(127) who had less than 1% red blood cell ADA activity, 
but a residual ADA activity in the lymphocytes. These data on ADA 
deficiency in relation to SCID indicate that the nature of the mutations 
that lead to ADA deficiency must be rather heterogeneous. In this con­
text the term "deficiency" is meant to indicate a mutant ADA activity 
resulting in SCID. 
Altered levels of purine metabolites have been described in cells 
and body fluids from SCID patients. Elevated levels of adenosine and 
deoxyadenosine, both substrates for ADA, have been observed in urine 
(49,106). In plasma of these patients, elevated levels of adenosine 
were reported(38,106,117,130). Levels of phosphorylated derivatives 
of adenosine and deoxyadenosine, namely ATP and deoxyATP, were reported 
to be increased in red blood cells(38,43,49,92,117) as well as in mono­
nuclear cells from ADA deficient SCID patients(49,147). However, also 
ATP values within the normal range were reported(2). The presence of 
elevated levels of adenosine and deoxyadenosine and their nucleotides, 
ATP and deoxyATP, in body fluids, erythrocytes and mononuclear cells 
from ADA deficient SCID patients indicated that these purines might 
play an essential role in the pathophysiological mechanism(s) leading 
to the immune dysfunction. A review on ADA deficiency and SCID has been 
published by Thompson and Seegmiller(170). 
Purine Nucleoside Phosphorylase Deficiency 
Purine nucleoside phosphorylase(PNP) catalyzes the conversion of 
inosine and deoxyinosine to hypoxanthine and (deoxy)ribose-l-phosphate 
and of guanosine and deoxyguanosine to guanine and the deoxyribose 
moiety(scheme 1, fig. 1). In several patients with severely defective 
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Τ cell immunity but with apparently normal В cell function, a deficiency 
of purine nucleoside Phosphorylase was found(4,66,72,156). In PNP 
deficient patients generally lymphopenia, decreased PHA responses and 
recurrent infections were noted. The number of cells bearing surface 
immunoglobulins(slg) and the formation of antibodies were found to be 
normal(141). Kinetic studies in erythrocytes of two PNP deficient 
brothers suggested that PNP deficiency is caused by a mutation in the 
structural gene(58). The heterogeneity in the expression of the disease 
may be accounted for by different residual activities caused by differ­
ent mutations. 
Inosine concentrations were found to be elevated in plasma(51,157) 
and relatively high inosine and guanosine concentrations(51,141,157) as 
well as deoxyinosine and deoxyguanosine(36) were detected in urine. In 
contrast low plasma levels of uric acid were observed(36,141,157). 
Guanosine and deoxyguanosine can be phosphorylated by a kinase to GMP 
or deoxyGMP, which are subsequently converted to GTP or deoxyGTP. The 
substrates for these enzymatic reactions(scheme 1) are present at rel­
atively high levels in body fluids of PNP deficient patients. Therefore, 
elevated levels of GTP and deoxyGTP in red and white blood cells of 
these patients can be expected. Indeed elevated deoxyGTP and GTP concen­
trations have been reported in erythrocytes of these patients(37,113). 
Since there is hardly any production of the free purine bases hypo-
xanthine and guanine in PNP deficiency, the formation of GMP and IMP 
through the salvage enzyme hypoxanthine-guanine phosphoribosyltrans-
ferase(HGPRT, scheme 1) will not be of any significance. This might 
lead to elevated levels of PRPP, the cosubstrate of this salvage reac­
tion. Indeed elevated PRPP levels were described in the erythrocytes, 
but not in the fibroblasts, from a PNP deficient child(36) 
In lyzed lymphocytes of one single patient with common variable 
immunodeficiency, decreased PNP(15% of control value) activity , and a 
decreased activity(15% of control value) of purine-5'nucleotidase was 
described(125). Although the number of Ε-rosette forming cells was 
rather high, a clearly depressed response of the Τ cells on phytohaem-
agglutinin(PHA) was observed. В cells were virtually absent and serum 
Ig levels were clearly decreased. The activity of ADA in this patient 
appeared to be in the normal range. It could not be shown whether this 
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case represents causal relation between purine metabolism and immune 
dysfunction: in the case of a maturational block the altered enzyme 
activities might merely reflect a stage of maturation in which these 
cells were arrested(paragraph 3). 
The same might be said about the decreased PNP activity described 
in Τ cells from a patients with the autoimmune disease systemic lupus 
erythematosus(107). The alterations in the balance of several subsets 
of white blood cells might be the cause of this, only slightly, decreased 
PNP activity. Any causal relation cannot be assumed from the data 
reported(107). 
Purine-5'nucleotidase Deficiency 
Purine-5'nucleotidase(5'NT) catalyzes the first enzymatic step 
in the degradation of purine nucleotides(e.g. AMP, deoxyAMP, GMP), 
leading to the formation of the corresponding nucleosides(scheme 1, 
fig. 1). Johnson et al.(97) and Edwards et al.(52) described decreased 
activities of 5'NT in patients with X-linked agammaglobulinaemia(Bruton 
type, XLA), measured both in lymphocyte lysates and in intact lympho­
cytes. These findings were confirmed and extended(186). It was shown 
that 5'NT activities were up to 25% of control value in XLA patients 
when using different mononucleotide substrates. ADA and PNP activities 
and several other purine enzyme activities were normal in these patients. 
The data described above were doubted by other authors(50). It was 
postulated that the increased amount of monocytes in XLA patients, which 
lack or have only low 5'NT activity(53,98), was responsible for the 
decreased 5'NT activity. The 5'NT activity in lymphocytes would be in 
the normal control range(50). However, this hypothesis was disproven in 
experiments on rosetting peripheral blood mononuclear cells(53). These 
E-rosetting cell populations in XLA patients, which contained less than 
2% monocytes, showed a clearly decreased ecto-5'NT activity as compared 
to control peripheral blood rosetting cells. Whether this decreased ac­
tivity should be ascribed to the В or Τ cell population or to both, 
could not be concluded according to the authors. More recent studies 
(39,54,169) indicated that both Τ and В cells have decreased 5'NT 
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activities in XLA. The presence of normal 5'NT activity in fibroblasts 
and T-colony lymphocytes indicate that a mutation in the structural 
gene for 5'NT is not likely. The findings of low 5'NT activity in XLA 
patients might be the reflection of a maturational disturbance of their 
lymphoid cells. Accumulation of deoxyribonucleotides in white and red 
blood cells of XLA patients has not been observed(113). 
2. PATHOPHYSIOLOGICAL MECHANISMS OF LYMPHOTOXICITY 
Elevated levels of adenosine and deoxyadenosine have been found in 
body fluids from ADA deficient patients with SCID(38,49,106,117,130,158) 
Intracellular levels of ATP, deoxyATP and cyclic AMP(cAMP) were found to 
be increased(38,43,49,92,117,147,170). In PNP deficient individuals 
increased levels of guanosine,deoxyguanosine, inosine and deoxyinosine 
were noted(36,141). Also elevated intracellular levels of deoxyGTP and 
PRPP have been reported in different cells of these patients(36,37,113). 
With these findings in mind, it is evident that much research has been 
focussed on the metabolic fate and the enzymatic handling of these 
compounds. Biochemical and biological studies have been performed in in 
vitro models and in human tissues. Five possible mechanisms that might 
lead to immune dysfunction have been proposed. Parameters as prolifera-
tive capacity, protein synthesis and immunocompetence have been inves-
tigated. Main attention will be given to ADA and PNP deficiency, since 
these "inborn errors of metabolism" have most extensively been studied. 
A. Adenosine Induced Pyrimidine Starvation 
Based on the finding that adenosine caused elevated levels of purine 
nucleotides and reduced levels of pyrimidine nucleotides, Green and 
co-workers postulated that adenosine toxicity might be mediated by 
pyrimidine nucleotide starvation(69,93). Comparable results were 
obtained in the human lymphblastoid cell line MGL-5, that was esta-
blished from blood cells of a patient with infectious mononucleosis. 
When culturing this cell line with adenosine at concentrations higher 
than IO-6 M, growth was strongly affected. This effect was not seen 
when uridine was provided as an extra source of pyrimidines(69,93). 
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This phenomenon indicated that indeed the lack of pyrimidines media­
ted the adenosine induced toxicity. 
Not only increased purine nucleotide and decreased pyrimidine 
nucleotide pools were observed, but also an accumulation of orotic 
acid was found to be induced by adenosine(93). Adenosine is capable 
of trapping Pi by phosphorylation to its nucleotides. Under physiol­
ogical conditions the decrease of intracellular Pi concentrations is 
accompanied by the inhibition of PRPP formation(paragraph 2B). Thus 
the accumulation of orotic acid might be explained by the ability of 
adenosine to limit the intracellular concentration of PRPP, a substrate 
for orotate phosphoribosyltransferase(128). This is not in accordance 
with the findings of Snyder et al.(77,167), who found mutants of the 
WI-L2 lymphoblast cell line deficient in adenosine kinase(AK) to be 
as sensitive to adenosine as the AK positive cell line. This sugges­
ted that adenosine does not need to be converted to its nucleotide 
in order to cause pyrimidine nucleotide starvation. 
Some arguments can be given to doubt a major role of adenosine 
induced pyrimidine starvation in the toxic mechanism(s), leading to 
immune dysfunction. 
1. Only mildly elevated levels of adenosine in plasma of ADA def­
icient patients have been reported. These levels were below 5 μΜ 
(38,117), whereas pyrimidine starvation induced toxicity occurred 
at adenosine concentrations of 10 μΜ or higher. 
2. Concentrations of the pyrimidine nucleotides UTP and CTP as well 
as deoxyTTP and deoxyCTP were found to be elevated in lymphocytes 
from ADA deficient SCID patients(92,147). The elevation of deoxy­
TTP and deoxyCTP seems to be contradictory with the inhibition of 
ribonucleotide reductase(paragraph 2D). This finding may be ex­
plained by the erythrocyte transfusions given to this child(92). 
3. ADA deficient children do not excrete elevated amounts of orotic 
acid(118,158). 
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В. PRPP Starvation 
Adenosine reduces the intracellular PRPP concentration in 
erythrocytes(59,128) and in human lymphoblasts(165,166). As PRPP is 
an important substrate for purine salvage(HGPRT and adenine phospho-
ribosyltransferase, APRT; scheme 1) as well as for purine and pyri-
midi ne(orotate phosphoribosyltransferase, OPRT; scheme 1) de novo 
synthesis, decrease of PRPP levels might have consequences for the 
absolute and relative amounts of the different purine and pyrimidine 
nucleotides in the cell. 
Nucleosides are capable of increasing or decreasing the intra­
cellular PRPP concentrations in vitro. When Pi is abundantly avai­
lable, nucleosides stimulate PRPP synthesis. When Pi is limiting, 
nucleosides inhibit PRPP formation. A decrease of the physiological 
intracellular Pi concentration accompanies the inhibition of PRPP 
formation(128). Nucleosides are capable of reducing intracellular 
Pi levels. This is related both to nucleosides that are predominant­
ly degraded to the purine base and to those that are substantially 
phosphorylated. Both these pathways trap Pi. It was shown that when 
erythrocytes were incubated under physiological Pi conditions the 
PRPP levels drop upon addition of nucleosides(128). However, in 
packed erythrocytes of a PNP deficient patient elevated levels of 
PRPP were found(36); this as a consequence of blocked purine salvage 
pathways and a sparing effect of PRPP. Therefore it becomes rather 
unlikely that in PNP deficiencies PRPP is an important mediator 
for the toxic effects. Further investigations are warranted. 
С Inhibition of S-Adenosyl Homocysteine Hydrolase(SAHH) by Adenosine 
and Deoxyadenosine 
As mentioned before, in body fluids of ADA deficient patients 
increased levels of adenosine and deoxyadenosine were found(49,106, 
117,130). From experiments with mutant AK deficient lymphoblastoid 
lines it appeared that adenosine needs not to be phosphorylated to 
exert inhibitory effects(167). Therefore eventual inhibition of SAHH, 
by adenosine and/or deoxyadenosine seemed to be a process that needed 
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Figure 2 : The metabolic pathway of s-adenosylhomocysteine in ADA and 
PNP deficiency. R=methylreceptor like RNA, DNA, lipids, etc. SAHH= 
s-adenosylhomocysteine hydrolase. CS=cystathione synthetase. The broken 
lines represent irreversible inhibition of SAHH (modified from 104). 
investigation. 
SAHH catalyzes the reversible hydrolysis of s-adenosylhomocys-
teine(AdoHcy) to adenosine and homocysteine(fig. 2, 48). Under phys­
iological conditions this reaction favours the catabolic direction 
(hydrolysis of AdoHcy in adenosine and homocysteine). The reaction 
products adenosine and homocysteine are readily removed by adenosine 
deaminase and cystathione synthetase(fig. 2), respectively. The 
equilibrium constant however, is most favourable for the anabolic 
direction(48). In experiments where adenosine(l μΜ) was incubated with 
crude lymphoblasts extracts, adenosine was preferently recovered from 
one peak after gelfiltration of the lysate. This protein peak had 
neither ADA nor AK activity. However, this peak appeared to have 
AdoHcy synthesizing capacity(78). It was concluded that SAHH binds 
adenosine with high affinity. In several systems it was shown, that 
addition of adenosine increased the level of AdoHcy. Mice 
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intraperitoneally injected with different concentrations of adenosine 
and homocysteine produced a dose related increase of AdoHcy levels 
in blood, liver and brain(145). Incubation of WI-L2 lymphoblasts and 
AK deficient mutants with adenosine and the ADA inhibitor EHNA leads 
to striking elevations of AdoHcy in these cells(104). Not only aden-
osine, but also deoxyadenosine appears to have an AdoHcy elevating 
effect in human lymphoblasts(79,80) and in erythrocytes(81). In this 
same study the binding of deoxyadenosine to SAHH appeared to cause 
an irreversible inactivation of the catalytic activity. This irre-
versible inhibition was also seen with adenosine(33). 
Among the nucleosides accumulating in PNP deficiency only 
inosine was able to cause a phosphate dependent irreversible inac-
tivation of human SAHH(82). This probably explains the low levels 
of SAHH found in hemolysate from PNP deficient patients(82,100). 
Hypoxanthine facilitated the SAHH inactivation by inosine. Hypo-
xanthine probably shifts the equilibrium of the PNP reaction into 
the direction of inosine formation. This might explain the decreased 
activity of SAHH in Lesch-Nyhan patients, who lack HGPRT activity. 
Inhibition of SAHH will lead to increased levels of AdoHcy, which is 
a potent inhibitor of numerous s-adenosylmethionine dependent methyl 
transfer reactions(81,99,146). Such inhibition appears to account 
for nucleotide independent adenosine toxicity to mouse(103) and 
human lymphoblasts(104). 
The inhibition of SAHH is an event that may also occur in ADA 
deficient patients, where adenosine and deoxyadenosine is accumulated. 
Recently it has been reported(119) that in an ADA deficient SCID 
patient the urinary excretion of AdoHcy is elevated. In an ADA 
deficient patient, who was not immunodeficient, no elevated urinary 
excretion of AdoHcy was reported. However, also SCID patients with 
apparently normal ADA activity with elevated AdoHcy excretion have 
been found(119). Although adenosine and/or deoxyadenosine induced 
inhibition of methylation pathways may play an important role in the 
mediation of the toxic defects in immunodeficiency, the exact role 
of this process has still to be elucidated. 
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D. Inhibition of Ribonucleotide Reductase by DeoxyATP and DeoxyGTP 
Much attention has been focussed on the allosteric inhibition 
of ribonucleotide reductase by deoxyribonucleotides. This enzyme 
catalyzes the conversion of ribonucleotides, at the diphosphate level, 
to deoxyribonucleotides; the conversions of ADP to deoxyADP, GDP to 
deoxyGDP, UDP to deoxyUDP and CDP to deoxyCDP(fig. 3). Since this is 
the only route known for synthesis of deoxynucleotides in mammalian 
cells(122,140), its action is essential for DNA synthesis. Using 
highly purified calf thymus ribonucleoside diphosphate reductase, it 
was shown that deoxyATP at a concentration of 5 μΜ inhibits 50% of 
the ADP, GDP, CDP and UDP reduction(56). The reduction of GDP, CDP 
and UDP was inhibited by deoxyGTP at concentrations of 50 to 100 μΜ. 
In ADA and PNP deficient patients, deoxyadenosine and deoxyguanosine 
are accumulated, respectively. These deoxyribonucleosides can be 
phosphorylated to monodeoxyribonucleotides which subsequently 
increase the intracellular levels of deoxyATP and deoxyGTP. Elevated 
deoxyATP and deoxyGTP levels have been found in cells of immuno-
deficient patients(paragraph 1). Inhibition of ribonucleotide reduc­
tase by either one of these compounds(fig. 3) will cause a disbalance 
of the intracellular deoxyribonucleotide pools and thus impairment 
of DNA synthesis. 
The phosphorylating capacity of the thymus, spleen and peri­
pheral lymphocytes is high when compared with other tissues(26). In 
experiments with the human Τ lymphoblast MOLT-4 and the В lymphoblast 
MGL-8 cell lines it was seen that, when culturing both cell lines 
with deoxyadenosine or deoxyguanosine, the cell growth was much more 
inhibited in the Τ cell line than it was in the В cell line(121). 
Together with this sélectivité toxicity a selective accumulation of 
deoxyATP and deoxyGTP in the Τ lymphoblasts was observed(121). In 
comparable experiments with deoxyadenosine in , partly other, Τ and 
В cell lines, this selective toxicity was confirmed(27). However, 
measuring the deoxyadenosine kinase activity(catalyzing the phosphor­
ylation of deoxyadenosine to deoxyAMP, scheme 1), showed that the 
explanation of this selectivity could not simply be given by the 
relative amounts of this enzyme present. Studies carried out in 
mouse Τ cell lymphoma lines(30,70) showed that deoxyguanosine, 
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Figure 3 : The inhibition of ribonucleotide reductase by deoxyATP and 
deoxyGTP in ADA and PNP deficiency(modified from 136). 
guanosine and deoxyinosine inhibited cell growth. A drop of deoxy­
CTP and deoxyATP levels, accompanied by a sharpe rise in deoxyGTP 
levels, pointed to a mechanism related to inhibition of ribonucleo­
tide reductase(fig. 3). 
As indicated above, the higher toxicity for Τ cell lines could 
not be explained solely by a significantly higher kinase activity 
than in В cell lines(27,124). Differences in 5'NT activities between 
Τ and В cells might contribute to this selectivity(chapter 5, 169, 
183). The most rapid accumulation of deoxyATP upon incubation with 
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deoxyadenosine was seen in Τ cell lines in several studies(28,121,188). 
The phosphorylating capacity of deoxyadenosine did not differ signif­
icantly in Τ and В cell 1 ines(121,188). However, marked differences 
in the nucleotide degrading capacity were noticed. 5'NT, the enzyme 
dephosphorylating deoxyAMP and other mononucleotides, to give the 
corresponding nucleosides, was found to have a much lower activity 
both in freshly isolated and in cultured Τ and В cells(chapter 5, 
169,183,188). Thus, the more rapid accumulation of deoxyATP might 
be considered to be the net result of both kinase and nucleotidase 
activity. This mechanism was not only suggested in the case of deoxy­
ATP accumulation, but also in the case of deoxyTTP(28) and deoxy-
GTP accumulation(121). 
Although the deoxynucleotide toxicity seems rather plausible, 
several points of criticism have to be made: 
1. It is hard to explain the selective toxicity towards Τ and В cells, 
only on the basis of differences in the 5'NT activity, an enzyme 
of which a considerable part of the catalytic activity is located 
at the outer surface of the cell membrane. Data supporting this 
doubt have recently been published(18). ADA deficient cell lines, 
which have relatively high ecto-5'NT activities exhibit a sensit­
ivity to deoxyadenosine intoxication, comparable to ADA deficient 
cell lines with relatively low ecto-5'NT activities. However, no 
data are given in this paper on the activity of nucleoside kina­
ses. The recent finding of a soluble deoxynucleotidase in lympho-
blasts, that is distinguishable from the membrane bound enzyme(29), 
might throw new light on this matter. 
2. A mutant human lymphoblastoid cell line that lacked deoxycytidine 
kinase, had less than 10% of the deoxyadenosine phosphorylating 
capacity as compared to the wild type(176). Deoxycytidine kinase 
is believed to catalyze the phosphorylation of deoxyguanosine and 
deoxyadenosine(105). With regard to growth this mutant was as 
sensitive to the toxic effects of deoxyadenosine as the wild type. 
A WI-L2 mutant deficient in adenosine kinase activity showed no 
significant difference in deoxyadenosine phosphorylating activity 
when measured in extracts as compared to the wild type. However, 
this mutant was 3-fold less sensitive to deoxyadenosine and 
accumulated far less deoxyATP from exogenous deoxyadenosine. 
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A mutant cell line lacking both adenosine and deoxycytidine kinase 
activities was less sensitive to deoxyadenosine than the adenosine 
kinase deficient mutant and did not accumulate deoxyATP. It was con-
cluded that although deoxyadenosine phosphorylation was associated 
with deoxycytidine kinase, the physiologically important deoxyaden-
osine phosphorylating capacity is associated with the adenosine 
kinase activity. 
E. Adenosine Induced Elevation of Intracellular cAMP 
It is known that PHA induced human lymphocyte blastogenesis(25, 
161) is inhibited by cAMP. Carson and Seegmiller(25) reported that, 
when normal peripheral blood lymphocytes were cultured with cAMP or 
dibutyryl-cAMP(db-cAMP), 3H-thymidine incorporation was inhibited. 
It was suggested that the action of cAMP was mediated by adenosine 
to which it has been catabolized. This can be concluded from exper-
iments in which EHNA(a potent inhibitor of adenosine catabolism) 
enhanced the cAMP effect. Not only lymphocyte blastogenesis could be 
inhibited by cAMP, also the excretion of antibodies(161) and lympho-
cyte mediated toxicity(19,168) were affected by this compound. 
db-cAMP nearly abolished cytotoxicity at a concentration of 1 mM. 
cAMP also caused a reduction of the concentrations of UTP and CTP 
in lymphocytes(166). Apparently, through breakdown to adenosine, cAMP 
is capable of causing a pyrimidine nucleotide starvation in human 
lymphoblasts. The effect could be reversed by the addition of uridine 
(25,166). 
Adenosine and deoxyadenosine are known to increase intracellular 
concentrations of cAMP(35,187). As a result of elevated adenosine 
and deoxyadenosine levels in ADA deficiency, intracellular cAMP 
levels in cells of the lymphoid system might be increased either as 
a result of metabolic transformation of adenosine to cAMP or as a 
consequence of adenyl cyclase activation, the enzyme that catalyzes 
the conversion of ATP to cAMP. 
Whether the elevation of intracellular cAMP plays an important 
role in the biochemical mechanisms leading to immune dysfunction in 
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Table 1: Possible Pathophysiological Mechanisms in ADA Deficiency 
Accumulation Consequence 
Adenine ribonucleotides -Pyrimidine ribonucleotide 
starvation 
-PRPP starvation 
S-adenosylhomocysteine -Decreased methylation of DNA, 
RNA, proteins, etc. 
Adenine deoxyribonucleotides -Inhibition of ribonucleotide 
reductase 
cAMP -Impaired inmune response 
ADA deficiency, is not yet clear. ADA deficient leukocytes contained 
a cAMP concentration^ pmol/106 cells) twice as high as in control 
leukocytes(2.6 pmol/106 cells, 147). In the reports described above, 
severe inhibitory effects of cAMP were seen only at concentrations 
over 100 wM(25,166). Moreover, mutants from S49 cells(mineral oil 
induced, Τ cell lymphosarcomas obtained from Balb/c mice) defective 
in some component of cAMP action or metabolism, are resistant to 
killing by isoproterenol, a hormone that increases cAMP levels, 
whereas they are sensitive to killing by adenosine and EHNA(175). 
Through these findings it becomes doubtful whether this mechanism is 
essential in the mediation of toxic effects of ADA deficiency. 
In table 1 the possible pathophysiological mechanisms in immuno­
deficiency disease are summarized. It is not likely that either one of 
these mechanisms is solely responsible for the immunodeficiencies caused 
by ADA or PNP deficiency. It is more likely that a combination of any 
of these mecahnisms may finally result in the immune defect. In view 
of the moderately elevated concentrations of adenosine(paragraph 2A), 
the elevated levels of PRPP in PNP deficiency(paragraph 2B) and the 
moderately elevated levels of cAMP in ADA deficient leukocytes(paragraph 
2E), the possibilities discussed under А, В and E in this paragraph, 
most probably will not play an essential role. Only low concentrations 
of adenosine and deoxyadenosine appear to be able to inhibit SAHH(para-
graph 2C). DeoxyATP(3 μΜ) inhibits 50% of ribonucleotide reductase activ-
ity(paragraph 2D). In conclusion, the inhibition of SAHH and/or ribo­
nucleotide reductase is likely to play a major role in the pathophys­
iological mechanisms of immunodeficiency disease. 
159 
3. ENZYMOLOGICAL ASPECTS OF LYMPHOID CELL DIFFERENTIATION 
The lymphocyte part of the immune system in birds and mammals con­
sists of two major differentiation pathways, which have a common origin. 
Lymphopoietic precursor cells migrate from yolk sac, fetal liver, spleen 
and bone marrow via the blood stream to the central lymphoid tissues, 
the thymus and the bursa of Fabricius in birds or its equivalent, fetal 
liver and bone marrow, in mammals. After having reached the thymus or 
the bursa equivalent, lymphocyte precursor cells undergo proliferation 
and differentiation to become immunologically competent lymphocytes. 
The newly differentiated lymphocytes migrate from the central lymphoid 
tissues to the peripheral lymphoid tissues(spleen, lymph nodes and gut-
associated lymphoid tissues) where .subpopulations populate distinct 
anatomical locations(55). Peripheral lymphocytes, which have undergone 
differentiation in the thymus before emigrating to peripheral lymphoid 
tissues, are referred to as Τ lymphocytes or Τ cells. Mature Τ cells 
are responsible for cell mediated immunological reactions. Peripheral 
lymphocytes, which differentiated in the bursa of Fabricius or its 
mammalian equivalent, are referred to as В lymphocytes or В cells. 
Mature cells are responsible for antibody mediated immunological reac­
tions. Cooperative interactions between Τ cells, macrophages(cells with 
a highly phagocytic capacity) and/or В cells are required for most 
immunological reactions to occur(55). 
Differences in Purine Metabolism in Normal Lymphoid Cells 
In cells from immunologically different lymphoid subpopulations, 
as well as in cells from subpopulations in various differentiation 
stages, differences in purine metabolism have been described. Differen­
ces in ADA activity between mature Τ and В lymphocytes do not seem to 
be significant(chapter 5, 124,174,183). Only one report(123) describes 
a significantly higher(40%) activity of ADA in Τ than in В cells. 
Although the relative activities of the Τ and В cell fractions in this 
report are in the same range as in other reports, in the latter this 
difference is not considered significant. 
PNP activity has been suggested as a histochemical marker for 
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Τ cells in man(15). However, the data on this enzyme are rather confu­
sing. Whereas in one report the higher PNP activity in Τ cells is con-
firmed(123), we could not find a significant difference between Τ and 
В lymphocytes(chapter 5, 183). 
Many reports have been dealing with differences of 5'NT activity 
in Τ and В lymphocytes. It is generally accepted that ecto-5'NT activity 
is higher in human peripheral blood В cells than in Τ cells(chapter 5, 
53,142,169,183). The relative differences however,vary from a moderately 
(53) to even a 15-fold(169) higher activity in В cells. The activity of 
ecto-5'NT appeared to be age dependent both in Τ and in В cel Is(17). 
From 40 years of age on, 5'NT activity decreases in peripheral blood 
Τ cells. In В cells a decreased ecto-5'NT activity was only seen at ages 
of 60 years or higher. To our knowledge no data have been reported on 
differences in AK activity between Τ and В cells. 
Relatively little is known about differences in purine enzyme 
activities in Τ cell subfractions. We found that APRT, PNP and AK activ­
ities are significantly higher in Τ-Τγ peripheral blood cells than in 
Τγ cells(cells with a receptor for the Fc portion of IgG; chapter 5, 
183). In contrast.a higher ADA activity was found in Τγ cells. Although 
in our studies this difference had no statistical significance, it 
should be mentioned that comparable results were reported by another 
group(159). Τγ cells have lower 5'NT activity than Τ-Τγ cells(chapter 5, 
17,183). It was postulated that this difference in 5'NT together with 
the relative increase in the number of Τγ cells with age, explains the 
relatively low 5'NT activity in senescence(17). 
According to the hypothesis that a relatively low 5'NT/kinase 
activity ratio causes cells to be more vulnerable towards deoxynucleo-
side toxicity(paragraph 2), one can reason that Τ cells are more vul­
nerable than В cells and that Τγ cells can be affected more easily than 
Τ-Τγ cells. However, especially concerning the last comparison more 
data have to be collected. 
Not only peripheral blood lymphocytes exhibiting different pheno-
types, but also lymphocytes from various lymphoid organs have been 
studied. Two major reasons could be given to study purine metabolism 
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in different lymphoid organs: 
1. To know the possible variation of purine enzymes in different stages 
of lymphoid development may contribute to a better understanding of 
the role of purine metabolism in normal lymphoid differentiation. Not 
only differences between various subsets of PBL, but also differences 
between lymphocytes at various differentiation stages may cause selec-
tive sensitivity for purine nucleosides or their analogues. 
2. If differences were found, this might help to a better understanding 
of the relation between purine metabolism and immune function. 
Purine Metabolism in Different Mammalian Tissues 
ADA activity, measured in several human tissues, was found to be 
high in thymus(chapter 9, 1,26,87,184). Intermediate ADA activities 
were found in human spleen(26,87) and peripheral blood lymphocytes 
(chapter 9, 31,87,184) and lymph node(l,87). Brain, kidney, liver and 
lung were found to have relatively low ADA activities(26,87). Consider-
able activities of several deoxynucleoside kinases were predominantly 
found in lymphoid tissues, where the thymus seemed to have the highest 
activity(26,40). 
In contrast to the high activities of ADA and several deoxynucleo-
side kinases found in thymus tissue, a reletively low activity of 5'NT 
was seen(chapter 9, 40,53,184). The 5'NT activity in thymocytes could 
be increased by culturing them in medium containing thymic epithelial 
cell derived factors(41). As could be expected, the different enzymatic 
make-up of thymocytes as compared to PBL, leads to a different sensit-
ivity towards deoxynucleosides. When culturing both thymocytes and PBL 
with deoxyguanosine, the proliferative response was affected mostly in 
the thymocytes(40). It was assumed that this phenomenon was due to the 
relati vily poor ability of thymocytes to breakdown the accumulated 
deoxyGTP. 
Our findings were not completely in agreement with these data 
(chapter 9). This might be ascribed to the different culturing condi-
tions used. In our experiments thymocytes were cultured in the presence 
of thymic epithelial derived factor. Such factors are capable of 
162 
inducing 5'NT activity in thymocytes(chapter 9, 41), thus providing 
these cells with a better possibility to breakdown toxic deoxyribonuc-
leotides. In experiments with deoxyadenosine comparable data were 
obtained(chapter 9, 184). Experiments carried out in thymocyte subfrac­
tions showed a good correlation between the ecto-5'NT/deoxycitidine 
kinase activity ratio and deoxynucleoside induced inhibition of PHA 
response(chapter 9, 184). Thymocytes were separated on size, with a 
centrifugal elutriation technique. It appeared that the fractions con­
taining predominantly small sized cells were relatively immature. The 
fractions containing predominantly medium sized cells were found to be 
relatively mature(149). The thymocyte fraction with the highest ecto-
5'NT/deoxycytidine activity ratio was affected least after culturing in 
the presence of deoxynucleosides, whereas the fraction with the lowest 
ratio was most seriously affected. 
Besides differences in ecto-5'NT and deoxycytidine kinase activity, 
also differences in ADA and PNP activity were detected at the intrathymic 
level. Using an immunohistochemical technique, Chechik et al.(31) have 
shown that ADA positive cells were predominantly seen in the cortical 
regions of the human thymus. In the thymic medulla, ADA reactivity was 
observed only occasionally. It has been shown that the thymic cortex 
contains less mature lymphocytes than the medulla(chapter 9, 20). In 
the thymocyte fractions described above, the ADA/PNP activity ratio was 
highest in the relatively immature fractions and relatively low in the 
mature fractions(chapter 9, 184). From our experiments and ADA and PNP 
measurements in different rat lymphoid organs, where similar data were 
obtained(chapter 9, 11,12), it was suggested that the ADA/PNP activity 
ratio is a marker for Τ cell development. Deficiencies of each of these 
enzymes might affect Τ cells at separate stages of differentiation. 
Although the physiological consequences of deficiencies of some 
purine enzymes have been extensively studied(paragraphs 1 and 2), the 
physiological role of purine metabolism in immune function is not yet 
fully understood. 
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Effects of Purine Derivatives on Lympoid Cells 
The mechanisms which can lead to eventual cytotoxicity have exten­
sively been discussed above(paragraph 2). From a number of in vitro and 
in vivo studies(177) it becomes more· and more evident that purine 
analogues, metabolized especially by ADA and PNP, can act as regulators 
of several immune functions. 
cAMP seems to be a good candidate for modulating the immune res­
ponse. It is known that cAMP can stimulate both lymphocyte transforma­
tion and antibody secretion(83,84,101,161). Similar effects were seen 
with low concentrations of adenosine(150,180,183). These functions are 
inhibited by high concentrations of adenosine(chapter 10, 180). This is 
compatible with the finding that increased antibody production is 
related to increased ADA activity(71). 
Astaldi et al.(9) have performed some interesting studies on a 
serum factor, which appeared to be adenosine. It was shown that this 
serum factor(adenosine), which could not be derived from thymectomized 
myasthenia gravis patients, was mainly active on the thymocytes(5,8). 
Among thymocytes the activity of the serum factor(adenosine) was found 
to be restricted to hydrocortisone sensitive(relatively immature) 
thymocytes(6). In vitro it was found that the serum factor increased 
cAMP levels in thymocytes(7). Protein synthesis was found to increase 
in thymocytes 15 min. after the serum factor(adenosine) was added(189). 
It was suggested that adenosine binds to thymocytes and then stimulates 
adenylate cyclase with a subsequent rise in intracellular cAMP. It is 
likely that this leads to an activation of protein kinases, which are 
responsible for the phosphorylation of proteins. 
In relation to the sensitivity for theophylline(an inhibitor of 
phosphodiesterase, the enzyme that breaks down cAMP), different Τ cell 
subsets have been described(108). Those cells whose ability to bind 
sheep eryhtrocytes is not affected by theophylline treatment, are termed 
theophylline resistant(T ), while those cells that lose the ability to 
form rosettes with sheep erythrocytes are termed theophylline sensitive 
(T ). The Τ fraction contained mainly Τγ cells, whereas the Τ subset 
predominantly contained Τμ cell s(154). When adenosine is incubated with 
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peripheral blood Τ cells, an increase of the percentage of Τγ cells is 
seen(13). Adenosine however, not only increases the proportion of Τγ 
cells but also causes a loss of helper activity(13). 
Comparable results were obtained with deoxyadenosine. In experi­
ments where the number of plasma cells was counted after 7 days of 
cui turing of PBL, in the presence of PWM a decrease of the number of 
plasma cells induced was significantly correlated with the concentration 
of deoxyadenosine added(73). It was concluded that deoxyadenosine, under 
the conditions used, affected the Τ helper cells. At very low deoxy­
adenosine concentrations however, the Τ helper function seems to be less 
affected than the Τ suppressor function(chapter 10, 180). Adenosine 
also seems to affect the Τμ cell subset(bearing the receptor for the Fc 
part of IgM). It was described(62,151) that this Τ cell subset also 
contains the precursors of the effector cells for cell mediated lympho-
lysis. Wolberg et al. showed that adenosine inhibited the lymphocyte 
mediated lysis of tumor cells(187). Using a plaque forming cell assay, 
it was shown that deoxyguanosine at concentrations above 1 μΜ abol­
ished Τ suppressor activity(64). 
Apart of the studies mentioned in other paragraphs of this paper, 
some other data have to be mentioned about the relation of ADA and 
immune function. As could be expected from the foregoing, ADA plays an 
important role in Τ cell maturation. Incubation of precursor Τ cells 
from ADA deficient patients with thymic epithelial monolayers or 
thymosin, induced receptors for sheep erythrocytes(143,155). This induc­
tion could be prevented by adding the ADA inhibitor EHNA to the cultures 
(155). This indicated that, in particular at early stages of Τ cell 
maturation, the metabolic action of ADA is of importance. These results 
are compatible with data reported earlier(10,129). After 5 days of cul-
turing, tonsil derived lymphoid precursor cells, inable to form rosettes 
with sheep erythrocytes, developed the capacity to form E-rosettes. 
When coformycin was added to the culture, no significant rosette 
forming capacity was found, even at 10 days of culturing(lO). Addition 
of ADA to lymphocyte cultures of an ADA deficient SCID patient, restored 
the proliferative capacity of these cells(129). 
Thuillier et al.(171) showed that immunocompetent rat thymocytes 
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were able to produce a Τ cell growth factor(TCGF) upon mitogen stimul­
ation, but were not able to do so under ADA deficient conditions. 
Immuno-incompetent rat thymocytes differentiate and maturate in response 
to concanavalin A(ConA) if TCGF is added. This process can be inhibited 
by adding deoxycoformycin and deoxyadenosine. Through its catabolic 
activity, adenosine deaminase has been proposed as an enzyme controlling 
the amount of substrate available to xanthine oxidase(scheme 1). The 
latter enzyme produces 0„ radicals accompanying plasma membrane pertur­
bation during phagocytosis of polymorphonuclear leukocytes(172). This 
illustrates that, when studying nucleoside toxicity towards the immune 
system, not only lymphoid cells should be considered. 
The above data strongly indicate that normal immune function is 
strongly related to a properly functioning purine metabolism. These 
studies reported indicate that purine nucleosides not only affect the 
differentiation of Τ cells, but also modulate the functional activity 
of these cells. Adenosine, deoxyadenosine and deoxyguanosine may be 
considered as immunosuppresive and immunostimulatory agents, depending 
of the concentrations used, with a certain selectivity in their action. 
4. BIOCHEMICAL PHENOTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA(ALL) 
Patients with ALL can be classified by means of immunological 
markers. ALL patients with bone marrow that contains predominantly 
malignant cells bearing slg, are referred to as B-ALL(table 2). When 
the lymphoblasts are predominantly forming Ε-rosettes and/or are posit­
ive with the anti-T cell antiserum, the patients are classified in the 
T-ALL group(68). The major subclass of ALL is the nonBnonT-ALL group 
(table 2), which can be discriminated from B-ALL by the absence of 
immunoglobulins on the lymphoblast membranes, and from T-ALL by the 
absence of E-rosetting capacity or reactivity with anti-T cell antiserum 
(57,68). However, patients who apparently had a considerable number of 
anti-T cell antiserum positive cells, have also been classified in the 
nonBnonT-ALL group, because no Ε-rosettes could be detected and the 
number of cells positive for the cALL(ALL with the major or common 
phenotype) antiserum(24,67), was predominant(34,68,91,181). The cALL 
antiserum provides a marker for further division of the nonBnonT-ALL 
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Table 2: Immunological Classification of Acute Lymphoblastic Leukemia 
Classification Relative Incidence Markers 
nonBnonT-ALL 
une.-ALL 
CALL 
preB-ALL 
T-ALL 
B-ALL 
+ 80% 
± 15% 
± 65% 
± 20% 
± 2% 
± 20% 
Ε , 
Ε , 
E , 
E , 
+ 
E , 
Ε", 
slg , 
slg , 
slg , 
slg , 
slg , 
+ 
slg , 
anti-T 
anti-T 
anti-T 
anti-Τ 
anti-T 
anti-T 
CALL 
cALL+ 
CALL 
CALL 
CALL 
clgM 
CALL patients may occasionally have an anti-T phenotype, whereas some 
T-ALL patients may occasionally have an E phenotype. E=rosette forming 
capacity with sheep erythrocytes. slg=surface immunoglobulins. anti-T= 
anti-T cell antiserum. cIgM=cytoplasmic IgM heavy chains. cALL=common-
ALL antiserum. 
group. NonBnonT-ALL patients with leukemic cells positive for this anti­
serum are referred to as cALL(table 2), whereas the remaining patients, 
cALL negative, Ε-rosette negative, anti-T cell antiserum negative and 
slg negative, are referred to as unclassified-ALL(unc.-ALL, table 2). 
The presence of cytoplasmic IgM heavy chains(cIgM) in the absence of 
slg can be considered as a preß cell marker(63,135). Thus, nonBnonT-ALL 
patients with cells containing clgM can be considered to be of the 
preB-ALL type(23,181). 
In table 2 the classification of ALL patients is summarized. It 
appears that about 80% of the ALL patients cannot be classified as T-
or B-ALL. From this nonBnonT-ALL group, about 65% of the patients can 
be classified as cALL, whereas about 15% remains unclassified(unc.-ALL, 
68). From the cALL patients about 20% appeared to have clgM and could 
be classified as preB-ALL(185). The phenotypes T-ALL and B-ALL were 
observed in about 15% and 2% of the ALL patients(68). 
Although the data reported are not completely unanimous, a rather 
consistent picture of the biochemical phenotypes of different subclasses 
of ALL is emerging. Elevated levels of ADA in ALL lymphoblasts, as 
compared to control PBL, have been described in childhood ALL(chapter 
6 and 7, 42,112,139,163,179,181). Conflicting findings by others(104, 
159,191) can be explained by the fact that the group of patients was 
not completely in the childhood range(109,159) or that the patients 
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were not newly diagnosed, but were in relapse or in remission(191). In 
our studies it has been shown that this might affect purine enzyme 
activities (chapter 7, 181). The highest ADA activities were found in 
T-ALL, whereas ηοπΒηοηΤ-ALL patients had ADA activities intermediate 
between control PBL and T-ALL lymphoblasts(chapter 6, 42,139,163,179). 
generally an ADA activity in the range of control PBL has been found in 
B-ALL lymphoblasts(chapter 7, 42,181). 
Differences in PNP activities in the various subgroups of ALL were 
not as pronounced as differences in ADA activity. In nonBnonT-ALL PNP 
activity levels were in the range of control PBL. In T-ALL however, 
a markedly decreased PNP activity was found(chapter 6, 14,179). The 
data on PNP activities in B-ALL patients are rather confusing. Patients 
with decreased(chapter 7, 139,181) as well as with increased PNP activ-
ity(chapter 7, 181) have been described. These different findings may 
indicate a heterogeneity in the leukemic cells isolated from B-ALL 
patients. 
An inverse linear relationship has been found with Τ lympho­
blasts, isolated from patients with T-ALL,between the number of E-rosette 
forming cells and the 5'NT activity(138). The 5'NT activity in T-ALL 
was significantly lower than in nonBnonT-ALL or in control PBL(chapter 
6, 102,138,139,179). The mean 5'NT activity in nonBnonT-ALL seemed to 
be elevated as compared to control PBL(chapter 6, 102,179). Kramers et 
al.(102) described a mean 5'NT activity of 2.9 ± 1.5 10"9 moles/mg 
protein.min. in normal lymphocytes. In nonBnonT-ALL cells a mean 5'NT 
activity of 5.2 ± 2.0 10"9 moles/mg protein.min. was found. In compar­
able experiments described earlier(chapter 6, 179), we.found mean 5'NT 
activities of 18.4 ± 11.7 and 25.9 ± 23.1 10"9 moles/106 cells.hour in 
control PBL and nonBnonT leukemic cells, respectively. Due to the huge 
standard deviations, these differences were not found to be significant. 
When analyzing the cells of a number of nonBnonT-ALL patients in more 
detail, we found a possible explanation for this phenomenon. NonBnonT-
ALL patients with clgM appeared to have a significantly higher 5'NT 
activity than patients not having this preß cell marker(chapter 7,181). 
The number of patients who were investigated in this respect was rather 
limited. Nevertheless, when separating the group of nonBnonT-ALL 
patients in those with and those without clgM in their cells, it 
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appeared that the first group(only 3 out of 7 patients) is responsible 
for the rather wide standard deviation and elevated mean 5'NT activity 
in the ηοπΒηοηΤ-ALL group. Considering the data described above, 5'NT 
activity cannot be a diagnostic marker for classification of subgroups 
of ALL. 
In a systematic analysis of purine metabolizing enzymes in ALL, 
described in chapter 6(179), also differences in subgroups of ALL with 
respect to other enzymes became apparent. In nonBnonT-ALL significantly 
higher activities of HGPRT and adenylate kinase(AdKin) were found as 
compared to these activities in control PBL. APRT activity on the other 
hand was found to be lower in nonBnonT-ALL. Since HGPRT is catalyzing 
the supply of nucleotides via the purine salvage pathway and AdKin 
regulates the conversions of adenine nucleotides, these findings seem 
to be in agreement with the elevated ATP concentrations found in 
nonBnonT-ALL cells(47). In T-ALL, where the ATP concentrations were not 
significantly elevated, HGPRT was only moderately higher and AdKin 
showed activities comparable to control PBL(chapter 6, 179). APRT 
activity in T-ALL was about half the mean activity of control PBL. 
When speculating on the biochemical differences caused by the 
different enzymatic make-up in nonBnonT-ALL and T-ALL, one might pos­
tulate that 5'NT is a key enzyme in this respect. Since 5'NT activity 
in nonBnonT-ALL seems to be normal to somewhat elevated, breakdown of 
adenine and other purine nucleotides can occur at a normal rate. Since 
ADA activity is higher, the catabolic action of 5'NT might be followed 
by rapid deamination of adenosine to inosine. Since there is no reason 
to assume that the apparently normal PNP activity is rate limiting in 
any way, the consequence of this might be a more extensive production 
of hypoxanthine and subsequently a more extensive loss of the purine 
base in uric acid. However, the cell has two rescue mechanisms. The 
first is the elevated capacity of HGPRT to salvage hypoxanthine formed, 
and recycle it into the nucleotide pool. The second is an elevated AdKin 
activity which helps the cell to protect the adenine nucleotides, formed 
from either IMP or the action of AK(scheme 1), from dephosphorylation 
by 5'NT more effectively. This is demonstrated by the elevated ATP pools 
in nonBnonT leukemic cells. 
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In the case of T-ALL, the very high ADA activity might be relativ­
ely unimportant, since both the relatively low 5'NT and PNP activity 
might be rate limiting in the catabolism of adenine nucleotides. In 
T-ALL the malignant lymphoblasts represent relatively early stages of 
Τ cell differentiation(chapter 9). Apparently a low nucleotide break­
down and a high adenosine catabolism is necessary for differentiating 
Τ cells. In this case the cell apparently does not need to have either 
high HGPRT or AdKin activity as is the case in nonBnonT-ALL. 
5. BIOCHEMICAL PHENOTYPES OF CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) 
In B-CLL patients markedly altered activities of ADA, PNP and 5'NT 
have been described. ADA activity in several patients with CLL was found 
to be considerably lower than in control PBL(chapter 8, 3,90,112,137, 
174,182) In a number of CLL patients ADA activity was in the range of 
the control value(chapter 8, 162,181). This apparently wide activity 
range in patients with CLL becomes also evident from the finding that 
B-CLL patients with paraproteinemia had a significantly lower ADA ac­
tivity than patients without paraproteinaemia(chapter 8, 182). 
Mean PNP activity was found to be relatively low in patients with 
CLL(chapter 8, 3,16,182). A comparable wide activity range was found 
with respect to PNP activity in CLL as was the case with ADA. However, 
no differences between CLL patients with and without paraproteinaemia 
were noted(chapter 8, 182). 5'NT activity was found to be low in CLL 
patients(chapter 8, 102,110,134,160,182). However, a clear distinction 
between the CLL patients with different phenotypes must still be made. 
5'NT activity was only found to be lowin B-CLL. In two patients with 
T-CLL a 5'NT activity comparable to the level found in control PBL was 
observed(102). In the B-CLL patients a considerable range in 5'NT ac­
tivities was seen(chapter 8, 110,182). In B-CLL with paraproteinaemia 
5'NT activity was 11.5 10~9 moles/106 cells.hour, whereas patients 
without paraproteinaemia had a mean 5'NT level of 1.2 10~9 moles/106 
cells.hour(chapter 8, 182). 
Significantly elevated activity levels of enzymes involved in 
adenine nucleotide metabolism(AK and AdKin) have been found(chapter 8, 
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182). Whether these different enzyme activities have any consequences 
for the nucleotide pools in B-CLL lymphoblasts, remains to be inves­
tigated. 
6. RELATIONS BETWEEN LYMPHOBLASTIC LEUKEMIA AND NORMAL LYMPHOID CELL 
DIFFERENTIATION 
The immunological markers typical for different subgroups of 
leukemia, are believed to reflect the stage of differentiation of the 
malignant clone(68). Thus, in principle, in should be possible to "map" 
the several subgroups of human lymphoid malignancies along the different 
lymphoid differentiation lines. Knowledge of the enzymatic make-up 
in various differentiation stages might contribute to a better under­
standing of the role of purine metabolism during normal lymphoid 
differentiation and in leukemia. 
Greaves and Janossy(68) proposed in their "phenotypic map of human 
malignancies" that the nonBnonT-ALL group represented a common stage in 
early В and Τ cell lineage. Indeed there is evidence that the so called 
nonBnonT-ALL(neither slg nor Ε-rosette positive, table 2) is a hetero­
geneous group of leukemias. A number of leukemias with undetectable 
conventional Τ and В cell markers appeared to have cIgM(chapter 7, 181, 
185) a preß cell marker(63). The cells of the latter patients were 
positive with the cALL antiserum. Stimulation of bone marrow cells from 
patients with nonBnonT-ALL with thymic factors, induced immuno-competent 
Τ cells as detected by a local Graft versus Host reaction(152,153). 
Chiao et al.(34) cultured cells lacking В and Τ lymphocyte markers from 
peripheral blood of two ALL patients in the presence of medium produced 
from PHA stimulated allogeneic lymphocytes. Within 18 hours these cells 
acquired the capacity to form rosettes with sheep erythrocytes and to 
bind IgM or IgG. These data support the view that the nonBnonT cell 
compartment of peripheral blood mononuclear cells appears to contain 
precursor cells capable of generating the entire spectrum of lympho­
poietic cells(32). As Greaves and Janossy stated: "some of the nonBnonT 
or common ALL'S are preB, some preT and some may be 'frozen' at the 
level of a common(T and B) lymphoid precursor cell or a pluripotent 
stem cell"(68). 
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Figure 4: The relative enzyme activities in different subtypes of 
human leukemia as compared to the enzyme activities in control per-
ipheral blood lymphocytes(=100 arbitrary units) is indicated. The 
relative enzyme activities from nonBnonT-ALL(chapter 6, 179), T-ALL 
(chapter 6, 179), T-CLL(102), preB-ALL(chapter 7, 181), B-ALL(chapter 
7, 181) and B-CLL(chapter 8, 182) are extrapolated from data obtained 
mostly by our own group, which are reported elsewhere. NT=not tested. 
As the nonBnonT-ALL can be considered as the malignant equivalent 
of a common lymphoid precursor cell, T-ALL can be considered as the 
malignant counterpart of a stage in the Τ cell lineage(68). This type 
of ALL could more or less be a phenotypical equivalent to the thymo­
cytes. The mature Τ cell has its equivalent in the T-CLL subgroup(68). 
As in the Τ cell lineage, several stages of the В cell lineage 
have their maligant counterparts. The preB ALL represents the preß cell 
differentiation stage, the mature В cells are represented by B-ALL and 
B-CLL(68). Myeloma cells are the malignant equivalent of actively Ig 
secreting В lymphocytes or plasma cells. 
Taking the peripheral blood cells as reference, a hypothesis for 
the enzymatic changes in human lymphoid differentiation based on the 
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data described above can be proposed(fig. 4). 
In nonBnonT-ALLa relatively high ADA activity is observed. T-ALL 
cells have ADA activities comparable to those in thymocytes, whereas 
in T-CLL, ADA activity was found to be in the range of control peripheral 
Τ cells(174). As depicted in fig 4., ADA activity is intermediate at the 
level of the lymphoid precursor cell, high at the preT/thymocyte level 
and relatively low in the more mature Τ cell. In the В cell lineage the 
ADA activity seems to be maximal in the very early differentiation 
stages(cf. nonBnonT/preB-ALL). In the more mature differentiation stages 
(cf. B-ALL and B-CLL) mean ADA activity is relatively low. 
The changes in PNP activity in this model of lymphoid cell differ­
entiation are not as pronounced as is the case with ADA. Both in В and 
Τ cell lineage the PNP activity levels of the common lymphoid stem cell 
compartment(cf. nonBnonT-ALL) are comparable to the activities in 
peripheral В and Τ cells. The intermediate stages of Τ cell differen­
tiation seem to have a moderately lower(cf. T-ALL) PNP activity. In 
B-CLL the PNP activity is slightly decreased. 
In relatively early(cf. nonBnonT-ALL) and relatively late(cf. 
T-CLL and PBL-T) stages of differentiation in the Τ cell lineage, com­
parable 5'NT activities were found. Intermediate stages of the Τ lineage 
seem to be characterized by low, if any, 5'NT activity(chapter 9, 184). 
The situation in the В cell lineage model seems to be rather different 
(fig. 4). Not only higher activities of 5'NT in peripheral В lympho­
cytes than in Τ lymphocytes were seen, but in contrast with preT cells, 
in preß cells a relatively high 5'NT activity was observed(chapter 7, 
181). 
AdKin activity seemed to be highest in the common В and Τ cell 
precursor cells(cf. nonBnonT-ALL). The stages of Τ cell differentiation 
comparable with T-ALL were found to have relatively low AdKin activities 
that were not changed significantly. An increased AdKin activity in 
В cell lineage apparently occurred at all differentiation stages shown 
(fig. 4), except for the stage that was related to B-ALL. 
The schematic representation of В and Τ cell lineage should be 
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considered as very provisional. The leukemias are depicted in positions 
equivalent to normal cells to which they appear to have the closest 
phenotypic resemblance(68). When studies are performed in more detail, 
it might become clear that, for instance T-ALL and thymocytes or B-CLL 
and B-ALL should be shifted somewhat along their respective lineages. 
Also with regard to T-CLL and the B-ALL subclasses, more patients should 
be investigated in order to establish a more realistic scheme. 
However, these points probably will not significantly alter the 
general conclusions, that 
1. T-cells at various stages of differentiation have higher ADA activ­
ities than differentiating В cells. 
2. PNP activities only seem to drop in preT cell stages. 
3. As compared to mature Τ cells, preT cells are characterized by high 
ADA, low PNP, low 5'NT and essentially normal AdKin activities. 
4. As compared to mature В cells, preB cells are characterized by inter­
mediate to low ADA, normal PNP, high 5'NT and high AdKin activities. 
Unfortunately, since the normal counterparts of these malignancies 
are not easily available, it is only possible to test these conclusions 
on a few points. From the foregoing it must be clear that not only the 
immunological phenotype of T-ALL cells is alike that of thymocytes, but 
also the biochemical characteristics have much in common. Τ lymphoblasts 
as well as thymocytes can be characterized by high ADA, low 5'NT and 
relatively low PNP activity. From the enzyme activities found in T-CLL 
and in B-CLL/B-ALL it might be concluded that the normal counterparts 
are indeed situated quite near the mature Τ and В cells in their respec­
tive lineages. The enzyme activities of PNP, ADA and 5'NT in T-CLL and 
B-CLL/B-ALL only show minor differences with the activities found in Τ 
and В cells, respectively. As suggested before, B-CLL and B-ALL might 
have to change places along the В cell axis. However, with regard to one 
enzyme activity(AdKin), they clearly seem to have more in common with 
the preB phenotype than with the mature В cell. 
The expression of purine enzyme activities during the differentia­
tion of lymphoid cells deserves to be studied in detail. Then enzymes 
of purine metabolism cannot only serve as diagnosticai markers in 
various lymphoid malignancies, but since a different enzymatic make-up 
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of purine metabolism might cause different sensitivities towards several 
purine analogues, this might also eventually lead to a chemotherapy 
specifically directed towards the (malignant) cells in a certain stage 
of lymphoid differentiation. If this approach appears to be successful, 
certain types of leukemia might be treated with less side effects on 
the normal lymphoid population and other tissues. 
7. NUCLEOSIDE TOXICITY AND POSSIBILITIES FOR ENZYME DIRECTED CHEMO-
THERAPY 
The point of view that chemotherapy with purine analogues can be 
directed against certain cells with a specific purine enzymatic make-up 
is supported by some experimental evidence. Some cells seem to be 
resistent against the broadly used anti-cancer agent and purine deriv-
ative 6-mercaptopurine(6MP). In a review(22) Broekman argued that not 
only bacteria, but also neoplastic cells resistant to 6MP and 8-aza-
guanine lacked the capacity to form nucleotides of these analogues. 
This failure seemed to be a consequence of a marked decrease or loss 
of HGPRT activity. It was suggested that loss of HGPRT activity in human 
leukemia cells should be recognized as a clinical resistance mechanism 
(21,22,46). Alternative explanations for resistence to purine analogues 
were among others: decrease or loss of kinase activity which prevents 
cells to form eventually toxic nucleotides and increased degrading 
capacity of the purine analogues to 6-thioxanthine or 6-hydroxypurines 
(22,75). 
Extrapolating these findings to leukemia, this might mean that 
leukemic cells having relatively high HGPRT(nucleotide synthesis, 
scheme 1) and low 5'NT(nucleotide breakdown) are affected more than 
normal cells with lower HGPRT and higher 5'NT activities. These 
enzymatic properties can be found in T-ALL lymphoblasts(chapter 6, 179). 
When these cells would be treated with 6MP, the formation of the toxic 
intermediate 6-thio-IMP pool can be expected to be more extended than 
in normal lymphocytes or preß leukemic cells that can easily breakdown 
(normal or high 5'NT activity, scheme 1) this nucleotide(chapter 7, 
181). Moreover in T-ALL blasts the side-way conversion of 6MP to 6-thio-
inosine by the action of PNP would be rather limited. 
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Not only enzyme activiti es are capable of influencing specific 
chemotherapeutic sensitivity in human lymphoid cells. Also altered 
kinetic properties may play a role in this respect. Jackson et al.(94) 
demonstrated that cultured lymphoid cells with a decreased affinity of 
dihydrofolate reductase for methotrexate(MTX) is accompanied by resis­
tance to the drug. Similar alterations in kinetic properties of dihydro­
folate reductase have been seen in human lymphoblastoid lines resistant 
to MTX(95). 
Resistance towards 5-fluorouracil(5FU) was seen(74) in cells where 
thymidilate synthetase has lost the binding capacity of 5-fluoro-deoxy-
UMP(5FdUMP). 5FdUMP is the activated inhibitor of 5FU which exerts a 
strong feed-back inhibition of thymidilate synthesis(45). Examples like 
these emphasize the need, not only for systematic analysis of purine 
and pyrimidine interconversions in malignant cells, but also for kinetic 
studies with respect to the affinity of antimetabolites or their deriv­
atives towards their targets. 
Perhaps even more important than the chemotherapeutic actions of 
synthetic drugs, the inhibitory effects of accumulated naturally occur­
ring purine and pyrimidine nucleosides may be considered. The differen­
tial sensitivity of Τ and В cells towards purine nucleosides has been 
discussed in another part of this paper(paragraph 2). Fox et al.(61) 
have shown that some nonBnonT leukemic cell lines exhibited a sensitiv­
ity towards deoxyguanosine, deoxyadenosine, deoxycytidine and thymidine 
comparable to the sensitivity shown in some leukemic Τ cell lines. 
According to these authors, the sensitivity of Τ and nonBnonT cells and 
the relative non-sensitivity of В cells could not be ascribed to a dif­
ference in ecto-5'NT activity as postulated before. NonBnonT leukemic 
cell lines were found to have ecto-5'NT activities significantly higher 
than Τ leukemic cell lines and in the range of Epstein-Barr-virus(EBV)-
transformed В cell lines(60). Recently, in a report from the same group, 
it was shown that Τ and nonBnonT cell lines were essentially deficient 
of ecto adenosinetriphosphatase(ecto-ATPase) activity, whereas В cell 
lines displayed a considerable activity of this enzyme. As this cell 
surface enzyme seems to have a broad substrate specificity and deoxyATP 
and deoxyGTP are believed to be the major toxic metabolites, low ecto-
ATPase activity may represent a mechanism for increased sensitivity to 
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deoxynucleoside growth inhibition(89). The many examples of the appar-
ently enzymatically regulated cytotoxicity of nucleosides, make these 
compounds appropriate candidates for developing lymphoid cell subtype 
specific chemotherapy based on the enzymatic make-up of the present 
subtype. 
Based on studies on the biochemical mechanisms leading to a combined 
immune defect in ADA deficiency and the enzymatic differences between 
leukemic and normal lymphoid cells, an alternative approach to anti-
leukemia chemotherapy was explored. Prentice and his group were able to 
induce a considerable decrease in lymphoblasts in bone marrow of two 
patients with T-ALL, who were resistant to conventional forms of chemo-
therapy. These authors(132) were able to induce an almost complete 
remission of leukemic blasts, using the ADA inhibitor deoxycoformycin 
(dCF). The dCF treatment was accompanied by a severe lymphopenia and 
the patients died of a progressive measles infection and leukemic menin-
gitis, respectively. In subsequent more extensive studies, dCF was admin-
istered to ALL patients irrespective of the subtype of the leukemias 
(131,164). In these studies also a severe lymphopenia was noted. In most 
of the patients no decrease in neutrophils, platelets and Hb in per-
ipheral blood were seen after 1 or more moderate courses of dCF(164). 
Only after 5 courses of 0.25 mg dCF/kg body weight, moderate decreases 
of these parameters were noted(164). In the 7 patients studied by Smyth 
et al.(164) three partial responses were seen. In the studies performed 
by Poplack et al.(131) dCF exerted an anti-tumor activity in 8 out of 
26 ALL patients, two of whome experienced a complete remission. 
The above data illustrate that the success of purine enzyme di ree- · 
ted chemotherapy might be related to the enzymatic make-up of the 
leukemic cells. Since nonBnonT and preB leukemias have normal to 
elevated activities of 5'NT, the accumulation of toxic deoxynucleotides 
from adenosine can relatively easily be overcome by the breakdown of 
these compounds by 5'NT. It can be surmized that the heterogeneous 
reactions to dCF in the patients in the two studies described above are 
due to the difference in enzymatic make-up of the subtypes of ALL. 
A correlation of dCF induced remission and deoxyATP accumulation 
has been reported recently(133,144). Subtypes of ALL which, due to the 
177 
enzymatic make-up, could not be expected to accumulate deoxyATP, do not 
respond to dCF therapy. From the 12 patients with T-ALL, treated with 
dCF, 7 went into complete remission, 2 others showed a good partial 
response and 3 patients were resistant to dCF(133). Three patients show­
ing a rapid in vitro accumulation of deoxyATP in the blast cells, 
achieved complete remission. Two patients, with no clinical response, 
showed poor deoxyATP accumulation. One case, having an intermediate 
pattern, had a good partial remission. When studying these patients in 
more detail, it appeared that the patients with complete remission 
accumulated deoxyATP relatively fast in the lymphoid cells. The deoxy­
ATP accumulation was accompanied by a reduction in ADA activity and the 
lymphoid blast count. In a patient with partial remission these proces­
ses went relatively slow and in the poorly responding patients a 
decrease in blasts was seen rather late(144). The inactivation of SAHH 
activity was following the decrease in the number of leukemic blasts. 
Thus potentially decreased methylation pathways, as a consequence to 
lowered SAHH activities, seem of limited importance in the toxic actions 
as a consequence of nucleoside intoxication. 
These data emphasize that a careful systematic analysis of adenine 
nucleotide metabolism anda selective use of dCF may contribute to the 
success of this approach. Although effects of dCF on other tissues(e.g. 
nervous system, 111) should be evaluated, it seems that "nucleoside 
intoxication" might be promising with respect to certain types of ALL. 
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SCHEME 1: Simplified Scheme of Purine and Pyrimidine Metabolism 
Enzymes: 
1 - HGPRT, hypoxanthine-guanine phosphoribosyltransferase 
2 - APRT, adenine phosphribosyltransferase 
3 - ADA, adenosine deaminase 
4 - PNP, purine nucleoside Phosphorylase 
5 - AK, adenosine kinase 
6 - AdKin, adenylate kinase 
7 - dCK, deoxycytidine kinase 
8 - 5'NT, purine-5'nucleotidase 
9 - AMPD, AMP deaminase 
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SUMMARY 
After the intr ductory remarks(chapter 1), the developement of an 
enzymatic micromethod and its application in the enzymatic analysis of 
purine metabolism in lymphocytes and subpopulations is described in the 
section "Enzymological Analysis of Purine Metabolism in Lymphoid Cells". 
Lyophilization of the cells and subsequent resuspension of the freeze-
dried material appeared to yield maximum enzyme activities(chapter 2). 
The method was improved by adding 0.67%(v/v) BSA to the cell suspensions 
(chapter 3). Purine enzyme activities in lymphocytes stimulated with PHA 
did not change significantly, whereas in PWM stimulated lymphocytes, 
contaminated with some monocytes, markedly increased HGPRT, ADA and 5'NT 
activities were observed(chapter 4). Differences in purine enzyme 
activities found in subpopulations of human peripheral blood lymphocytes 
are described in chapter 5. Τ cells have lower HGPRT, AK, 5'NT and AMPD 
activities than В cells. Differences in PNP and AdKin activities found 
in the subpopulations could, at least in part, be ascribed to platelet 
contamination of the В cell fraction. When comparing enzyme activities 
in lymphoid cell subfractions it is necessary to carefully characterize 
the various subfractions, in order to account for the different isolation 
procedures. Τγ cells had lower activities of APRT, PNP and AK than Τ-Τγ 
cells. It is suggested that Τγ cells might be more vulnerable to purine 
(deoxy)núcleosi de intoxication than Τ-Τγ cells. 
In the second section, the expression of purine metabolism in dif­
ferent lymphoid leukemia's is described. In chapter 6 evidence is 
presented that certain purine enzymes can be useful as markers for the 
subclassification of the two major ALL subclasses, T-ALL and nonBnonT-
ALL. As compared to control PBL, cells from patients with nonBnonT-ALL 
have higher HGPRT, ADA and AdKin activities and a lower APRT activity. 
In T-ALL, HGPRT and ADA activities were also elevated as compared to 
control PBL, whereas APRT, PNP, 5'NT and AMPD activities were found to 
be lower. In chapter 7 several purine enzyme activities have been cor­
related with immunological markers of ALL patients. Relatively high ADA, 
low PNP and low 5'NT activities were associated with the presence of the 
Ε-rosette marker and the absence of the cALL marker. Intermediate ADA 
activities and high AdKin activities were associated with the presence 
of the cALL marker and the absence of the E-rosette marker. PreB-cALL 
193 
cells appeared to have about twice the 5'NT activity of cALL cells 
lacking the preB marker. The enzymatic make-up of malignant cells from 
two B-ALL patients differed markedly. 5'NT activity was found to be low 
in these patients. Therefore, 5'NT cannot serve as a biochemical marker 
for different subtypes of ALL. On the other hand,ADA and AdKin activity 
seem to be promising in this respect. The decrease in ADA activity in 
nonBnonT-ALL patients after prednisone monotherapy could not be correl­
ated with a decrease in the number of proliferating cells. NonBnonT-ALL 
patients in relapse show 5'NT activities of about 30% of the 5'NT activ­
ities in leukemic cells from newly diagnosed nonBnonT-ALL patients. It 
is concluded that due to the specific enzymatic make-up several sub­
groups of ALL will display a different sensitivity towards purine (deoxy)-
nucleosides. In lymphoblasts from CLL patients(chapter 8) low ADA, 5'NT 
and PNP activities and high AK and AdKin activities as compared to 
control PBL have been observed. CLL patients without paraproteinemia 
had about twice as high an ADA activity and about 10 times as low a 
5'NT activity as compared to patients with paraproteinaemia. A relation 
between 5'NT activity and Ig production is suggested. No correlations 
between purine enzyme activity levels and the Ε-rosette marker or the 
slg marker were found. The percentage of cells rosetting with mouse 
erythrocytes however, seemed to correlate significantly with 5'NT 
activity. 
Some aspects of nucleoside toxicity in mature and immature lymphoid 
cells are described in the third section. Thymocytes appeared to have 
higher ADA, lower PNP and lower ecto-5'NT activities than peripheral 
blood Τ cells. When separating thymocytes into six subfractions accor­
ding to stage of maturation, it appeared that the ADA/PNP activity ratio 
was highest in fraction l(containing the relatively most immature cells) 
and lowest in fraction 6(containing the relatively most mature thymo­
cytes). It was concluded that the ADA/PNP activity ratio was a marker 
for intrathymic maturation. The ecto-5'NT/dCK activity ratio was found 
to be maximal in fraction 3. This activity ratio parallelled the inhib­
ition of the PHA response by (deoxy)núcleosi des. From the experiments 
described in chapter 10 it was concluded that Τ suppressor cells might 
be more vulnerable to (deoxy)nucleoside intoxication than Τ helper 
cells. In these experiments, where the mitogen induced proliferative 
response, protein synthesis and Ig secretion were assessed, it was 
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shown that deoxyadenosine at low concentration enhanced Ig secretion, 
whereas the proliferative response was inhibited. 
In chapter 11 the relation between purine metabolism, leukemia and 
lymphoid cell differentiation is reviewed and considered in the context 
of the findings reported in this thesis. 
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SAMENVATTING 
Na enkele introducerende opmerkingen(hoofdstuk 1), is in de sectie 
"Enzymological Analysis of Purine Metabolism in Lymphoid Cells" de ont­
wikkeling vaneen enzymatische micromethode en de toepassing hiervan bij 
de enzymatische analyse van het purine metabolisme in lymphocyten en 
subpopulaties beschreven. Droogvriezen van de cellen en het vervolgens 
weer opnemen van het droog gevroren materiaal bleek maximale enzymacti­
viteiten te geven(hoofdstuk 2). De methode werd verbeterd door 0.67% 
(v/v) BSA aan de celsuspensie toe te voegen(hoofdstuk 3). Purine enzym­
activiteiten in lymphocyten, gestimuleerd door PHA, veranderen niet of 
nauwelijks, terwijl in door PWM gestimuleerde lymphocyten, vermengd met 
enkele monocyten, aanmerkelijk verhoogde activiteiten van HGPRT, ADA en 
5'NT werden gemeten(hoofdstuk 4). Verschillen in purine enzymactivitei­
ten, die gevonden zijn in subpopulaties van menselijke perifeer bloed 
lymphocyten, zijn beschreven in hoofdstuk 5. Τ cellen hebben een lagere 
activiteit van HGPRT, AK, 5'NT en AMPD dan В cellen. De verschillen in 
PNP en AdKin activiteit, die gevonden zijn in deze subpopulaties, konden, 
tenminste voor een deel, worden toegeschreven aan verontreiniging van 
de В cell fractie met bloedplaatjes. Als men de enzymactiviteiten in 
lymphoide cell subfracties vergelijkt, is het noodzakelijk om de ver­
scheidene subfracties zorgvuldig the karakteriseren i.v.m. de 
verschillende isolatie procedures. Τγ cellen hebben een lagere activi­
teit van APRT, PNP en AK dan Τ-Τγ cellen. De suggestie wordt gedaan dat 
Τγ cellen kwetsbaarder zouden kunnen zijn voor purine (deoxy)nucleoside 
vergiftiging dan Τ-Τγ cellen. 
In de tweede sectie wordt de expressie van het purinemetabolisme 
in verschillende lymphoide leukemieën beschreven. In hoofdstuk б 
worden gegevens gepresenteerd, die ondersteunen dat bepaalde purine 
enzymen bruikbaar kunnen zijn bij de subclassificatie van de twee voor­
naamste ALL subclassen, T-ALL en nonBnonT-ALL. Vergeleken met controle 
PBL hebben cellen van patiënten met nonBnonT-ALL hogere HGPRT, ADA en 
AdKin activiteiten en een lagere APRT activiteit. In cellen van patiënten 
met T-ALL werden de activiteiten van HGPRT en ADA ook verhoogd gevonden 
ten opzichte van controle PBL, terwijl de activiteiten van APRT, PNP, 
5'NT en AMPD lager waren. In hoofdstuk 7 zijn verscheidene purine 
enzymactiviteiten gecorreleerd met immunologische kenmerken van ALL 
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patiënten. Relatief hoge ADA, lage PNP en lage 5'NT activiteiten waren 
geassocieerd met het aanwezig zijn van het E-rozet kenmerk en de afwezig-
heid van cALL kenmerken. Intermediaire ADA activiteiten en hoge AdKin 
activiteiten werden geassocieerd met de aanwezigheid van het cALL pheno-
type en de afwezigheid van het E-rozet kenmerk. PreB-cALL cellen bleken 
ongeveer de dubbele 5'NT activiteit te hebben van cALL cellen die het 
preß kenmerk misten. De enzymatische "make-up" van maligne cellen van 
twee B-ALL patiënten verschilde aanzienlijk. Onder andere werd een lage 
5'NT activiteit gevonden bij deze patiënten. Daarom kan 5'NT niet dienen 
als biochemische parameter voor de verschillende subtypen van ALL. 
Anderzijds schijnen ADA en AdKin in dit opzicht veel belovend te zijn. 
De verlaging van de ADA activiteit in patiënten met nonBnonT-ALL na 
Prednison monotherapie kon niet worden gecorreleerd met een verlaging 
van het aantal delende cellen. Patienten met nonBnonT-ALL in "relapse" 
hebben 5'NT activiteiten, die ongeveer 30% zijn van de 5'NT activiteiten 
in nieuw gediagnostiseerde patiënten met nonBnonT-ALL. De conclusie 
wordt getrokken, dat door de specifieke enzymatische "make-up" verschei-
dene ALL subgroepen een verschillende gevoeligheid voor purine (deoxy)-
nucleosiden zullen hebben. In lymphoblasten van patiënten met CLL(hoofd-
stuk 8) zijn lage ADA, 5'NT en PNP activiteiten en hoge AK en AdKin 
activiteiten gevonden, vergeleken met de controle PBL. CLL patiënten 
zonder paraproteinaemie hadden ongeveer een twee maal zo hoge ADA 
activiteit en een ongeveer 10 maal lagere 5'NT activiteit dan de patiën-
ten met paraproteinaemie. Een relatie tussen de 5'NT activiteit en Ig 
productie wordt gesuggereerd. Er zijn geen relaties gevonden tussen 
purine enzymactiviteiten en het E-rozet kenmerk. Het percentage cellen, 
dat rozetteert met muizen rode bloed cellen, scheen echter significant 
te correleren met de 5'NT activiteit. 
Enkele aspecten van nucleoside intoxicatie in rijpe en onrijpe 
lymphoide cellen worden beschreven in de derde sectie. Thymocyten bleken 
een hogere ADA, lagere PNP en lagere ecto-5'NT activiteit te hebben dan 
perifeer bloed Τ cellen. Als thymocyten gescheiden werden in zes sub­
fracties, naar het stadium van rijping, bleek dat de ADA/PNP activiteits 
ratio het hoogst was in fractie l(de meeste onrijpe cellen) en het 
laagst in fractie 6(het meeste rijpe cellen). De conclusie was, dat de 
ADA/PNP activiteits ratio een kenmerk is voor de rijping in de thymus. 
De ecto-5'NT/dCK activiteits ratio was maximaal in thymocyten fractie 3. 
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Deze ratio liep parallel aan de remming van de PHA respons door (deoxy)-
nucleosiden. Uit de experimenten beschreven in hoofdstuk 10 werd gecon­
cludeerd, dat Τ suppressor cellen kwetsbaarder zouden kunnen zijn voor 
(deoxy)nucleosiden vergiftiging dan Τ helper cellen. In deze experimen­
ten, waarin de mitogeen geïnduceerde delingsrespons, eiwit-synthese en 
Ig secretie werden bepaald, werd aangetoond dat lage concentraties van 
deoxyadenosine de Ig secretie verhoogden, terwijl de delingsrespons 
geremd werd. 
In hoofdstuk 11 wordt een overzicht gegeven van de relatie tussen 
purine metabolism, leukemie en lymphoide cell differentiatie en 
beschouwd in samenhang met de bevindingen beschreven in dit proefschrift. 
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STELLINGEN 
bij het proefschrift 
STUDIES ON PURINE METABOLISM 
IN RELATION TO LEUKEMIA 
AND LYMPHOID CELL DIFFERENTIATION 
I 
De verandering in de ratio van de activiteit van adenosine deaminase 
en purine nucleoside Phosphorylase is een goed kenmerk voor Τ cel 
differentiatie. 
II 
Het is niet geoorloofd om het effect van purine nucleosiden op de 
stimulatie van de totale thymocyten populatie door phytohaemagglutinine, 
te relateren aan de activiteit van purine nucleosiden metaboliserende 
enzymen. 
III 
Bij de interpretatie van verschillen in activiteiten van enzymen uit 
het purine metabolisme tussen lymphoide cel subpopulaties, speelt de 
methode van celscheiding een essentiële rol. 
IV 
Bij het ontwikkelen van chemotherapeutica dient meer dan voorheen 
aandacht geschonken te worden aan specifieke metabole eigenschappen 
van maligne cellen. 
V 
Recente ontwikkelingen bij de bestudering van o.a. hematologische af-
wijkingen, immuun deficiënties en spi'erklachten, wijzen op de noodzaak 
van screening van purine- en pyrimidine verbindingen bij een groot 
aantal patiënten. 
VI 
Het vermelden van de resultaten van de koude lymphocytotoxische anti-
lichaam test zonder opgave van de isolatieprocedure van de targetcellen, 
is weinig zinvol 
VII 
Bij de diagnostiek van maligne lymphomen heeft onderzoek naar het 
immunologisch phenotype aan celsuspensies geïsoleerd uit de lymfeklier 
een beperkte waarde. 
VIII 
De biochemische screening van patiënten met mentale retardatie is 
slechts van betrekkelijke waarde. 
IX 
Ook dragers van volledige gebits-prothesen moeten jaarlijks naar de 
tandarts. 
X 
Als medium om hoog radioactief afval op te slaan is "synrock" beter 
geschikt dan glas. 
XI 
De huidige consumptie van sojaproducten in de westerse wereld draagt 
niet bij tot het oplossen van het hongerprobleem in Latijns-Amerika. 
XII 
Beperken van de kosten van de gezondheidszorg is meer een kwestie van 
beheersing dan van bezuiniging. 
XIII 
Door inkomensmatiging en het daardoor toenemend aantal werkzoekenden 
zal de werkloosheid niet afnemen. 
XIV 
Het inzetten van de Chinese graskarper als slootreiniger dient 
achterwege te blijven. 
XV 
In de kaken van Homo sapiens is steeds minder plaats voor verstands-
kiezen. 
XVI 
In het kader van de kostenbeheersing in de gezondheidszorg dient de 
uitdrukking "de pil vergulden" uit het nederlands taalgebruik geschrapt 
te worden. 
J.P.R.M, van Laarhoven 7 oktober 1982 

ISBN 90-9000360-6 
